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ABSTRACT 
Current feed formulations within the aquaculture industry have tended to rely on 
high dietary lipid thus offsetting relatively expensive protein as a source of energy.  In this 
way, protein can be ‘spared’ for synthesis of new tissue and the high lipid content can also 
fulfil both fish and consumer essential fatty acid (EFA) requirements.  However, the main 
disadvantage of feeding high lipid levels to farmed fish is a surplus of fat deposition in the 
flesh and other important tissues, which can detrimentally impact on quality characteristics 
central to the human consumer.  However, based on previous work in other animal models, 
it is entirely feasible that supplementation of the diet with bioactive fatty acids such as 
conjugated linoleic acid (CLA) and tetradecylthioacetic acid (TTA) may mitigate the 
deleterious effects of feeding farmed fish high fat diets by reducing fat deposition in 
particular.   
The general objective of this research work was to test the hypothesis that CLA 
and/or TTA could augment growth, reduce fat deposition and enhance fatty acid 
composition via incorporation of these bioactive fatty acids, and increase n-3 highly 
unsaturated fatty acid (HUFA) levels in the flesh of commercially important fish species 
such as Atlantic salmon (Salmo salar), Atlantic cod (Gadus morhua L.) and rainbow trout 
(Oncorhynchus mykiss).  This project also considered the influence of CLA and TTA on 
enzymes and transcription factors thought to be pivotal in lipid metabolism and fatty acid 
oxidation in particular.  A subsidiary aim of this research work was to investigate the 
immunological impact of dietary CLA and TTA administration in these fish.   
Abstract 
 iv
The results of this project have revealed that the hypothesis was only partly proved.  
There was no effect in growth or biometry after either CLA or TTA supplementation in any 
of the fish species investigated.  Additionally, there were few physiologically significant 
effects on fat levels on fish as a result of TTA or CLA administration.  However, there 
were a number of effects on fatty acid metabolism including inhibition of steroyl coenzyme 
desaturase (SCD) in cod and trout in particular and also enhancement of hepatic n-3 HUFA 
levels in trout.  Importantly, it was determined that both TTA and CLA could be 
incorporated into the flesh thus providing a vehicle through which these bioactive fatty 
acids can be delivered to the consumer.  There were also a number of beneficial effects on 
activity and gene expression of a number of enzymes and transcription factors thought to 
be fundamental to the modulation of fatty acid oxidation in particular.  However, the 
effects on gene transcription and biochemistry had little impact at the whole body level.  
This research work also showed that there were no detrimental effects on immune status 
after supplementation with dietary CLA or TTA.  Conclusively, this thesis has contributed 
to the overall understanding of the influence of dietary CLA and TTA in farmed fish. 
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CHAPTER 1. GENERAL INTRODUCTION 
1.1 Fatty Acid Metabolism 
1.1.1 Structure and Nomenclature 
Lipids constitute a large and diverse group of oils and fats that are organic in nature 
and characteristically are soluble in organic solvents but only sparingly soluble in aqueous 
solvents.  Fatty acids are a family of lipids, which are generally aliphatic monocarboxylic 
acids that have the ability to be liberated via hydrolysis from naturally occurring fats and 
oils.  Fatty acids can be broadly classed into three structurally and ergo, functionally, 
diverse groups based on the presence or absence of carbon to carbon double bonds within 
the hydrocarbon chain of the molecule.  A fatty acid is referred to as saturated when it 
contains no carbon to carbon double bonds.  Conversely, monounsaturated fatty acids 
(MUFA) contain one double bond whilst fatty acids with two or more double bonds are 
termed polyunsaturated fatty acids (PUFA).  Methylene-interrupted (non-conjugated) 
bonds constitute the most common structural configuration of double bonds.  PUFA 
consisting of non-conjugated unsaturation can be of cis (Z) or cis (Z) and/or trans (E) 
configuration, which are terms used to denote geometry of the double bonds in this 
instance (Gunstone et al., 1994). Highly unsaturated fatty acids (HUFA) are a subgroup of 
PUFA distinguished by having chain lengths of ≥ C20 and with ≥ 3 double bonds; an 
abbreviation used frequently in aquaculture nutrition (Sargent et al., 2002). 
Fatty acid nomenclatures have to define chain length, degree of unsaturation and 
double bond position.  There are two accepted nomenclature systems used within lipid 
biochemistry.  Both systems are similar in view of the fact that a numerical value denotes 
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chain length followed by a colon, which in turn is followed by the number denoting the 
double bonds.  However, the two nomenclatures differ in how they represent double bond 
position.  The delta configuration (∆) uses numerical values in order to detail the position 
of each double bond in relation to the carboxyl terminus of the chain whilst the omega/n 
system designates the location of the first double bond from the methyl end of the fatty 
acid.  For example, arachidonic acid (ARA), 20:4 ∆5, 8, 11, 14 has a carbon chain length of 20 
and contains 4 double bonds, which are situated at carbons 5, 8, 11 and 14 from the 
carboxylic end of the fatty acid, respectively.  Using the n nomenclature, ARA is presented 
as 20:4n-6, indicating the first double bond is situated 6 carbons from the methyl moiety.  
In view of the fact that the majority of PUFA within organisms contain methylene-
interrupted double bonds, specifying only the position of the first double bond is usually 
sufficient.  Some key fatty acids denoted by their trivial and IUPAC names and their 
respective nomenclatures are illustrated in Table 1.1. 
Table 1.1 Structure and nomenclature of common long chain fatty acids. 
20:5n-3 20:5∆5,8,11,14,17 5,8,11,14,17-eicosapentaenoic EPA
20:4n-6 20:4∆5,8,11,14 5,8,11,14-eicosatetraenoic arachidonic acid
18:3n-3 18:3∆9,12,15 9,12,15-octadecatrienoic α-linolenic acid
18:2n-6 18:2∆9,12 9,12-octodecadienoic linoleic acid
n-designation ∆-designation Systematic Name Common Name
Saturated
12:0 12:0 dodecanoic lauric acid
14:0 14:0 tetradeconoic myristic acid
16:0 16:0 hexadecanoic palmitic acid
18:0 18:0 octadecanoic stearic acid
20:0 20:0 eicosanioc arachidic acid
Unsaturated
22:6n-3 22:6∆4,7,10,13,16,19 4,7,10,13,16,19,-docosahexanenoic DHA
16:1n-7 16:1∆9 9-hexadecenoic palmitoleic acid
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1.1.2 Biosynthesis 
All vertebrates share a similar fatty acid biosynthesis pathway, which principally 
begins with mitochondrial acetyl-CoA production via oxidative decarboxylation of 
pyruvate or mitochondrial β-oxidation.  Two cytoplasmic, multi-enzymatic polypeptide 
structures named acetyl-CoA carboxylase (ACC) and fatty acid synthetase (FAS) are 
responsible for fatty acid biosynthesis in animals, with energy from NADPH oxidation 
principally driving the reaction  (Wakil et al., 1983).  After transfer from the mitochondria 
to the cytoplasm, acetyl-CoA is carboxylated to form malonyl-CoA via ACC, which is the 
first and rate-limiting step of fatty acid synthesis.  
 Regulation of ACC is achieved via a combination of mechanisms including 
hormone-mediated phosphorylation, allosteric binding and feedback inhibition by local 
metabolites.  In this way, the activated polymeric form of ACC is elevated through 
allosteric binding of citrate whilst inhibition results from feedback inhibition via long chain 
fatty acyl-CoAs. Acetyl-CoA and malonyl-CoA both bind to FAS and then undergo a 
series of cyclic condensation, reduction and dehydration processes each facilitated in turn 
by four enzymatic subcomponents of FAS, namely beta-keto-acyl carrier protein (ACP) 
synthase, beta-keto-ACP reductase, 3-OH acyl-ACP dehydratase and enoyl-CoA reductase.  
With each cycle, two successive saturated carbon atoms from malonyl-CoA are added to 
the original acetyl-CoA moiety, ultimately forming 16:0 (palmitic acid) and to a lesser 
extent, 18:0 (stearic acid).  These fatty acids are then able to undergo separate elongation 
and/or desaturation reactions in order to yield longer and/or unsaturated fatty acids 
respectively.  
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1.1.3 Desaturation and Elongation 
Fatty acid desaturation and elongation pathways are a necessity particularly when 
dietary long chain fatty acids are inadequately supplied. There are two main eukaryotic 
fatty acid elongation pathways localised to two different organelles within the cell.  
Mitochondrial fatty acid elongation predominates when fatty acyl CoA substrates are 
primarily shorter than 16 carbons.  This pathway is essentially the reversal of the β-
oxidation pathway described in section 1.1.4 except that one NADPH and one NADH are 
required (β-oxidation yields two NADH).  The second and most active pathway is confined 
to the endoplasmic reticulum (ER) and involves separate, ER-specific enzymes that are 
functionally similar to the enzymatic sub-domains of FAS.  Fatty acids sequestered for 
elongation must be activated to CoA derivatives; thus providing energy for attachment of 
the donor group to a growing fatty acyl chain.  A subsequent condensation reaction 
between malonyl-CoA and fatty acyl-CoA results in the addition of a two carbon moiety, 
thus the chain is lengthened.  It is noteworthy that the enzyme responsible for this first 
condensation step in the elongation process is aptly termed ‘elongase’ and furthermore, is 
rate limiting and determines fatty acyl specificity (www.medlib.med.utah.edu/Netbiochem/ 
fattyacids/6_2a.html). 
Further modification involves the addition of carbon-carbon double bonds in order 
to produce unsaturated fatty acids.  The family of enzymes that facilitate the introduction of 
double bonds between defined carbons of fatty acyl chains are named ‘desaturases’.  Delta 
(∆) desaturases are nonheme iron-containing enzymes that display broad chain length 
specificity and share the ability to create a double bond at a fixed position generally 
counted from the carboxyl end of the fatty acid.  The acyl-CoA desaturation pathway is 
localised to the ER of particular tissues and is an aerobic process involving the reduction of 
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CoA-linked substrates via a multi-component electron transport system comprising 
cytochrome b5 and cytochrome b5 reductase together with a terminal desaturase.   
All animals have the capacity to introduce double bonds at positions ∆5, ∆6 and ∆9 
of a fatty acid.  Monounsaturated fatty acids are synthesised from saturated fatty acids via 
∆9 desaturase; otherwise known as stearoyl-CoA desaturase (SCD).  Broad chain length 
specificity allows SCD to catalyse the desaturation of fatty acyl-CoA with 12 to 19 
carbons, including 16:0 and 18:0, thus producing 16:1∆9 (16:1n-7 or palmitoleic acid) and 
18:1∆9 (18:1n-9 or oleic acid) respectively (Nakamura and Nara, 2004).  ∆9 desaturase is 
of particular physiological significance given that regulation of cell membrane viscosity is 
achieved via introduction of 16:1n-7 and 18:1n-9 to constituent phosphoglycerides 
imbedded in the phospholipid bilayer (Tocher, 2003). 
In most animals, HUFA are synthesised from dietary PUFA via trans-membrane ∆6 
and ∆5 desaturases.  Higher animals, including all vertebrates and fish, lack desaturases 
with the ability to introduce double bonds between the ∆9 position and the methyl end of 
the carbon chain, which can only be facilitated by ∆12 and ∆15 (or n-3) desaturases 
generally found only in plants and insects (Tocher, 2003). Thus, the n-3 and n-6 fatty acid 
HUFA precursors (18:3n-3 and 18:2n-6), synthesised by ∆12 and ∆15 desaturases, are 
termed essential fatty acids (EFA) since most animals are unable to manufacture these de 
novo and therefore are reliant on dietary sources.  Furthermore, both ∆5 and ∆6 desaturase 
exhibit affinity towards EFA (18:3n-3 > 18:2n-6) over MUFA (Sargent et al., 2002).  It is 
therefore apparent that EFA, especially n-3 fatty acids in the case of fish, are nutritionally 
of major importance and as such are discussed in section 1.2.  The desaturation/elongation 
pathway outlined in Figure 1.1 appears to be the same, at least qualitatively, for rainbow 
trout (Oncorhynchus mykiss) (Buzzi et al., 1996, 1997) as in rats (Voss et al., 1991). 
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Figure 1.1. The vertebrate ∆5/∆6 desaturation/elongation pathway 
 
1.1.4 Cellular Transport, Esterification and Oxidation 
Outer membrane transport and cytosolic solubilisation of fatty acids are facilitated 
by a family of proteins collectively termed fatty acid binding proteins (FABP).  
Specifically, FABPs are responsible for fatty acid desorption into the cytosol and cytosolic 
transport itself (Chmurzynska, 2006) and are present in both mammalian and non-
mammalian organisms including fish (Londraville, 1996).  Once transported into the 
cytosol, fatty acids are usually esterified into different lipid classes or oxidised as a source 
of energy.  It is common for fatty acids to be assimilated into triacylglycerol (TAG) and 
stored in lipid droplets, particularly in adipose tissue, when energy supply exceeds 
expenditure.  Fatty acids that enter the cell can also be incorporated into phospholipids 
(PL) that form the lipid bilayer of biological membranes.  A small quantity of fatty acids 
can be esterified to cholesterol to form cholesteryl ester, which is the storage form of 
cholesterol in cells (Buzzi, 1996).  Esterification into PL, TAG and cholesteryl esters 
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proceeds following fatty acid activation in order to produce fatty acyl-CoA.  The formation 
of fatty acyl-CoA is catalysed by acyl-CoA synthetase, which is active in different 
subcellular compartments depending on tissue type (Buzzi, 1996).  Acyltranferase enzymes 
subsequently facilitate the incorporation of fatty acyl-CoA into PL and TAG.  However, 
esterification is a selective process in fish, by which PUFA are preferentially incorporated 
into PL or TAG based on degree of unsaturation.  For example, 18:3n-3 and 18:2n-6 may 
be more esterified into TAG, whilst eicosapentaenioc acid (20:5n-3), docosahexaenoic acid 
(22:6n-3) and arachidonic acid (20:4n-6) are found to a higher concentration in PL 
(Henderson and Tocher, 1987).  Early studies utilising rainbow trout hepatocytes showed 
that exogenous C18 fatty acids are retained in TAG for subsequent utilisation as 
desaturation and elongation substrates, which are later incorporated into 
phosphatidylcholine (PC) and phosphatidylethanolamine (PE) (Sellner and Hazel, 1982a; 
1982b).  The pathways of de novo glyceride synthesis are essentially the same in fish as in 
higher vertebrates (Sargent et al., 1989).   
In a process analogous to fatty acid esterification, fatty acids destined for 
mitochondrial oxidation must first be modified via the addition of a CoA moiety in order to 
aid translocation through the outer mitochondrial membranes.  The fatty acyl CoA binds to 
carnitine in a reaction facilitated by a specific acyltransferase named carnitine palmitoyl 
transferase-1 (CPT-1).  The subsequent acyl carnitine esters are therefore able to transverse 
the inner mitochondrial membrane.  CPT-1 activation is rate limiting and the enzyme is 
allosterically inhibited by malonyl-CoA, thus preventing simultaneous cellular synthesis 
and degradation of fatty acids.  Once fatty acyl carnitine enters the mitochondrial matrix it 
interacts with CoA in a reaction facilitated by carnitine palmitoyl transferase-2 (CPT-2) to 
yield carnitine and fatty acyl-CoA.  Long chain fatty acyl-CoA can then be utilised in 
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mitochondrial β-oxidation.  Unlike cytosolic fatty acid synthesis, the β-oxidation pathway 
is compartmentalised to specific organelles, namely mitochondria and peroxisomes.  
Mitochondrial β-oxidation involves cyclic dehydration, hydration, second dehydration and 
cleavage of long chain fatty acyl-CoA in order to produce acetyl-CoA along with FADH2 
and NADH, the latter of which is oxidised by the mitochondrial electron transport system 
to yield cellular energy in the form of ATP (Lehninger, 1975). Moreover, acetyl-CoA can 
then be metabolised via the tricaboxylic cycle to produce additional NADH.  Peroxisomal 
β-oxidation produces the same two carbon acetyl-CoA, however it produces hydrogen 
peroxide in place of FADH2 and has a different fatty acid specificity compared with 
mitochondrial β-oxidation since there is no membrane transport system required for very 
long chain fatty acids to enter peroxisomes, thus they are able to freely diffuse.  Many of 
the enzymes involved in both mitochondrial and peroxisomal β-oxidation are genetically 
different but share common functionality.  Piscine β-oxidation is prevalent in liver, heart, 
white and red muscle.  High levels of peroxisomal β-oxidation have been observed in red 
muscle and liver of Atlantic salmon (salmo salar) (Frøyland et al., 2000) and haddock 
respectively (Nanton et al., 2000).  
 
1.2 Nutritional Aspects of Essential Fatty Acids 
1.2.1 EFA in Human Nutrition 
Fundamentally, essential fatty acids (EFA) are fatty acids that an organism must 
obtain through dietary means as the enzymatic processes required for de novo synthesis are 
not present.  Humans like all vertebrates and most animals, display an absolute dietary 
requirement for 18:2n-6 and α-linolenic acid (18:3n-3).  However, as a consequence of 
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modern civilisation, the human diet has significantly changed principally in the amount and 
type of fat consumed.  It is now apparent that saturated fat and n-6 PUFA constitute the 
majority of fat consumed in ‘western’ countries with an n-6/n-3 PUFA ratio estimated to be 
10:1 to 25:1, averaging around 15:1 whilst the purported optimum value should be closer to 
5:1 (Simopoulos, 1999b).  This is noteworthy considering n-3 and n-6 PUFA are not 
metabolically interconvertable and have different physiological functions or efficacies.  
Indeed, the observed changes in dietary fat intake have been linked with the occurrence of 
many pathologies and health disorders common in the modern industrialised world, which 
now extends to Asia (Janus et al., 1996; Okuyama et al., 1997; Bulliyya, 2000).  
Nonetheless, n-6 PUFA are still of physiological importance in humans.  For instance, 
18:2n-6 deficiency is known to interfere with growth, reproduction and skin function in 
mammals (Burr, 1942; Holman, 1968; Hansen and Jensen, 1985).  18:3n-3 is also 
responsible for maintaining normal growth and skin function (Burr, 1942; Fu and Sinclair, 
2000).  HUFA such as 20:4n-6, 20:5n-3 and 22:6n-3 derived from 18:2n-6 and 18:3n-3 are 
also physiologically important.  22:6n-3 is found largely in brain, retina and other neural 
tissues (Uauy et al., 1999) and is a requirement for normal cognitive and visual 
development particularly in foetal and newly born infants (Hornstra et al., 1995; Laurtizen 
et al., 2001).  There is also evidence to suggest that adult brain disorders such as 
schizophrenia, Alzheimer’s disease and clinical depression are associated with relatively 
low levels of n-3 HUFA, particularly 22:6n-3, in brain and adipose tissue (Mamalakis at 
al., 2002; Conquer and Holub, 1997)  
Eicosanoids are essentially a family of active fatty acid metabolites that include 
prostaglandins, leukotrienes and thromboxanes, which can collectively mediate many 
humoral and cellular immune functions and are derived primarily from the C20 HUFA, 
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20:3n-6, 20:4n-6 and 20:5n-3 (Fischer, 1989).  Moreover, increased consumption of n-3 
HUFA results in the prevention or attenuation of many inflammatory conditions that are 
prevalent in the developed world, including rheumatoid arthritis, atopic illness, psoriasis, 
multiple sclerosis, bronchial asthma and  type I diabetes among others (Leaf and Weber, 
1988; Harris, 1989; Kinsella et al., 1990; Calder, 1997; de Deckere et al., 1998; 
Simopoulos, 1990a; Connor, 2000).  There is also evidence to suggest that consumption of 
fish containing high levels of 20:5n-3 and 22:6n-3 helps prevent coronary heart disease 
(Dyerberg et al., 1975,1978; Stansby, 1990; Kelly, 1991), and dietary HUFA have been 
speculated to lower the risk of atherosclerotic plaque formation, colon and breast cancer 
(Bougnoux et al., 1994; Caygill et al., 1995).  Fish are the most abundant natural source of 
n-3 HUFA in the human food basket.  Therefore, increasing the amount of oily fish in the 
human diet will help rebalance the n-6/n-3 ratio and reduce many of the abovementioned 
diseases associated with n-3 HUFA deficiencies (British Nutrition Foundation, 1999).  
1.2.2 EFA in Fish Nutrition 
Fish, like other vertebrates, must obtain dietary sources of non-synthesisable fatty 
acids in order to sustain optimum health.  A lack of dietary EFA is known to interfere with 
growth, and reproduction, and in severe cases results in death through various pathologies 
(Castell et al., 1972; Watanabe, 1982; Sargent et al., 2002).  Moreover, lipids and their 
constituent fatty acids are also very important as a source of energy in fish, especially 
carnivorous species, which do not rely heavily on carbohydrate due to its low abundance in 
natural diets.  As aforementioned, vertebrates including fish lack an inherent ability to 
synthesise 18:3n-3 and 18:2n-6 and must therefore rely on dietary sources.  It is interesting 
to note that both 18:3n-3 and 18:2n-6 play no direct functional role in fish and rather serve 
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only as precursors of the functionally bioactive HUFA; 20:4n-6, 20:5n-3 and 22:6n-3 
(Tocher, 2003).  20:4n-6 is a component of PL contributing to the structural integrity of 
membranes and together with 20:5n-3, is the primary precursor of eicosanoids such as 
prostaglandins and leukotrienes (Cook and McMaster, 2002).  The most abundant n-3 fatty 
acids in fish are 20:5n-3 and 22:6n-3, which contribute the same basic structural functions 
in cell membrane phospholipids in fish as 20:4n-6 in terrestrial mammals (Sargent et al., 
1995).  Visual and neural impairment have also purported to be caused by dietary n-3 
HUFA deficiencies in juvenile herring (Clupea harengus) (Bell et al., 1995).  Thus, it is 
probable that n-3 HUFA share similar physiological roles in fish and humans. 
The fundamental EFA requirements of fish vary depending on species and habitat.  
Generally, freshwater/herbivorous fish can survive by converting dietary C18 PUFA to 
HUFA whereas marine/carnivorous fish rely on preformed dietary HUFA.  Thus, HUFA 
can be regarded as EFA in certain instances, particularly when considering the dietary 
requirements of marine and carnivorous species.  The habitual inadequacy of marine fish to 
convert C18 PUFA to HUFA is believed to be caused by enzymatic insufficiency within the 
desaturation/elongation pathway, specifically impairment of ∆5 desaturase and/or C18-20 
elongase (Owen et al., 1975, Tocher et al., 1989).  Anadromous fish such as Atlantic 
salmon display the EFA requirements of freshwater fish prior to parr-smolt transformation 
and, during adaptation prior to migration to seawater, develop fatty acid profiles similar to 
marine species.  Studies have suggested that the changes observed in the fatty acid profiles 
of anadromous fish are not solely dictated by dietary changes as a result of environment but 
instead may be due to an innate ability to alter desaturase activity (Bell et al., 1989).  It is 
clear that an important aspect of fish nutrition is the provision of sufficient amounts of the 
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correct EFA to satisfy growth and development by taking into account particular species 
specificities.   
1.3 Issues in Aquaculture 
1.3.1 High energy Diets 
With the continuing decline of wild fish stocks the consumer market has become 
increasingly reliant on the aquaculture industry to provide farmed fish that mirror the 
nutritional qualities of wild fish. High lipid levels, traditionally provided by fish oil (FO), 
are utilised in commercial aquaculture diets in order to offset relatively expensive protein 
as a source of energy.  In this way, protein can be ‘spared’ for synthesis of new tissue 
(Wilson, 1989; Bell, 1998) and the high lipid content can also fulfil both fish and consumer 
EFA requirements.  Paradoxically, the aquaculture industry relies on wild fisheries to 
provide FO and fish meal (FM) required to satisfy the dietary EFA requirements of 
cultured fish.  It is noteworthy that the recent average yield of FO from industrial fisheries, 
circa 1.4 million tonnes in 2000 (Sargent and Tacon, 1999) is unlikely to be exceeded in 
the future and climatic phenomena such as El Niño can significantly reduce this tonnage.  
Furthermore, 57% of the total world supply of FO in 2000 was used in aquaculture, with 
farmed salmon and trout consuming over 60% of that total (Sargent and Tacon, 1999).  
Global aquaculture has grown at 11.6% per annum compound growth since 1984 (Tacon, 
1996) and this rate shows no sign of abating greatly.  Thus, it is estimated that around 98% 
of the total world supply of FO will be required for aquafeeds by 2010 (Barlow, 2000). 
Compounding this issue is the growing consumer perception that pollutants such as 
dioxins, polychlorinated biphenyls (PCBs) and flame retardants in FOs have now reached 
unacceptable levels in farmed fish. In addition, high energy diets can promote excessive fat 
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deposition, particularly in the liver and flesh, which can compromise the overall market 
quality of the fish through various mechanisms including reduced pigment visualisation 
and smoking performance in the case of salmon (Sheehan et al., 1996; Johansen and 
Jobling, 1998).  Although early nutritional studies elucidated that dietary HUFA derived 
from FO is a requisite for optimum fish health (March, 1992), it has now been concluded 
that generally, levels of 20:5n-3 and 22:6n-3 in current aquafeeds are well in excess of the 
minimum n-3 EFA requirements (Sargent et al., 2002).  Despite this, technical advances in 
extruded feed production have enabled pelleted diets to continue an upward trend in dietary 
lipid quantity, particularly in the case of Atlantic salmon where diets containing up to 40% 
lipid have been used (Tocher, 2003).  Thus, research into feed formulation is necessary to 
address many of the aforementioned issues.   
1.3.2 FO Replacement 
It is apparent that alternatives to FO must be sought in order to increase current 
global production levels of farmed fish.  Although more judicious use of fish trimmings, 
offal and discards could increase FO output, it is a temporary solution given that the wild 
fish catch will ultimately decline.  It has been suggested that marine crustaceans such as 
krill and copepods could be harvested for FO however concerns have been raised over the 
potential impact on ecosystems reliant on such organisms.  Probably the most viable 
sustainable alternative involves the partial or complete replacement of FO with 
vegetable/plant derived, vegetable oils (VO). However, plant derived oils are rich in C18 
PUFA such as 18:2n-6 and 18:3n-3 but are devoid of n-3 HUFA abundant in FO.  
Nevertheless, it has been elucidated that some species of fish including Atlantic salmon 
display limited ability to convert 18:2n-6 to 20:4n-6, and 18:3n-3 to 20:5n-3 and 22:6n-3.  
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Therefore, current research has focussed on partial inclusion of VO in aquafeeds in order to 
test the hypothesis that some fish, such as Atlantic salmon, may be able to endogenously 
convert 18:3n-3 to n-3 HUFA.  To date, there is an extensive body of literature 
encompassing the biochemical and physiological effects of VO replacement on cultured 
fish; a review of which is beyond the scope of this discussion.  However, a number of 
studies have elucidated that substitution of FO by VOs is feasible (Torstensen et al., 2000; 
Bell et al., 2001, 2002; Rosenlund et al., 2001; Tocher et al., 2002).  Obviously, it is 
imperative that any replacement should not compromise fish health, welfare or growth 
performance, which in turn may affect health benefits, taste and other quality 
characteristics important to consumers.  Some of the key findings have shown that in 
salmon and trout, replacement of FO with VO up to 100% did not influence growth and 
feed conversion and that flesh lipid content was unaffected by dietary lipid source (Bell et 
al., 2004).  Thus, a diet rich in VO can provide the same energy for growth as one 
composed purely of FO.  Furthermore, it has been reported that a high level of dietary VO 
shows little to no effect on the organoleptic properties of salmon and trout, and organic 
pollutants such as PCBs and dioxins are also significantly reduced (Berntssen et al., 2005).  
However, a number of studies have also elucidated that flesh 22:6n-3 and 20:5n-3 
concentrations are significantly reduced in salmonids fed high levels of VO indicating that 
desaturation/elongation of 18:3n-3 is not sufficient in providing the same quantity of n-3 
HUFA found in FO (Bell et al., 2005).  Therefore, the obvious implications are that 
consumers cannot obtain the same quantity of n-3 HUFA from fish fed VO as opposed to 
FO but this has, to some extent been resolved by the introduction of FO ‘finishing’ diets.  
Although flesh lipid content is unaffected by VO, salmon fed linseed oil exhibit a higher 
incidence of ‘fatty liver’, which in severe cases has been known to  result in increased risk 
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of mortality (Bell et al., 2004).  Investigations into the immunological consequences of VO 
replacement concluded that 20:4n-6 derived prostaglandin production is reduced whilst 
incidences of cataract in salmon were significantly increased, raising potential fish welfare 
issues (Waagbo et al., 2004)  Linseed oil supplementation also altered a number of basic 
immune parameters including haematocrit, leukocyte numbers and macrophage respiratory 
burst (Good, 2004).   It is possible that some of these concerns can be resolved through VO 
and VO/FO blending however, the research described in this thesis investigating the 
physiological and biochemical effects of prospective dietary ‘bioactive’ fatty acids, is 
highly pertinent to this area as it was hypothesised that they may minimise detrimental 
effects of feeding cultured fish a diet high in lipid or VO.   
1.4 Conjugated Linoleic Acid (CLA) 
1.4.1 Introduction 
One prospective ‘functional’ fatty acid that has garnered a lot of interest within 
nutritional research is conjugated linoleic acid (CLA).  CLA was probably first identified in 
1935 after ultraviolet analysis established the presence of conjugated fatty acids in cow 
milk fat (Booth et al., 1935).  However, the nutritional potential of CLA was not realised 
until 1978 when Michael Pariza and colleagues identified a ‘beef-derived mutagenesis 
factor’ when studying the effects of temperature and time on mutagen formation in grilled 
ground beef (Pariza, et al., 1979).  Subsequent studies indicated that the mutagen displayed 
anti-carcinogenetic properties and was in fact a conjugated derivative of linoleic acid 
(Pariza and Hargaves, 1985; Ha et al., 1987).  Since that time, a vast amount of work 
concerning the structural and functional aspects of CLA has been conducted. It is now 
accepted that conjugated linoleic acids represent a mixture of positional and geometric 
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isomers of octadecadienoic acid with ‘non-methylene-interrupted’ double bonds.  The 
range of potential health benefits associated with CLA in experimental models now include 
anti-obesity, anti-atherogenic and immunomodulatory effects however only two isomers 
(cis-9, trans-11 and trans-10, cis-12) are thought to exhibit biological activity (Pariza et al., 
2001).  Both isomers are illustrated in Figure 1.2 below.  
  
Figure 1.2 The two principal biological isomers of conjugated linoleic acid (CLA) in 
comparison with linoleic acid 
 
 
A. Linoleic Acid. B. c9t11 CLA. C. t10c12 CLA. 
CLA are produced naturally mainly by bacterial biohydrogenation of linoleic acid 
(18:2n-6) in the ruminant gut by a variety of species including Butryrivibrio fibrosolvens 
(Kepler, 1966 in Riserus 2003; Griinari et al., 2000; Ogawa et al., 2006).  As a 
consequence, food products derived from ruminants are the major source of CLA in the 
human diet; with the cis-9, trans-11 (c9t11) and trans-10, cis-12 (t10c12) isomers 
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comprising 80 – 90 % and 3 – 5 % of the total, respectively (Khanal and Dhiman, 2004).  
However, recent studies have ascertained that c9t11 CLA can also be endogenously 
synthesised via ∆9 desaturation of trans-vaccenic acid in the mammary glands of cows, and 
monogastrics such as mice and humans  (Adolf et al., 2000; Santora et al., 2000; Turpeinen 
et al., 2002; Mosley, et al., 2006a, b).  In addition, 1:1 mixtures of the two bioactive CLA 
isomers are being produced commercially via alkaline isomerisation or partial 
hydrogenation of either linoleic acid itself or, more usually, sunflower or safflower oils that 
are rich in linoleic acid (Banni, 2002), and currently CLA is being marketed as a dietary 
supplement in amounts up to 1000 mg/capsule.  This is around five times the average 
purported natural human daily intake of CLA of 200 mg per day for men and 150 mg per 
day for women (Ritzenthaler et al., 2001).  It is likely that the current natural daily intake 
of CLA will not increase and perhaps may even decrease given that the amount of red meat 
and dairy produce consumed is declining as a consequence of the consumer understanding 
that excessive saturated fatty acids are promoters of chronic disease.   
The goal of increasing the quality of animal-derived food has, and continues to be, 
of major importance in the agricultural sector.  As a result, additional focus has been given 
to designing and enhancing foods with components that have beneficial effects on human 
health.  Thus, the majority of current CLA research is focused on the adjustment of animal 
diets in order to raise the CLA levels found in milk, meat and other agricultural foodstuffs.  
By introducing CLA into aquafeeds it is hoped that the reported physiological changes, 
particularly the anti-adipogenic and immunomodulatory effects (see following sections) 
established in other animals, could also be mirrored in fish.  
Chapter 1  
 18
1.4.2  CLA and Body Composition in Experimental Animals 
Most studies to date have explored the influence of mixed isomer preparations of 
dietary CLA (referred to as CLA for the remainder of this chapter).  Reductions in body 
weight and/or fat deposition in animals supplemented with CLA have been the most 
commonly reported effect thus far.  A decrease in body fat mass, an increase in lean body 
mass and growth rate, and improvements in feed efficiency were initially described in 
Fischer rats and ICR (Institute of Cancer Research) mice supplemented with 0.5 – 1 % 
CLA (Chin et al., 1994; Park et al., 1997).  In fact, recent studies have shown that dietary 
CLA concentrations as little as 0.4 % of total diet have decreased fat mass and increased 
lean mass in BALB/C male mice fed over a 14 week period (Bhattacharya et al., 2006). A 
reduction in fat deposition in brown and/or white adipose tissue has been particularly 
evident in C57BL/6J mice fed ≥ 1 % CLA (West et al., 1998; Tsuboyama-Kasaoka et al., 
2000; Whigham et al., 2000; Takahashi et al., 2002).  Similarly, 1 % CLA significantly 
reduced the weight of epididymal and perirenal adipose tissues in ICR mice (Akahoshi et 
al., 2002).  Studies investigating the interaction between dietary CLA and fat level found 
that concentrations of 0.5 – 1 % reduced fat deposition equivalently in AKR/J mice fed 
either a high-fat (45 % of calories) or a low-low fat (15 % of calories) diet (Delany et al., 
1999).  Thus, it seems likely that the attenuation of body fat evidenced through CLA 
supplementation is independent of dietary fat intake, at least in mice.  It is evident that the 
type of dietary lipid used does influence the anti-adipogenic capability of CLA however.  It 
has recently been shown that CLA, when fed in combination with coconut or soybean oil, 
can decrease body mass and epididymal fat mass in mice.  Mice fed CLA in combination 
with FO showed no effect on adiposity however (Hargrave et al., 2005). 
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The observed changes in body composition caused by dietary CLA are most 
obvious in mice, however doses as low as 0.25 % of total diet have also been shown to 
reduce retroperitoneal and parametrial fat pad weights without effecting growth rate or 
food intake in Sprague-Dawley rats (Azain et al., 2000).  Similar studies have also 
elucidated that 1.5 % dietary CLA can decrease white adipose tissue weight and fat pad 
mass in male Sprague-Dawley and ZDF rats, respectively (Ryder et al., 2001; Yamasaki et 
al., 2003).  Conversely, recent studies have shown that 2 % dietary CLA has no effect on 
body composition in adult male Wister rats (Mirand et al., 2004), and long term feeding of 
1 % CLA to Fischer rats for 18 months has shown no effect on body composition (Park et 
al., 2005).  Studies evaluating the impact of dietary fat on the anti-adiposity effects of CLA 
have shown that 1.5 % of a mixed isomer preparation had no effect in Sprague-Dawley rats 
given alongside diets rich in either coconut oil (EFA deficient) or corn oil (Kloss et al., 
2005).  It has been suggested that the effects of CLA on body composition may be limited 
to growing, lean animals. Feeding lean and obese rats diets containing 0.5 % CLA for 5 
weeks induced a reduction in fat mass of growing rats, but not in rats established with 
obesity (Sisk et al., 2001).  Taken together, it seems likely that the effects of CLA on fat 
deposition are based on dose, age, length of treatment, dietary lipid content and/or 
genotype variability in rats.   
Improved growth rates and feed efficiencies together with reductions in carcass fat 
have been observed in the majority of studies analysing the influence of mixed isomer 
preparations of CLA in pigs (Dugan et al., 2004).  Preliminary studies suggest that low 
concentrations of dietary CLA have no effect on adiposity in cats or dogs however (Jewell 
et al., 2006; Leray et al., 2006).  Advances in the manufacture of individual CLA isomers 
have made possible the independent analysis of t10c12 and c9t11 CLA.  A number of 
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studies have now indicated that t10c12 CLA is responsible for the attenuation of fat 
deposition in vitro and in vivo (Park et al.,1999; Gavino et al., 2000; Choi et al., 2001 
Ryder et al., 2001; Navarro et al., 2003; Wargent et al., 2005; Simon et al., 2006).   
1.4.3 CLA and Body Composition in Humans 
There are relatively few papers reporting the effects of CLA or its individual 
isomers in humans and current information available suggests the results are inconclusive.  
A 12 week study in which normal-weight exercising subjects were administered 1.8 g/d of 
a CLA mixture showed a 4 % decrease in body fat with no affect on body weight compared 
to that of the control group fed a hydrogel placebo (Thom et al., 2001). An earlier study 
carried out by the same laboratory administered 1.7, 3.4, 5.1, and 6.8 g/day CLA to 
exercising obese humans concluding that a dose of 3.4 g/day was enough to significantly 
decrease body fat without affecting body weight (Blankson et al., 2000).  Interestingly, 
exercising overweight subjects initially fed a fat-reducing diet and subsequently 1.8 to 3.6 
g/day CLA, increased their resting metabolic rate and lean mass without affecting body 
weight regain (Kamphuis et al., 2003).  The abovementioned studies seem to indicate that 
CLA has the ability to decrease fat and improve lean mass in humans who lead a physically 
active lifestyle in particular. Another study revealed that 4.2 g CLA/day for 4 weeks was 
enough to reduce sagittal abdominal diameter without effecting body weight in middle-
aged obese men with signs of metabolic syndrome (Riserus et al., 2001).  Thus, it may be 
concluded that dietary CLA can decrease fat mass without affecting cardiovascular health.  
Additionally, healthy individuals fed 0.7 g/day for 4 weeks and thereafter 1.4 g/day CLA 
for 4 weeks decreased in fat mass relative to control subjects (Kreider et al., 2002). 
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In contrast, a 64 day investigation into the effects of 3 g/d dietary CLA in sedentary 
and exercising healthy women found that lean body mass, body weight, energy 
expenditure, fat oxidation, rate of lypolysis and FA esterification were not altered (Zambell 
et al., 2000).  A similar trial involving 2.1 g/day CLA administered to sedentary women 
had no effect on body composition (Petridou et al., 2003). Two studies have evaluated the 
impact of CLA administered in the form of dairy products.  The first study analysed the 
effects of purified isomers at 1.5 and 3 g/day for 18 weeks supplemented as a drinkable 
dairy product and found that there were no differences in body composition in middle-aged 
overweight subjects (Malpuech-Brugere et al., 2004).  Similarly, abdominal and 
subcutaneous adipose tissue did not change in overweight and obese men fed butter fat 
comprising 4.2 % CLA (Desroches et al., 2005).   
The long-term effects of CLA on body composition have been addressed in two 
trials. In the first study, subjects of average body mass index were administered either CLA 
as a free fatty acid (CLA-FFA) or CLA in the form of TAG (CLA-TAG) for 12 months. 
Both forms of CLA decreased body fat mass significantly and a higher lean body mass was 
evidenced in subjects fed CLA-FFA (Gaullier et al., 2004).  A follow-up study purported 
that subjects administered 3.4 g/day CLA-TAG for 12 months could maintain a decrease in 
fat mass over a period of 24 months (Gaullier et al., 2005).  At present, the presumption 
that CLA can elicit an effect on body composition in humans is questionable considering 
the inconsistencies between studies.  The dramatic effects seen in animal studies, especially 
in mice, have not been reflected in human studies.  This may be attributed to lower CLA 
dosage in humans in comparison with experimental animal studies.  In humans, Isomer-
specific effects of t10c12 CLA have not been investigated, which is believed to be the 
causative agent of reduction in body composition in animal studies.  Age seems to be a 
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critical factor in determining CLA-specific effects.  Experiments using rodents have been 
conducted with growing animals and there is little evidence of CLA effectiveness in adult 
animals. Conversely, human studies have been performed solely with adults. However, 
preliminary evidence suggests that long-term supplementation of CLA can induce a fat-
lowering effect in humans.  Moreover, it would seem that dietary CLA administered in 
conjunction with regular exercise helps promote fat loss and improve lean body mass in 
humans. 
1.4.4 CLA and Immunomodulation  
The immune response in fish, like all other vertebrates, consists of two closely 
related defence mechanisms – the innate and adaptive immune system.  The adaptive  
immune system allows for specific cellular responses (such as antibody production) that are 
tailored to specific pathogens or pathogen-infected cells; a review of which is beyond the 
scope of this project.  The innate immune response is the first line of defence against 
pathogens and consists of a multitude of cells, proteins and peptides in tissue and body 
fluids (Robertson, 1999).  Skin, gills, mucus, macrophages, eicosanoids, cytokines, 
phagocytes and neutrophils all contribute to the innate immune system in fish.   
Macrophage activation, increased eicosanoid and cytokine production, increased 
phagocytosis, greater lymphocyte numbers and enhanced lysozyme activity are indicators 
of an elevated innate immune response (Sakai, 1999; Grannam and Schrock, 2001).  This 
non-specific defence system is routinely reported to be modulated by dietary 
supplementation with immuno-stimulants.  There is increasing evidence to suggest that 
CLA confers an immumo-modulatory effect in animals when fed as a dietary supplement 
(O’Shea et al., 2003).  For instance, CLA has been shown to inhibit cytokine (specifically 
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TNF-α) production in rat macrophages (Yang and Cook, 2003), ICR mice (Akahoshi et al., 
2002), and Sprague-Dawley rats (Yamasaki et al., 2003), and reduce prostaglandin 
synthesis in a variety of studies (Liu et al., 1998; Kavanaugh et al., 1999; Shen et al., 2004; 
Lai et al., 2005), suggesting this bioactive fatty acid may act as an anti-inflammatory agent. 
However, the majority of current evidence suggests that the inflammatory response is 
unaffected by dietary CLA in adult humans (Albers et al., 2003; Nugent et al., 2005; 
Gaullier et al., 2007; Mullen et al., 2007).  Recently, in vitro studies have revealed that 
t10c12 CLA increased phagocytosis in porcine blood cells (Kang et al., 2007). Moreover, 
dietary CLA increased serum lysozyme activity and enhanced phagocytic ability in broiler 
chicks (Zhang et al., 2005).  It is therefore plausible that dietary CLA may modulate the 
immune system, in part by enhancing the non-specific immune response in selective 
species.  Thus, dietary manipulation through provision of CLA may prove to be one of the 
optimal ways of improving fish health.   
 
1.4.5 Dietary CLA in Fish 
Another aspect of CLA research concerns the beneficial effects dietary CLA may 
elicit on cultured animals, including fish.  For example, it is hoped that some of the 
immuno-modulatory effects of CLA may have application in aquaculture as an alternative 
to feed antibiotics, by enabling increased stocking density or as a means of improving the 
response to vaccination and conferring disease resistance.  Of equal importance is the 
impact dietary CLA may have on feed efficiency, body composition and growth, which 
have all been improved in previous mammalian studies.   
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There are very few papers reporting the effects of CLA in fish.  On commencement 
of the project, only four papers had been published in the peer-reviewed literature.  The 
papers focussed in particular on the influence of dietary CLA on growth and biometry and 
in some instances the hepatic and muscle fatty acid compositions of freshwater species.  
Species studied included hybrid striped bass (Morone cyhrysops x M. saxatilus), yellow 
perch (Perca flavescens), channel catfish (Ictalurus punctatus), Nile tilapia (Oreochromis 
niloticus), rockfish (Sebastes schlegeli) and common carp (Cyprinus carpio) (Choi et al., 
1999; Twibell et al., 2000, 2001; Twibell and Wilson, 2003).  All these studies used dietary 
fat levels (< 10 % of total diet), which were arguably too low to adequately test the 
proposed protein sparing effect of dietary CLA.  Indeed, dietary CLA did not influence 
growth in yellow perch or channel catfish.  However, tilapia and rockfish fed CLA at 2.5 – 
10 % of total diet and carp fed 10 % CLA exhibited significantly lower weight gain and 
feed efficiencies compared with fish fed no CLA, suggesting a growth-inhibiting and 
possibly toxicological response when CLA was fed at extremely high levels.  In contrast, 
dietary CLA concentrations of up to 1 % of total diet significantly increased weight gain in 
carp (Choi et al., 1999) and improved feed efficiency in hybrid striped bass (Twibell et al., 
2000). Additionally, total liver lipid concentration decreased significantly in hybrid striped 
bass and yellow perch whilst HSI increased in bass fed 1 % CLA.  Hepatic and muscle 
fatty acid compositions have been assessed in yellow perch and hybrid striped bass fed 
CLA.  Of note is that flesh concentrations of 20:5n-3 and 22:6n-3 were significantly 
decreased in hybrid striped bass supplemented with 1 % CLA, but this was not reported in 
any other trial.  In addition, all the aforementioned trials were carried out using juvenile 
fish and so the effect of CLA on adult fish that were actively depositing lipid in the tissues 
had not been investigated.  Arguably the main and most consistent finding is that CLA 
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deposition occurs in fish muscle and liver and the amount of CLA retained in these tissues 
after supplementation can be higher than deposited in meat or milk fat derived from natural 
ruminant sources.  Thus, consumption of CLA-supplemented fish may be an effective 
means of increasing human intake of these fatty acids (Wahle et al., 2004).  In summary, it 
has been shown that the effects of CLA in fish are species-specific and dose-dependant.  It 
is also clear from other animal studies that experimental differences in CLA isomer 
content, dietary lipid source and/or amount, and age of fish may be of importance when 
detailing the physiological influence of dietary CLA. 
1.4.6 Prospective Biochemical Mechanisms of Action 
CLA have been reported to increase both the activity and gene expression of 
enzymes implicated in fatty acid catabolism in a number of animal studies.  Arguably the 
best gauge of mitochondrial fatty acid oxidation capacity is the measurement of carnitine 
palmitoyl transferase-1 (CPT-1) activity.  A number of studies are in agreement that t10c12 
CLA is implicated in enhancing mitochondrial fatty acid oxidation through increasing 
CPT-1 activity (Martin et al., 2000; Degrace et al., 2004; Marcarulla et al., 2005; Zabala et 
al., 2006) and gene expression  (Wang et al., 2005; LaRosa et al., 2006) particularly in 
liver and skeletal muscle.  Furthermore, elevated peroxisomal β-oxidation capacity has 
been reported to be caused by increased enzyme activity and/or transcript levels of hepatic 
acyl coenzyme-A oxidase (ACO) in animals fed CLA (Moya-Camarena et al., 1999; 
Yamasaki et al., 2001; Choi et al., 2004; Degrace et al., 2004). 
Transcriptional regulation of a number of enzymes involved in hepatic β-oxidation 
(including CPT-1 and ACO) is mediated, in part by peroxisome proliferator-activated 
receptor alpha (PPARα).  PPARα is known to instigate rapid increases in the size and 
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number of hepatic peroxisomes since it increases the activity of enzymes required for β-
oxidation (Ruyter et al., 1997).  CLA may arbitrate its effects via this transcription factor; 
indeed both c9t11 and t10c12 isomers are ligands for all three isoforms of PPAR (α,β,γ) 
(Moya-Camarena et al., 1999; Clement et al., 2002;).   
Other direct effects of CLA on lipid metabolism extend to encompass an increase in 
lipolysis and apoptosis, principally in adipocytes (Park et al., 1997; Tsuboyama-Kasaoka et 
al., 2000; Miner et al., 2001; Evans et al., 2002).  Studies exploring the effects of 
individual CLA isomers on primary cultures of stromal vascular cells from human adipose 
tissue identified t10c12 as the only lypolytic agent (Brown et al., 2001) and the resultant 
reduction in TAG content is associated with the differential localisation and expression of 
lipid droplet-associated proteins (Chung et al., 2005).  However, recent studies have argued 
that the fat lowering effects of t10c12 CLA is not due to increased apoptosis (Xu et al., 
2003) but rather reduced preadipocyte differentiation into mature adipocytes (Brodie et al., 
1999; Satory and Smith., 1999; Evans et al., 2000; Simon et al., 2005). Indeed, t10c12 
CLA did not appear to cause apoptosis in human adipocytes (Brown et al., 2003a, 2004).  
Modulation of preadipocyte differentiation and adipogenesis has been suggested to 
be mediated in part by PPARγ.  Activation of PPARγ is known to increase adipogenesis 
(Desvergne et al., 2006).  Both in vitro studies in human and 3T3-L1 adipocytes (Evans et 
al., 2000; Kang et al., 2003; Brown et al., 2003a, 2004; Granlund et al., 2003, 2005) and in 
vivo work in mice (Tsuboyama-Kasaoka et al., 2000; Takahasi et al., 2002; Kang et al., 
2004) hamsters (Zabala et al., 2006) and pigs (Brandebourg and Hu, 2005) have identified 
that upon CLA supplementation, with the t10c12 isomer in particular, there is a decrease of 
PPARγ expression.  Consistent with this, down-regulation of PPARγ downstream targets 
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aP2, perilipin-A and acyl-CoA-binding protein (ACBP) have been observed in rodents fed 
CLA (Houseknecht et al., 1998; Belury, 2002).  
Inhibition of lipogenesis is well documented in studies detailing the mechanisms 
behind the anti-obesity effects of CLA.  Indeed, reductions in TAG content after CLA 
supplementation have been verified in vitro and in vivo (Azain et al., 2000; Evans et al., 
2000; Tsuboyama-Kasaoka et al., 2000; Poulos et al., 2001; Rahman et al., 2002).  This 
has been purported to be caused by reductions in expression of adipocyte ACC 
(Tsuboyama-Kasaoka et al., 2000; Brown et al., 2003a; Peterson et al., 2003; Lin et al., 
2004; Zabala et al., 2006) and FAS (Tsuboyama-Kasaoka et al., 2000; Kang et al., 2003; 
Peterson et al., 2003; Lin et al., 2004; Zabala et al., 2006).  Moreover, evidence suggests 
that the glucose transporter GLUT 4 gene expression is down-regulated in human 
preadipocytes, white and brown adipose tissue during CLA supplementation (Takahishi et 
al., 2002; Brown et al., 2003a), and in 3T3-L1 adipocytes treated with 25 µm t10c12 CLA 
(Granlund et al., 2005).  Indeed, significantly higher levels of glucose and fatty acid have 
been found in serum, plasma, liver and surrounding tissues after CLA supplementation 
(Baumgard et al., 2002; Brown et al., 2003a).  The inhibitory effect of CLA on lipogenesis 
is also correlated with inhibition of uptake and transport of fatty acids as evidenced by 
decreased lipoprotein lipase (LPL) and FABP levels (Bretillion et al., 1999; Park et al., 
1999) and is probably due to the t10c12 isomer in particular (Peterson et al., 2003).  The 
fact that LPL and FABP are regulated via PPARγ only serves to strengthen the notion that 
CLA mediates its anti-lipogenic effects through this transcription factor in mammals (Khan 
and Vanden-Heuvel, 2003).  In vivo evidence of a TAG-lowering effect after CLA 
supplementation has also arisen from decreased gene expression levels of enzymes directly 
responsible for TAG synthesis (Baumgard et al., 2002).  Thus, the reduction in uptake of 
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glucose and fatty acids together with the inhibition of de novo fatty acid and TAG synthesis 
is likely to account for the reduction in the TAG content of adipocytes in this instance. 
Lipid-droplet size has also been shown to decrease in 3T3-L1 adipocyte cells 
treated with t10c12 CLA and has been attributed to reduced amounts of palmitoleic and 
oleic acid (Choi et al., 2000).  In vivo experiments with rats (Sebedio et al., 2001), mice 
(Lee et al., 1998) and pigs (Gatlin et al., 2002), and in vitro studies with HepG2 cells (Eder 
et al., 2002) and human preadipocytes (Brown et al., 2003a) have confirmed an increase in 
the ratio of saturated fatty acids to monounsaturated fatty acids in particular. Decreases in 
adipocyte size have also been noted in mice (Tsuboyama et al., 2000) and rats (Azain et al., 
2000; Ohnuki et al., 2001; Poulos et al., 2001).  In support of these findings, a number of 
studies have determined that SCD gene expression and/or activity is significantly decreased 
in mice, pigs and poultry fed CLA, particularly the t10c12 isomer (Lee et al., 1998; Choi et 
al., 2001; Park et al., 2001; Smith et al., 2002; Shang et al., 2005).  Thus, there is evidence 
to suggest that decreased lipogenesis and therefore cellular TAG content is as a result of 
decreased lipogenic enzyme activity/expression in studies involving t10c12 CLA. 
However, it is also likely that increased fatty acid oxidation could contribute to the TAG 
lowering effect in adipocytes.  
1.5 Tetradecylthioacetic Acid (TTA) 
Tetradecylthioacetic acid (TTA) belongs to a family of 3-thia fatty acids that 
contain a sulphur atom at the third position from the carboxyl terminus. Hence, TTA 
cannot be catabolised via the β-oxidation pathway and instead is processed via ω-oxidation 
(Skrede et al., 1997).  The chemical structure of TTA is illustrated in Figure 1.3 below. 
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Figure 1.3 The chemical structure of tetradecylthiocacetic acid (TTA). 
 
 
 
Although structurally very different from CLA, dietary TTA is responsible for a 
number of similar physiological and biochemical responses.  For instance, TTA fed in 
combination with a high fat diet is known to decrease epididymal adipose tissue mass in 
Wister rats (Madsen et al., 2002).  Furthermore, TTA has been shown to stimulate both 
hepatic peroxisomal and mitochondrial β-oxidation of fatty acids (Berge and Hvattum, 
1994) and increase the activity and up-regulate the gene expression of a number enzymes 
associated with both metabolic pathways.  For example, short term dosing of TTA in vitro 
resulted in up-regulation and increased enzyme activity of ACO in addition to an increase 
in activity of both CPT-I and CPT-II (Vaagenes et al., 1998).  Similar studies have also 
noted an increase in both gene expression and enzyme activity of CPT-II and ACO in 
isolated hepatocytes of rats fed 150 mg/kg body weight TTA for 10 days (Willumsen et al., 
1997).  Conversely, CPT-II, but not CPT-1, transcript level and associated activity 
increased in hepatocyte mitochondria after chronic treatment of rats with dietary TTA 
(Madsen and Berge, 1999; Madsen et al., 1999).  Both hepatic TAG synthesis rate and 
level are suppressed in rats supplemented with TTA (Berge et al., 2005) and preliminary 
evidence suggests that TTA can also modulate the immune response by acting as an anti-
inflammatory agent in peripheral blood mononuclear cells (Aukrust et al., 2003) and 
patients infected with HIV (Fredriksen et al., 2004)   
Although dietary CLA and TTA share a similar influence on lipid metabolism and 
both induce an anti-inflammatory response, TTA also elicits a number of effects which 
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have not been documented in trials involving CLA.  For example, TTA lowers serum lipid 
levels (Asiedu et al., 1996; Frøyland et al., 1997), increases the flux of plasma free fatty 
acids to the liver ready for catabolism, (Berge et al., 2005) and increases proliferation of 
both peroxisomes and mitochondria (Berge et al., 1989; Bremer, 2001) which are all likely 
to contribute to the overall anti-adipogenic and hypolipidemic effects associated with this 
bioactive fatty acid (Berge et al., 2005).   
The hypolipidemic and anti-inflammatory effect has been speculated to be caused 
by the ability of TTA to activate PPARα (Berge et al., 2001; Dyroy et al., 2005).  Indeed, 
like CLA, TTA is a potent ligand for all three PPAR isoforms (α,β,γ) (Gotticher et al., 
1993; Forman et al., 1996; Berge et al., 1999) in both human and murine cell lines (Berge 
et al., 2001; Westergaard et al., 2001).  Interestingly, mitochondria from TTA-treated rats 
were found to have a lower electrochemical potential and an increased UCP-2 expression 
(Grav et al., 2003) indicative of an enhancement in energy expenditure.  
1.6 General Objectives 
To summarise, there is a considerable body of evidence to suggest TTA and, 
particularly, CLA bestow a wide variety of biological effects in mammals.  These effects 
extend to encompass beneficial alterations in body composition via reduction in body fat 
mass, enhanced growth rate and immune function and anticarcinogenetic properties.  
Nevertheless. it has been evidenced in this chapter that the effects of CLA are variable in 
animals and not fully investigated in fish.   
Prior to this project no published data was available determining the influence of 
dietary CLA in salmonid or marine species. In addition, all of the previous studies on 
freshwater species utilised juvenile fish fed low lipid diets and focussed primarily on 
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potential alterations in growth and fatty acid compositional changes as a consequence of 
CLA supplementation. The potential influence of CLA on lipid metabolism and the 
mechanisms underpinning these effects had only previously been explored in mammals.  
Moreover, no effects of dietary TTA in cultured fish had been recorded prior to 
commencement of this study.   
It is clear that the physiological effects of dietary CLA and TTA described in other 
studies could have the potential for application in aquaculture, particularly in relation to 
issues pertaining to high fat or FO-substituted diets, fish welfare and human health 
benefits. The general hypothesis tested by this project was that CLA and TTA could elicit 
physiological and biochemical effects in fish leading, but not limited, to augmentation of 
growth, reduction in fat deposition and enhancement of fatty acid composition via 
incorporation of these bioactive fatty acids, and increased n-3 HUFA levels in the flesh of 
fish.  Additionally, it was also important to consider the impact of feeding CLA and TTA 
on fish health and welfare considering the reported immunomodulatory effects in other 
animal models.  
In detail, the specific aims of the present project were:- 
 
1. To determine the effects of dietary CLA on growth, biometry, lipid and fatty acid 
metabolism, and selected innate immune function parameters of Atlantic salmon, 
rainbow trout and Atlantic cod. 
2. To investigate the influence of dietary CLA in Atlantic salmon in response to 
dietary lipid level. 
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3. To determine the effects of dietary CLA and TTA on the gene expression of 
proteins and enzymes involved in lipid homeostasis and fatty acid oxidation in 
salmonids. 
4. To develop suitable analytical methods that would allow an accurate 
representation of the effects of dietary CLA and TTA on gene expression and 
fatty acid composition in fish. 
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CHAPTER 2. MATERIALS AND METHODS 
2.1  Materials 
 [1-14C] Palmitoyl CoA (50-55 mCi/mmol) and [methyl-3H] L-carnitine (60-86 
Ci/mmol) were obtained from Amersham Biosciences (Little Chalfont, Bucks, U.K.). [1-
14C]18:3n-3 (50-55 mCi/mmol), was obtained from NEN Brand Radiochemicals (Perkin 
Elmer Life and Analytical Sciences (U.K.) Ltd., Beaconsfield, Buckinghamshire, U.K.). 
Adenosine triphosphate (ATP), aminotriazole, butylated hydroxytoluene (BHT), carnitine, 
coenzyme A, dichlorofluorescein diacetate, dimethylformamide, dithiothreitol, EDTA, 
fatty acid free–bovine serum albumin (FAF-BSA), glutathione, horseradish peroxidase, 
leuco-2, 7-dichlorofluorescein (DCF), magnesium chloride, N-acetylcysteine, NADP, 
nicotinamide, palmitoyl–CoA, potassium chloride, potassium fluoride, silver nitrate, 
sodium dodecyl sulphate (SDS), TriReagent and Triton X-100 were obtained from Sigma 
Chemical Co. (Poole, U.K.). TLC (20 cm × 20 cm × 0.25 mm) and HPTLC (10 cm × 10 
cm × 0.15 mm) plates, precoated with silica gel 60 (without fluorescent indicator) were 
obtained from Merck (Darmstadt, Germany). All solvents were HPLC grade and were 
obtained from Fisher Scientific UK, Loughborough, England.  All compressed gases were 
obtained from the British Oxygen Company (BOC, Glasgow, UK). 
2.2 Experimental Fish and Diet Formulations  
The fish that were used in this project are described in the relevant experimental 
chapters.  The experimental diets were formulated to satisfy the nutritional requirements 
for the species used in each experiment (U.S. National Research Council, 1993), and were 
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formulated and manufactured by Biomar A/S, Brande, Denmark.  The specific dietary 
formulations for each dietary trial are described respectively in the appropriate chapters. 
2.2.1 Determination of Growth Parameters 
Growth parameters were measured using the following formulae. 
Feed Conversion Ratio: 
 
(g)gain  wet weight
(g) intake feed FCR =  
Specific Growth Rate: 
days ofnumber 
)Wln()ln(W
 100 %/day  SGR, o1
−×=  
where Wo and W1 represent initial and final body weight, respectively. 
Thermal Growth Coefficient: 
C)( Temp.days
WW
 1000  TGC o
3
0
3
1
×
−×=  
Hepato-somatic index:  
 HSI = 100 x liver weight x body weight-1 
Viscero-somatic index:  
 VSI = 100 x viscera weight x body weight-1 
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2.3 Lipid Metabolism 
2.3.1 Preparation of Tissue Homogenates and Liver Microsomes 
Portions of tissues (liver, white and red muscle) were weighed and homogenised to 
10 % (w/v) in sucrose buffer, which was 0.25 M sucrose in 40 mM phosphate or HEPES 
buffers pH 7.4 containing 1 mM EDTA, 0.15 M KCl, 40 mM KF and 1 mM N-acetyl 
cysteine. The homogenates were centrifuged at 1880 x g for 10 min at 4˚C, the floating fat 
layer aspirated and the post-nuclear fractions collected, and 100 µl taken for protein 
determination according to Lowry et al. (1951) after incubation with 400 µl of 0.25% (w/v) 
SDS/1M NaOH for 45 min at 60 oC as described in section 2.3.6. The homogenates were 
used directly for assay of fatty acid oxidation, and associated enzyme assays.  To prepare 
microsomes for HUFA synthesis assays, the liver homogenate was centrifuged at 25,000 g 
for 15 min at 4 oC, the floating fat layer removed by aspiration and the remaining 
supernatant centrifuged at 105,000 g for 60 min at 4 oC.  The floating fat layer was 
aspirated and the supernatant decanted.  The pelleted microsomal fraction was resuspended 
in 1 ml of sucrose buffer and 50 µl taken for protein determination as described above.   
 
2.3.2  Determination of HUFA Synthesis  
The assay mixture, in sucrose buffer pH 7.4, contained 5 mM MgCl2, 1.5 mM 
glutathione, 0.5 mM nicotinamide, 1 mM NADH, 100 µM coenzyme A, and 5 mM ATP in 
a total volume of 0.75 ml. Fifty µl of [1-14C]18:3n-3 (0.25 µCi, 5 µM final concentration), 
as a FAF-BSA complex (Ghioni et al., 1997), was added and the reaction initiated by the 
addition of 200 µl of microsomes.  Incubation continued for 1 h at 20 oC and the reaction 
was stopped by the addition of 5 ml of chloroform/methanol (2:1, v/v) containing 0.01% 
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BHT, and total lipid extracted, transmethylated and FAME prepared according to section 
2.3.9. The extracted methyl esters were redissolved in 100 µl isohexane containing 0.01 % 
BHT and applied as 2.5 cm streaks to TLC plates impregnated by spraying with 2 g silver 
nitrate in 20 ml acetonitrile and pre-activated at 110 oC for 30 min.  Plates were fully 
developed in toluene/acetonitrile (95:5, v/v) (Wilson and Sargent, 1992).  Autoradiography 
was performed with Kodak MR2 film for 6 days at room temperature.  Areas of silica 
containing individual PUFA were scraped into scintillation mini-vials containing 2.5 ml of 
scintillation fluid (Ecoscint A, National Diagnostics, Atlanta, Georgia) and radioactivity 
determined in a TRI-CARB 2000CA scintillation counter (United Technologies Packard, 
U.K.).  Results were corrected for counting efficiency and quenching of 14C under exactly 
these conditions.  
2.3.3 Assay of Fatty Acyl Oxidation Activity in Selected Tissues. 
Fatty acyl β-oxidation in selected tissue homogenates was estimated by 
determination of acid-soluble radioactivity as described previously (Frøyland et al., 1996).  
Briefly, 30 µl of liver or red muscle or 300 µl of white muscle homogenate in sucrose 
buffer (prepared as described in section 2.3.1) was added to 250 µl of an assay master mix 
containing 16.5 mM MgCl2, 82.5 mM KCl, 13.2 mM DTT, 6.6 mM ADP, 0.2 mM NAD+, 
0.7 mM EDTA and 1.2 mM carnitine.  The tubes were left at room temperature to 
equilabrate for 2 min. 10 µl of [1-14C]palmitoyl-CoA substrate (0.1 µCi/100 µM) was 
subsequently added and the tubes left to incubate at room temperature for precisely 10 min.  
The reaction was stopped by the addition of 150 µl of 1.5 M KOH and 25 µl FAF-BSA 
(100 mg/ml) added as carrier and to bind any unreacted labelled fatty acyl substrate.  After 
briefly vortexing, 500 µl of ice-cold 4 M HClO4 (perchloric acid) was added to precipitate 
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protein.  The tubes were then centrifuged at 1880 g for 10 min and 500 µl of the resultant 
supernatant was measured for radioactivity as described in section 2.3.2   
2.3.4 Assay of Carnitine Palmitoyl Transferase-I Activity 
CPT-1 activity in tissue homogenates was determined according to the method 
described by Saggerson and Carpenter (1986).  Briefly, 90 µl of an assay master mix 
comprising 100 mM Tris buffer pH 7.4, 5 mg/ml BSA, 1 mM DTT, 4 mM MgCl2, 15 mM 
KCl, 1 mM KCN, 2 mM carnitine and 1 µl 3H-carnitine was added to 10 µl of tissue 
homogenate (prepared previously as described in section 2.3.1).  Five µl of a 100 µM 
palmitoyl-CoA substrate (in sucrose buffer) was then added to initiate the reactions.  After 
15 min at room temperature, the reactions were terminated by the addition of 60 µl of 1 M 
HCl followed by the addition of 500 µl of water-saturated butanol.  The samples were 
vortexed for 30 s and centrifuged for 5 min at 5000 g  in a microfuge to accelerate phase 
separation after which 300 µl of the upper butanol layer was recovered.  The recovered 
phase was back extracted by vigorous mixing with 1 ml of water for 30 s before 
centrifugation was repeated.  One hundred µl of the resultant upper butanol phase was 
transferred to a scintillation mini-vial and radioactivity determined as described in section 
2.3.2.  
2.3.5 Assay of Acyl CoA Oxidase Activity 
The spectrophotometric determination of ACO utilised the method devised by 
Small et al. (1985).  The assay is based on determination of H2O2 production, which is 
coupled to the oxidation of leuco-2, 7-DCF (leuco-DCF) in a reaction catalysed by 
exogenous peroxidase.  Precisely, 1 ml of peroxidase buffer comprising 0.08 mg/ml 
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horseradish peroxidase in 20 mM phosphate buffer pH 7.4, containing 40 mM 
aminotriazole and 0.02% (v/v) Triton X-100, was added to 30 µl of DCF reagent (1.6 mM 
2’,7’ dichlorofluorescein diacetate in NN-dimethylformamide/0.01 M NaOH, 1 : 9 by 
volume), and the appropriate volume of tissue homogenate (50 µl for red muscle and liver, 
500 µl for white muscle), with the final assay volume adjusted to 1.5 ml with 20 mM 
phosphate buffer pH 7.4.  This mixture was preincubated at room temperature in the dark 
for 5 min before being measured spectrophotometrically (RSA Cecil 2021 
spectrophotometer) at an absorbance of 502 nm for 2 min to determine autoxidation rate.  
The reaction was then initiated with the addition of 30 µM palmitoyl-CoA and the 
enzymatic reaction rate was determined.  Rates were then corrected for the substrate blank.  
2.3.6 Protein Determination 
Protein concentration in tissue homogenates or liver microsomes was determined 
according to the method of Lowry et al. (1951) after digestion.  In summary, 400- 450 µl of 
1 M NaOH/0.25 % (w/v) SDS were added to appropriate volumes of tissue homogenates or 
microsome preparations (see section 2.3.1).  Samples were incubated at 60 oC for 45 min in 
a water bath in order for solubilisation of cellular components to occur.  A standard curve 
of 0 – 100 µg protein in increments of 20 µg was prepared by addition of bovine serum 
albumin (1 mg/ml) to individual plastic test tubes and volumes adjusted to 100 µl with 
distilled water.  One percent (w/v) CuSO4 and 2% (w/v) sodium potassium tartrate was 
added to 2% (w/v) Na2CO3 (at a ratio of 1:1:100 respectively), and 2.5 ml of this solution 
was added to standards and samples.  After 15 min incubation at room temperature, 250 µl 
of Folin-Ciocaulteau phenol reagent, diluted 1:1 with water, was added to the standards and 
samples.  After vigorous mixing, the absorbance at a wavelength of 660 nm was read on a 
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spectrometer (RSA Cecil 2021) 30 min later.  Protein concentration (in mg/ml) was 
calculated from the resultant standard curve. 
2.3.7 Total Lipid Extraction and Quantification 
Total lipids of liver, flesh and diet were extracted by homogenisation in 
chloroform/methanol (2:1, v/v) containing 0.01 % (w/v) BHT as an antioxidant, according 
to the method of Folch et al. (1957).  Principally, 1 g of tissue or diet was homogenised 
using an UltraturraxTM tissue disrupter in quickfit boiling tubes (50 ml) with 16 ml of ice-
cold 2:1 chloroform/methanol and left for 1 h on ice.  After incubation, non-lipid impurities 
were removed by the addition of 4 ml aqueous 0.88 % (w/v) KCl and thorough mixing. 
After a further 5 min the tubes were centrifuged (Jouan C312, France) at 400 gave (1500 
rpm) for 2 - 3 min and the resultant upper aqueous phase containing non-lipid impurities 
was drawn off by aspiration and discarded.  The lower organic layer was transferred into a 
clean, pre-weighed 10 ml test tube, through a pre-washed (with chloroform/methanol, 2:1) 
9 cm filter paper (Whatman No.1).  Solvent was evaporated under a stream of oxygen-free 
nitrogen (OFN) on an N-Evap evaporator (Organomation Associates, Inc. USA). The 
weight of lipid was determined gravimetrically after overnight desiccation in vacuo prior to 
reconstitution in chloroform/methanol (2:1) at a concentration of 10 mg/ml and stored 
under nitrogen at -20 oC for future analyses. 
2.3.8 Determination of Lipid Class Composition 
Separation of lipid classes was performed by single-dimension double-development 
high performance thin-layer chromatography (HPTLC).  A 10 x 10 cm HPTLC plate was 
washed and ‘activated’ by fully developing in chloroform/methanol (2:1, v/v) and then 
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drying in an oven at 110 oC for 15 min.  Approximately 20 µg (2 µl of a 10 mg/ml lipid 
solution) of each total lipid sample was applied in 2 mm streaks 1 cm up from the bottom 
of the plate.  Plates were developed up to 5 cm in methyl acetate/isopropanol/ 
chloroform/methanol/0.25% KCl (25:25:25:10:9, by vol).  The plate was then briefly 
desiccated in vacuo prior to being fully developed in isohexane/diethyl ether/acetic acid 
(85:15:1, by vol).  The lipid classes were visualised by charring at 160 oC for 15 min after 
spraying with 3 % (w/v) cupric acetate in 8 % phosphoric acid and quantified by 
densitometry using a Camag 3 TLC Scanner (Camag, Muttenz, Switzerland) and winCATS 
software (Henderson and Tocher, 1987).  The identities of individual lipid classes were 
confirmed by comparison with reference to Rf values of authentic standards run alongside 
samples on HPTLC plates developed in the above solvent solutions.  
2.3.9 Analysis of Fatty Acid Composition 
Total lipids were subjected to acid-catalysed transesterification based on a standard 
method described by Christie (2003).  However, this basic method was modified as 
necessary to take account of problems associated with the quantitative preparation of fatty 
acid methyl esters (FAME) from CLA and TTA.  Thus, FAME were produced under 
conditions specific to each dietary trial, which are specified in the relevant sections of the 
experimental chapters.  Irrespective of the detailed transmethylation procedure, after 
methylation, FAME were extracted using 5ml isohexane/diethyl ether (1:1, v/v) with BHT 
(0.01%) (w/v) and centrifugation at 350-400gave (1500rpm) for 2 min.  The upper organic 
layer was transferred to a clean test tube.  Five ml of isohexane/diethyl ether (1:1, v/v), 
without BHT, was added to the original tube before mixing and centrifuging for a second 
time.  Again the upper organic layer was transferred to the tube containing the organic 
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portion of the previous extraction and the aqueous layer discarded.  Solvent was then 
evaporated under a stream of OFN on an N-Evap and the resultant FAME resuspended in 
100 µl of isohexane.  Methyl esters were purified prior to gas chromatography.  Briefly, 
FAME solutions were applied to 20 x 20 cm TLC plates using microsyringes (Hamilton) 
onto previously marked 1 cm origins and the plates developed using isohexane/diethyl 
ether/acetic acid (90:10:1 v/v) as the developing solvent as described previously (Tocher 
and Harvie, 1988).  After separation, the plate was partially sprayed with 1 % (w/v) iodine 
in chloroform to visualise the FAMEs. The bands were scraped from the TLC plate into 
test tubes using a straight edged scalpel.  FAME were eluted from the silca with 10 ml 
isohexane/diethyl ether (1:1, v/v) containing 0.01 % BHT, then vortexed and centrifuged at 
350-400gave (1500rpm) for 2 min in order to precipitate the silica.  The solvent was 
carefully decanted into a 15 ml glass quickfit tube and evaporated under OFN. The 
recovered FAME were dissolved in an appropriate volume of isohexane containing 0.01 % 
(w/v) BHT to make a 1-2 mg/ml solution of methyl esters. FAME were quantified by gas-
liquid chromatography using a Fisons GC8600 gas chromatograph (Fisons Ltd., Crawley, 
U.K.) equipped with on-column injection and a 60 m x 0.32 mm i.d. wall-coated capillary 
column (CP wax 52CB; Chrompak Ltd., London, U.K). Hydrogen was used as a carrier gas 
and temperature programming was from 50 oC to 150 oC at 40 oC/min and then to 225 oC at 
2 oC/min.  Individual methyl esters were identified by comparison with known standards 
and by reference to published data (Ackman, 1980). Data were collected and processed 
using Chromcard for Windows, Version 1.19 computer package (Thermoquest Italia 
S.p.A., Italy) 
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2.3.10 Whole Body Proximate Composition 
Fish were weighed to determine wet weight of whole fish.  Fish were cut into pieces 
and placed in a pre-weighed dish. Moisture content of whole fish was determined after 
drying in an oven at 80 oC for a minimum of 72 h.  The dishes were allowed to cool in a 
desiccator, reweighed and the dry sample weight determined and hence the percentage 
moisture rate determined by the formula:- 
 
% Moisture = Wet Sample weight (g) – Dried Sample Weight (g) x 100 
    Wet Sample Weight (g) 
 
The dried fish samples were then blended into a homogeneous crumble/meal and 
used for determination of percent protein, lipid and ash content. 
Lipid content of dried fish crumb was determined using the Soxhlet method of 
extraction (Avanti Soxtec 2050 Auto Extraction apparatus; Foss, Warrington, UK).  
Briefly, 1 g of fish crumb was accurately weighed (W1) and placed in an extraction thimble 
along with some glass beads, and the thimble then sealed with cotton wool.  The Soxtec 
extraction unit was switched on and the oil bath heated to 115 oC, the cold water supply to 
the condensers opened and the sample thimbles fixed into the unit.  Approximately 50 ml 
of petroleum ether (Sigma-Aldrich, Surrey, UK) was added to the extraction collection 
cups, which were subsequently attached to the Soxtec apparatus.  The samples were boiled 
for 20 min, then rinsed for 2 h before the solvent was evaporated for 15 min.  The cups 
were removed, dried at 100 oC for 1 h, and cooled in a desiccator before being reweighed 
(W2).  The percentage lipid was thus calculated using the formula:- 
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 % Lipid =  W2 (g) x 100 
  W1 (g) 
 
Protein content was determined in the fish crumble using the automated Kjeldahl 
method (Tecator Kjeltec Auto 1030 Analyser, Foss, Warrington, UK).  Two hundred mg of 
fish crumble was accurately weighed into a digestion tube and 2 mercury kjeltabs with 5 ml 
concentrated sulphuric acid added.  The samples were subsequently digested at 400 oC for 
1 h and then allowed to cool for 20 mins.  Then 20 ml of de-ionised water and 5 ml of 
sodium thiosulphate solution were added to the tubes prior to distillation and titration.  
Fifty mg of urea was used as a positive standard and background titre effects were taken 
into consideration by measuring tubes containing no sample.  Percent protein/nitrogen was 
calculated as follows:- 
 
*%  Nitrogen in the standards = (standard titre – blank titre) x 280.14 
     Standard weight (mg) 
 
**%  Protein in the samples = (sample titre – blank titre) x 1750.875 
     Sample weight (mg) 
 
* Derived from 14.007 (N2) x 0.2 (acid molarity) x 100 (%) 
** Derived from 14.007 x 0.2 x 100 x 6.25 (protein factor) 
 
Percent ash content of samples was determined by placing 1 g of dried crumb into a 
porcelain crucible, which was subsequently heated to 600 oC overnight in a muffle furnace. 
The samples were allowed to cool and then reweighed. Percentage ash composition was 
determined using the formula:- 
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% Ash =  Ash weight (g) x 100  
   Sample weight (g) 
2.4  Basic Haematology and Non-Specific Immune Response Analyses 
2.4.1 Extraction and Preparation of Blood  
Fish were bled by caudal venepuncture using 1 ml syringes pre-coated with lithium 
heparin (2500 U/ml in Leibovitz L-15 medium) with varying needle gauge sizes depending 
on size of fish (Terumo Europe N.V. Belgium).  As much blood as possible was removed 
from the fish before samples were placed into microcentrifuge tubes (ThermoLife Sciences, 
Basingstoke, Hampshire, UK) after collection.  Whole blood samples were stored at 4 oC.  
Plasma was extracted by centrifuging whole blood samples at 7000 rpm for 10 min at 4 oC 
(IEC micromax centrifuge, International Equipment Co. MA, USA).  The plasma 
supernatant was extracted and frozen at -20 oC for further analyses. 
2.4.2 Blood Cell Counts 
From whole blood samples, 10 µl was removed and mixed with 990 µl of 0.2 M 
phosphate buffered saline (PBS,  0.2 M NaH2PO4.2H2O, 0.2 M NaHPO4.1H2O, pH 5.8) 
and a drop of the 1:100 dilution placed on a Neubauer haemocytometer (Hawksley and 
Son, England).  Round and refractile cells were counted as white blood cells (WBC) under 
a phase contrast microscope at 100 x magnification.  The counts were expressed as WBC 
per ml of blood. 
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For red blood cell measurement, 100 µl of the 1:100 dilution prepared previously 
was added to 900 µl of PBS (1:1000 dilution)  Red blood cells (RBC) were then counted as 
described above and quantified per ml of blood. 
2.4.3 Total Packed Cell Volume 
A heparinised 25 µl capillary tube was inserted into the blood sample and the tube 
allowed to fill via capillary action until almost full.  One end of the tube was sealed with 
Critaseal (BDH) and then centrifuged at 800 g using a Hawksley Micro-haematocrit 
centrifuge (Hawksley and Son, England, UK).  The haematocrit was calculated by 
expressing the red blood cell layer as a percentage of the total sample volume. 
2.4.4 Lyzozyme Activity 
Lysozyme activity was measured turbidimetrically using a modified 96 multiwell 
plate method (Peddie et al., 2002).  Lyophilised Micrococcus lysodiekticus was added to 
0.04 M sodium phosphate buffer, pH 5.8 (0.2 M NaH2PO4.2H2O, 0.2 M Na2HPO4.H2O) to 
a concentration of 0.2 mg of bacteria/ml and incubated at 25 oC for 20 min.  To four 
replicate wells of a non-coated 96 multiwell plate (NUNC, BDH), 10 µl of plasma were 
added, with exception to the last column which contained only buffer as a negative control.  
To the plasma samples, 190 µl of bacterial suspension was quickly added to all except 
control well.  After 1 min the sample absorbance was read at 540 nm and again at 5 min, 
using a Dynex MRX II plate reader (Dynex Technologies, USA).  Lysozyme activity was 
expressed as the amount of sample causing a decrease in absorbance of 0.001 min-1 (U 
min/ml). 
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2.4.5 Phagocytosis by Head Kidney Macrophages 
A field technique developed by Crumlish et al. (2000) was utilised in order to 
isolate head kidney macrophages from fish due to the large number of samples required.  
Using aseptic technique, the kidney was dissected and placed on to sterile 100 µm nylon 
mesh.  The kidney sample was then teased through the mesh using the flat end of a sterile 
syringe into 5 ml of Leibovitz-15 medium (L-15, Sigma, Dorset, UK) containing 10 U/ml 
of heparin.  The resulting kidney suspension was then transferred to a sterile bijoux ready 
for analysis. 
Microscope slides were prepared by dipping in ethanol and then 2 wells drawn on 
the slide using a PAP pen (AGAR Scientific).  One hundred µl of kidney suspension was 
then placed onto each well and incubated for 1 h at room temperature to allow the 
macrophages to attach to the slide.  After this time, any non-adhered cells were washed off 
by rinsing with ice-cold L-15 medium.  Fifty µl of a 5 mg/ml yeast (Saccharomyces 
cerevisiae) suspension in L-15 medium were added to one of the wells containing the 
adhered macrophages and after 1-2 hours incubation at room temperature, subsequently 
washed off using L-15 media.  Slides were then fixed with 70 % ethanol and allowed to air 
dry before being stained using Rapi-diff staining kit (Sigma, Dorset, UK).  Slides were 
examined using oil immersion x1000 magnification and the number of yeast particles 
engulfed by 100 macrophages determined.  Phagocytic index (PI), which indicates the 
average number of particles engulfed per macrophage and also phagocytic ratio (PR), 
which is the ratio of phagocytic cells in the population (equation) were measured. 
 
PI =  Total number of ingested particles 
 Total number of macrophages counted 
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PR = No. of macrophages with 1 or more ingested particles x 100 
 Total number of macrophages counted 
2.4.6 Respiratory Burst of Head Kidney Macrophages 
Head kidney macrophages were isolated and prepared as described in section 2.4.5.  
A modified method adapted from Rook et al. (1985) was used to determine respiratory 
burst.  One hundred µl aliquots of head kidney suspension were placed into 8 replicate 
wells of a 96-well microtitre plate (NUNC) and left for 4 - 5 hours at 4 oC to allow the 
macrophages to adhere.  The non-adhered cells were then washed off by rinsing with L-15 
medium. The 96-well plate was divided into three separate sections. One hundred µl of 
1mg/ml nitrobluetetrazolium (NBT) in L-15 medium was added in triplicate to one section 
of the plate.  To separate wells on the same plate, 100 µl of L-15 medium containing 100 µl 
of 1 mg/ml NBT solution and 1 µl/ml of phorbol 12-myristste 13-acetate (PMA, phorbol 
ester) was added in triplicate.  One hundred µl of lysis buffer (0.1 M citric acid, 1 % (v/v) 
Tween 20, 0.05 % (w/v) crystal violet) was added to the remaining two columns of the 
plate.  The plate was then left for 1 h at room temperature after which all wells containing 
the NBT and NBT + PMA had the solution removed and 100 µl of methanol was added 
and incubated for 5 min at room temperature to stop the reaction.  The wells previously 
containing the NBT and NBT + PMA were rinsed three times with 70 % methanol and 
allowed to air dry.  One hundred and twenty µl of dimethylsulphoxide (DMSO) and 140 µl 
of 2 M potassium hydroxide were added to each of the washed wells to dissolve the blue 
formazan residue.  The absorbance of each well was then read at 610 nm (Dynex MRXII 
ELISA plate reader).  The number of attached cells was determined using a Neubeuar 
haemocytometer by counting released nuclei in wells containing lysis buffer.  The 
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absorbance and thus the respiratory burst activity in each well was adjusted to represent 
that from 1 x 104 cells. 
2.5  Gene Expression Analyses 
2.5.1 RNA Extraction 
Approximately 50-100 mg tissue was homogenised with 1 ml of TRIzol® in a 1.5 
ml microcentrufuge tube using an Ultramax TS S8N5G (IKA Labortechnik, Staufen, 
Germany).  The homogenised sample was then incubated at room temperature for 5 min 
before the addition of 200 µl of chloroform (Sigma-Aldrich, Dorset, UK).  The tube was 
then lightly mixed by inversion and then shaken vigorously for 15 s, incubated for a further 
3 min at room temperature and then centrifuged in a refrigerated centrifuge (4 oC) at 12,000 
g for 15 min (Sigma 4K15 centrifuge).  The aqueous phase was transferred to a clean 1.5 
ml microcentrifuge tube and 500 µl of isopropanol (Sigma-Aldrich, Dorset, UK) added in 
order to precipitate the RNA.  The mixture was subsequently incubated for 10 min at room 
temperature after which it was centrifuged at 12,000 g for 10 min at 4 oC.  The resultant 
supernatant was discarded and the pellet washed with 1 ml of 75 % ethanol (v/v).  The 
ethanol was aspirated and the pellet was allowed to air dry until it began to turn transparent 
and thereafter 50-100 µl of ultrapure H2O was added (volume dependant on pellet size) in 
order to resuspend the RNA.  The integrity of the RNA was verified by running a 1.2 % 
agarose gel with 1 x TBE buffer including 10 ng ethidium bromide (see appendix 1) and 
the ratio of absorbances at 260/280 nm determined spectrophotometrically (NanoDrop ND-
1000, Spectrophotometer, Sussex, U.K.).  The RNA solution was then stored at -70 oC for 
further analyses. 
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2.5.2 First Strand cDNA Synthesis 
cDNA was prepared by adding 5 µg (in the case of salmon) or 2 µg (in the case of 
cod and trout) RNA (diluted with ultrapure H2O) to 1 µg Oligo (dT) primer (Promega, 
Madison, WI, USA) in a sterile RNase-free 0.2 ml PCR tube, making a total volume of 14 
µl.  The mixture was then heated to 70 oC for 5 min in a PTC-100 thermocycler PCR 
machine (MJ Research, MA, USA) and then cooled on ice for 5 min.  5 µl of M-MLV 
(molony-murine leukaemia virus) reverse transcriptase (RT) reaction buffer (250 mM Tris-
HCl, pH 8.3, containing 375 mM KCl, 15 mM MgCl2 and 50 mM DTT), (Promega, 
Madison, WI, USA) was added to the mixture together with 1.25 µl of 10 mM dNTP 
(Promega, Madison, WI, USA), 1 µl of 200 U/µl M-MLV RT (H-) and brought to 11 µl 
with ultrapure H2O.  The tube was then mixed gently and incubated at 40 oC for 10 min, 
then 48 oC for 50 min and finally the RT enzyme was inactivated by heating for 15 min at 
70 oC according to the manufacturer’s protocol.  The resultant cDNA was diluted 1 in 5 
with ultrapure H2O and stored at -20 oC for future analyses.  
2.5.3 Preparation of Amplicons 
Sequences of interest (target and reference genes) were selected from the NCBI 
database and appropriate primers were designed for each gene using Primer 3 HTML 
applet.  PCR was performed on cDNA from liver in order to isolate the genes of interest.  
Briefly, the PCR consisted of 10 µl of 2x PCR master mix (50 U/ml Taq Polymerase, 400 
µM dATP, 400 µM dGTP, 400 µM dCTP, 400 µM dTTP, 3 mM MgCl2 (pH 8.5)) and 1 
µl/primer and 3 µl H2O.  The generic PCR reaction procedure consisted of 45 cycles of 15 
s at 95 oC, 15 s at 50 - 60 oC (depending upon gene) and 30 s at 72 oC.  An optimal 
annealing temperature was selected for all genes after temperature gradient analysis. 
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 One µl of the PCR product was visualised on a 1.2 % agarose gel containg 1x TBE 
buffer and 10 ng of ethidium bromide using a UV transilluminator (UVP, San Gabriel, CA, 
USA) in order to verify amplification. The remainder of the PCR product was subsequently 
purified using a GFXTM PCR DNA Purification Kit (Amersham Pharmacia Biotech, 
Buckinghamshire, UK), according to the manufacturers protocol (see appendix 2).   
2.5.4 Production of Recombinant DNA 
A pBluescript II KS (+/-) vector was first linearised at the polycloning site by 
digesting 4.4 µl of 1.1 µg/µl vector with 2 µl EcoR V (20 U/µl) enzyme (NewEngland 
Biolabs., MA, USA), 5 µl of 10X NEB Buffer 3 (100 mM NaCl, 50 mM Tris-HCl, 10 mM 
MgCl2, 1 mM DTT, pH 7.9) (NewEngland Biolabs, MA, USA), 5 µl of 10X BSA 
(NewEngland Biolabs., MA, USA) and the final volume brought to 50 µl with ultrapure 
H2O in a sterile 0.2 ml PCR tube.  The mixture was incubated at 37 oC for 1 h and then 
purified using a GFXTM column (Amersham Pharmacia Biotech, Uppsala, Sweden) (see 
appendix 2). 
TA overhangs were added by incubating 1.25 µl of digested vector with 0.05 µl 
Thermoprime plus polymerase (Abgene, Surrey, UK), 1 µl of the corresponding buffer 
(750 mM Tris-HCl, pH 8.8, containing 200 mM (NH4)2SO4 and 0.1% v/v Tween 20), 0.6 
µl 25 mM of MgCl2, 0.5µl of dTTP’s (5mM) and made up to a total volume of 10 µl with 
ultrapure H2O in a 0.2 ml sterile PCR tube.  The mixture was incubated for 30 - 40 min at 
72 oC and then put on ice to await ligation with PCR product. 
One µl of the previously isolated PCR product (section 2.5.3) was added to a 
ligation mixture consisting of 1.25 µl TA-vector, 1 µl of T4 ligase (Promega, Madison, WI, 
USA), 1µl of 10X ligation buffer (10 mM HCl (pH 7.0), 50 mM KCl, 1 mM DTT, 0.1 mM 
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EDTA and 50 % glycerol) and the final volume brought to 10 µl with ultrapure H2O.  The 
ligation mixture was gently mixed and left at 14 oC overnight in order for the reaction to 
take place.  Ligation of the PCR product to the TA-vector was verified against known 
standards using gel electrophoresis. 
For each transformation, 2 µl of the ligation reaction was added to 50 µl of 
competent TOP10F’ E.coli freshly thawed on ice.  The tubes were mixed gently and then 
incubated on ice for 30 min before being heat shocked at 42 oC for precisely 40 s. The 
tubes were then incubated on ice for a further 2 min after which 250 µl of LB broth 
(appendix I) was added and the tubes shaken horizontally at 37 oC for 1 h at 225 rpm in a 
rotary shaking incubator (Gallenkamp, Loughbourgh, UK).  125 µl of the resultant cell 
suspension was spread onto a Petri dish containing LB agar/X-gal/IPTG/ampicillin 
(appendix I) The plates were inverted and placed in a 37 oC incubator for 48 h 
(Gallenkamp, Loughborough, UK).   
Recombinant (white) colonies were picked from plates and grown overnight in 3 ml 
LB broth containing 50 mg/ml ampicillin  (appendix) at 37 oC in a shaking incubator 
(Gallenkamp, Loughbourgh, UK) before being harvested and the plasmids extracted from 
the cells using the GFXTM miscroplasmid preparation kit (appendix).  The integrity of 
recombinant DNA was determined by adding 1 µl of a 1 in 50 dilution of plasmid to a 0.2 
ml microcentrifuge tube along with PCR reagents and appropriate primers at reaction 
conditions identical to that detailed in section 1.6.3.  The subsequent PCR product was then 
visualised and verified using gel electrophoresis.  The plasmid was linearised using an 
appropriate endonuclease determined using Restriction Mapper software.  One µl of 
endonuclase (type dependent on gene) was added to 31 µl of uncut plasmid DNA together 
with 4 µl of BSA and 4 µl of endonuclease-specific buffer and incubated at 37 oC for 2 h.  
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The digestion was deactivated by heating to 65 oC for 15 min. The cut plasmid was 
visualised once again using gel electrophoresis to verify linearity and to ensure that the 
plasmid had only been cut once.  The recombinant plasmid was then diluted to 1 x 109 
copies/µl and subsequently serially diluted to produce a standard curve of known copy 
number. 
2.5.5 Quantitative Real-Time Polymerase Chain Reaction Analysis 
Measurement of gene expression was carried out using quantitative real-time 
polymerase chain reaction (qPCR) on a Rotor-GeneTM 3000 (Corbett Research, Sydney, 
Australia).  Fifteen µl of a master mix containing 10 µl 10X SYBR-green (Qiagen, 
Crawley, UK), 3 µl of molecular grade water, 1µl (10 pmol) of each primer (forward and 
reverse) was added to a 0.2 ml Rotor-GeneTM tube together with 5 µl of an appropriately 
diluted cDNA sample.   Amplification of cDNA samples was carried out using the 
QuantiTect® SYBR Green PCR Kit (Qiagen, Crawley, UK) with the following conditions: 
15 min at 95 oC to activate the HotStarTaq DNA polymerase, followed by 45 cycles of 15 s 
at 95 oC, 15 s at 56 oC and 30 s at 72 oC, followed by product melting to check purity of 
PCR product. Thermal cycling and fluorescence detection were conducted using the Rotor-
Gene 3000 system (Corbett Research, Cambridge, UK).  Expression of genes was 
normalised and expressed relative to total RNA or selected flat-liner (housekeeping genes) 
as described in detail in the appropriate chapters.  
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CHAPTER 3. INFLUENCE OF DIETARY OIL CONTENT 
AND CLA ON GROWTH AND LIPID DEPOSITION IN 
ATLANTIC SALMON 
3.1 Introduction 
Atlantic salmon is an anadromous fish mainly found in the temperate and Arctic 
regions of the northern hemisphere.  The culture of Atlantic salmon has been practised in 
northern Europe, the North America and Chile since the latter half of the 20th century 
(FAO, 2004) and is presently the most intensively farmed fish in the western world, with 
production in 2004 reaching more than 1.2 million tonnes, estimated to be worth around 4 
billion US$ (FAO, 2007).  This boom in production has helped maintain market supply of 
Atlantic salmon in a climate where wild stocks have been steadily decreasing and, in some 
instances, decimated by over fishing, climatic changes and pollution.  Aside from the many 
environmental concerns voiced by opponents of the aquaculture industry, many believe that 
cultured Atlantic salmon does not provide the same nutritional quality as wild salmon.  
This is partly due to current dietary formulations, which have tended to see an upward 
trend in dietary lipid as the principal source of energy, to enhance protein sparing, improve 
feed conversion and minimise fish waste (Tocher, 2003).  The corollary of maintaining fish 
on high oil level diets is that despite beneficial increases in growth, potentially detrimental 
effects including deposition of excess lipid in tissues, specifically flesh in the case of 
salmon, can reduce nutritional quality (Sargent et al., 2002; Tocher, 2003).  As well as 
dietary lipid levels, lipid deposition can be related to a number of factors including size, 
season and disease (Sargent et al., 2002).  Consequently, it is important to gain a clearer 
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understanding of the physiological mechanisms that control energy metabolism, and 
determine lipid and fatty acid homeostasis in fish.   
As described previously, CLA is a bioactive fatty acid that has been shown to 
bestow several beneficial effects on lipid metabolism in mammals (DeLany and West, 
2000), particularly in relation to body composition (Wang and Jones, 2004).  Specifically, 
CLA decreased body fat and increased lean body mass in mice (Ohnuki et al., 2001; 
Terpstra et al., 2002), rats (Yamasaki et al., 2003) and pigs (Thiel-Cooper et al., 2001; 
Tischendorf et al., 2002).  Decreased body fat has also been observed in human studies 
(Riserus et al., 2001; Smedman and Vessby, 2001; Thom et al., 2001) although the effect 
was much less than that observed with mice (Terpstra, 2004).    CLA is also known to 
affect activity and gene expression of mammalian stearoyl CoA ∆9 desaturase (SCD) (Choi 
et al., 2001, 2002) and may also influence ∆6 and ∆5 desaturases (Chuang et al., 2001a; 
Eder et al., 2002) and fatty acid elongase (Chuang et al., 2001b).  Further studies have 
suggested that CLA may enhance growth and feed efficiency in young rodents although 
this has not been consistently observed (Pariza et al., 2001).   
At the initiation of this studentship, there were no reports in the literature on the 
effects of dietary CLA in salmonids. However, recently, some studies investigating the 
physiological and biochemical influences of dietary CLA on lipid and fatty acid 
metabolism in farmed salmonids have appeared in the literature.  A 12 week study feeding 
Atlantic salmon fry graded levels of CLA up to 2 % of the diet did not increase growth rate 
or influence body proximate composition (Berge et al., 2004).  However, fatty acid 
composition of the fish was strongly affected by dietary CLA such that levels of saturates 
including 14:0, 16:0 and 18:0 were increased while monoenes 16:1 and 18:1 decreased.  In 
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a similar trial with rainbow trout juveniles fed graded levels of CLA up to 2 % of the diet 
over a 12 week period, feed conversion, body composition and growth rates were not 
influenced by dietary treatment (Figueiredo-Silva et al., 2005).  Moreover, hepatic enzyme 
activity of various lipogenic enzymes including malic enzyme and fatty acid synthase were 
also shown to be unaffected in rainbow trout.  A subsequent study performed by the same 
workers using an analogous dosing regime concluded that growth performance, FCR, HSI 
and VSI were unaffected in rainbow trout juveniles fed CLA (Bandarra et al., 2006).  This 
study also found that total monoene levels were decreased while total saturate levels 
significantly increased.  In a very recent study, graded levels of CLA up to and including 1 
% dietary CLA in rainbow trout, reported increased 18:0 and decreased 18:1n-9 levels, but 
there was no influence growth performance, feed conversion, nutrient or energy utilisation 
or body composition (Valente et al., 2007a). Of equal importance was the implication in all 
the aforementioned trials that CLA can be incorporated into the diet without adversely 
impacting fish quality characteristics. 
These other trials studying the effects of dietary CLA in salmonids (although, as 
noted above, none were published at the initiation of the present study) generally used 
small, young fish (fry and juvenile) fed diets with correspondingly low lipid contents. 
However, it would appear obvious that to fully test the possible efficacy of CLA in diets 
for salmonids, fish consuming higher dietary oil levels and at a developmental stage where 
lipid deposition is more likely to occur should be investigated.  Only by matching 
developmental stage of the fish and dietary oil level could a possible protein-sparing effect 
of CLA in salmonids be determined. Therefore, the trial described in the next two chapters 
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was designed to study dietary CLA in salmon smolts in seawater consuming diets with 
much higher lipid contents.  
Therefore, the aim of the present trial was to determine the effects of CLA on lipid 
and fatty acid composition in Atlantic salmon smolts.  The overall objective being to test 
the hypotheses that CLA has beneficial effects in Atlantic salmon including growth 
enhancement, improved flesh quality through decreased adiposity and lipid deposition 
thereby minimising detrimental effects of feeding high fat diets, and increased nutritional 
quality through increased levels of beneficial fatty acids including n-3 HUFA and CLA 
itself.  A further specific aim of this trial was to determine if absolute content of CLA in 
the diet (as percentage of total diet) or the level of CLA relative to other fatty acids in the 
diets were more important in eliciting effects, and thus the diets were specifically 
formulated to test this.  A subsidiary aim of this trial was to determine the minimum period 
required to obtain the maximum amount of CLA deposition in the muscle of Atlantic 
salmon smolts.  In the trial described, salmon smolts were fed diets containing two levels 
of dietary lipid (FO at 17 and 34 %) supplemented with three levels of CLA (0, 1 and 2 % 
of diet) for 3 months and the effects on growth performance, liver and flesh lipid contents 
and fatty acid composition determined.   
3.2 Materials and Methods 
3.2.1 Experimental Fish 
Photoperiod manipulated Atlantic salmon (Salmo salar  L.) smolts (S1/2) were 
obtained from a commercial salmonid farm (Howietoun Fish Farm, Sauchieburn, Scotland) 
in late October 2003 and transported to the Machrihanish Marine Environmental Research 
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Laboratory, Machrihanish, Scotland.  The fish were maintained in stock tanks for 3 weeks 
at ambient temperature of 10 - 11 oC to acclimatise during which time the fish were fed 
standard salmon diet, before being randomly distributed between eighteen indoor, round, 
conical tanks of 1.5 m3 volume (1.72 m diameter).  The initial stocking density was 100 
fish of average fish weight 87.5 ± 1.6 g per tank (5.8 kg/m3).  Water temperature was 
maintained at 11 oC (± 1 oC) throughout the trial, with a light regime of 12L:12D.   
3.2.2 Experimental Diets 
Salmon were fed diets formulated in order to satisfy the nutritional requirements of 
salmonid fish (U.S National Research Council, 1993) and were manufactured by BioMar 
Ltd, Brande, Denmark.  Dietary formulations and proximate compositions are given in 
Table 3.1. 
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Table 3.1Formulations (percentage of dry ingredients) and proximate compositions 
(percentage of total diet) of experimental diets 
 
 
Results for proximate compositions are means ± SD (n=3). Micronutrients, incl. essential 
amino acids (methionine and lysine), vitamins, minerals and astaxanthin (Carophyll 
pink®), BioMar A/S, Brande, Denmark. H0, H1, H2, diets containing FO at 34 % and 
supplemented with 0 %, 1 % and 2 % CLA; L0, L1 and L2, diets containing FO at 17 % 
and supplemented with 0 %, 1 % and 2 % CLA. 
 
The trial had a 3 x 2 factorial design with CLA added at three concentrations to 
diets with two oil contents (low and high).  Thus diets were produced with 0, 1 and 2 % 
CLA replacing standard northern hemisphere FO in smolt feeds containing either 17 or 34 
% total lipid.  The diets were thus formulated to investigate whether effects of CLA were 
more dependent upon absolute content of CLA in the diet (as percentage of total diet) or 
the relative level of CLA to other fatty acids. Diets were formulated to be isonitrogenous 
and so protein content was constant between diets of different oil content (Table 3.1).  
Component 
Fishmeal 
Sunflower meal 
Corn Gluten 
Legume seeds 
Cereal grains 
Micronutrients 
FO 
CLA 
Moisture 8.0 ± 0.3 8.7 ± 0.1 8.9 ± 0.1 3.1 ± 0.1 4.2 ± 0.4 4.4 ± 0.1
Lipid 18.2 ± 0.3 17.4 ± 0.1 16.4 ± 0.5 33.2 ± 0.6 32.4 ± 1.2 32.6 ± 1.6
Protein 44.8 ± 0.1 44.8 ± 0.2 45.8 ± 0.5 47.0 ± 0.3 47.0 ± 0.3 47.0 ± 0.3
Ash 7.8 ± 0.1 7.8 ± 0.1 7.9 ± 0.1 8.2 ± 0.1 8.1 ± 0.0 8.0 ± 0.0
1.7 3.4
2 2
25.3 23.6
9 9
0 0
4 4
8 8
H1 H2
50 50
0 1.7 3.4
23
27
0
10 
3 
11 
010 10
3
9.3 7.6
5044 44
15 415
8 8
99 9
8
44 
15 
8 
9 
L0 L1 L2 H0
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Diets within the low or high oil groups were identical in formulation other than fatty acid 
composition with CLA (LUTA-CLATM 60, containing 60 % CLA methyl esters as a 50:50 
mixture of c9t11 and t10c12 isomers; BASF AG, Ludwigshafen, Germany) balanced by 
FO (capelin oil, Norsemeal Ltd., London, UK). The fatty acid compositions of the diets are 
presented in Table 3.2.  
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Table 3.2. Fatty acid composition (percentage of weight) of experimental diets containing 
CLA fed to Atlantic salmon 
14:0 5.6 ± 0.2 4.7 ± 0.1 4.3 ± 0.3 6.8 ± 0.3 6.0 ± 0.2 5.8 ± 0.1
16:0 19.6 ± 0.5 18.1 ± 0.7 18.2 ± 0.7 19.9 ± 0.2 19.2 ± 0.2 19.2 ± 0.3
18:0 4.5 ± 0.2 4.5 ± 0.1 5.0 ± 0.4 4.3 ± 0.0 4.4 ± 0.1 4.6 ± 0.1
Total saturated1 30.7 ± 1.0 28.6 ± 1.1 28.9 ± 1.4 31.9 ± 0.4 30.6 ± 0.7 31.0 ± 0.8
16:1n-72 6.7 ± 0.1 5.7 ± 0.2 5.3 ± 0.5 7.5 ± 0.1 6.9 ± 0.1 6.7 ± 0.1
18:1n-9 13.4 ± 0.2 15.1 ± 0.2 17.7 ± 0.6 12.0 ± 0.2 13.1 ± 0.1 14.2 ± 0.0
18:1n-7 2.9 ± 0.1 2.6 ± 0.0 2.5 ± 0.1 3.0 ± 0.1 2.9 ± 0.1 2.9 ± 0.2
20:1n-93 3.0 ± 0.1 2.9 ± 0.3 2.5 ± 0.1 3.2 ± 0.1 2.8 ± 0.0 2.9 ± 0.0
22:1n-114 3.4 ± 0.0 3.1 ± 0.0 2.4 ± 0.1 3.2 ± 0.0 2.9 ± 0.0 2.7 ± 0.0
24:1n-9 0.7 ± 0.1 0.7 ± 0.0 0.6 ± 0.0 0.8 ± 0.0 0.7 ± 0.0 0.7 ± 0.0
Total monoenes 30.1 ± 0.7 30.0 ± 0.7 31.0 ± 0.9 29.8 ± 0.6 29.3 ± 0.4 30.2 ± 0.5
18:2n-6 6.4 ± 0.2 6.6 ± 0.1 6.8 ± 0.2 3.1 ± 0.1 3.3 ± 0.0 3.2 ± 0.0
20:4n-6 0.9 ± 0.0 0.8 ± 0.0 0.7 ± 0.0 1.0 ± 0.1 0.9 ± 0.0 0.8 ± 0.0
CLA (9c,11t) 0.0 ± 0.0 2.9 ± 0.5 4.8 ± 1.6 0.0 ± 0.0 1.6 ± 0.2 2.9 ± 0.7
CLA (10t,12c) 0.0 ± 0.0 3.0 ± 0.4 4.6 ± 1.7 0.0 ± 0.0 1.7 ± 0.4 2.9 ± 0.8
Total n-6 PUFA5 8.4 ± 0.1 8.2 ± 0.1 8.2 ± 0.2 5.1 ± 0.1 4.2 ± 0.0 4.0 ± 0.0
18:3n-3 1.2 ± 0.0 1.1 ± 0.0 1.0 ± 0.0 1.2 ± 0.0 1.2 ± 0.0 1.1 ± 0.0
18:4n-3 2.5 ± 0.1 2.1 ± 0.0 1.8 ± 0.0 2.7 ± 0.0 2.6 ± 0.0 2.3 ± 0.0
20:4n-3 0.7 ± 0.0 0.6 ± 0.0 0.5 ± 0.0 0.8 ± 0.0 0.8 ± 0.0 0.7 ± 0.0
20:5n-3 11.8 ± 0.7 10.2 ± 0.2 8.4 ± 0.5 13.6 ± 0.1 13.0 ± 0.1 11.5 ± 0.1
22:5n-3 1.8 ± 0.1 1.6 ± 0.0 1.3 ± 0.1 2.0 ± 0.0 1.9 ± 0.0 1.7 ± 0.0
22:6n-3 12.7 ± 0.9 11.5 ± 0.5 9.5 ± 0.1 12.9 ± 0.0 12.4 ± 0.2 10.9 ± 0.1
Total n-3 PUFA6 30.8 ± 1.8 27.3 ± 0.8 22.6 ± 0.7 33.2 ± 0.3 31.8 ± 0.4 28.2 ± 0.2
H1 H2L0 L1 L2 H0
 
Values are means ± SD of 3 samples. 1, contains 15:0, 20:0 and 22:0, present in some samples at up 
to 0.6 %; 2contains n-9 isomer; 3 contains n-7 isomer; 4, contains n-9 isomer; 5, totals include 18:3n-
6, 20:2n-6 and 22:5n-6 present in some samples at up to 0.4 %; 6, contains 20:3n-3 present at up to 
0.2 %.  H0, H1 and H2, diets containing FO at 34 % and supplemented with 0, 1 and 2 % CLA; L0, 
L1 and L2, diets containing FO at 17 % and supplemented with 0, 1 and 2 % CLA. 
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3.2.3 Sampling and Analyses 
At the initiation and termination of the trial, all the fish in each tank were 
anaesthetised with benzocaine (50 mg/L), and bulk weighed.  At termination, 24 fish per 
dietary treatment (8/tank) were individually weighed and sampled for analyses, with 6 
whole fish (2/tank) frozen immediately on dry ice for whole body compositional 
(proximate) analyses as described in section 2.3.10. The remaining sampled fish were 
eviscerated and used for biometric determinations (hepato-, and viscero-somatic indices) 
(see section 2.2.1) and for tissue lipid analyses.  Flesh samples (Norwegian quality cut) and 
livers were taken from each fish, pooled in six samples of 3 fish each, and frozen 
immediately in liquid nitrogen (livers) or dry ice (flesh).  All samples were subsequently 
stored at –20 oC prior to analyses.  Six fish per treatment (2/tank) were also collected after 
1 and 2 months for tissue lipid analyses.  
3.2.4 Analyses and Transmethylation Procedure 
Total lipids of liver, muscle and diet were extracted and quantified as described in 
section 2.3.7.  Lipid class analysis was carried out as detailed in section 2.3.8.  
There has been debate as to which methylation procedure is ideal for producing 
FAME in lipid samples containing CLA.  It has been suggested that base-catalysed 
tranesterfication using sodium methoxide is favourable over acid catalysis since the former 
does not produce allylic methoxy artefacts or isomerisation of CLA, which has been 
evidenced in the latter (Krammer et al., 1997).  More recently, methylation with boron 
triflouride has been shown to efficiently methylate the free fatty acid form of CLA by 
completely supressing artificial isomerisation (Igarashi, et al., 2004).  However, it is known 
that the majority of lipid in tissue is esterified, either stored as TAG or as membrane PL, 
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and therefore samples must initially be saponified before methylation can take place with 
boron trifluoride, incurring more time in sample preparation.  This may become crucial 
particularly when high throughput analysis is required.  In addition, impurities or artefacts 
in gas chromatograms have been detected as a result of both sodium methoxide and boron 
triflouride-catalysed methylation of CLA (Park et al., 2001).  Indeed, it has been conceded 
that no single method or combination of methods could adequately prepare FAME for all 
lipid classes within a sample (Krammer et al., 1997).  In this study investigating only CLA 
(not TTA), acid-catalysed transesterification, essentially as routinely utilised in this 
laboratory was employed for preparing FAME from diets and tissue total lipid.  Thus, 
FAME were prepared from total lipid by incubating at 50 oC overnight in the presence of 2 
ml 1 % (v/v) H2SO4 in methanol together with 1 ml of toluene under nitrogen essentially as 
described by Christie (2003).  FAME were subsequently extracted, purified and quantified 
as described in section 2.3.8. The fatty acid compositions obtained for the experimental 
diets justifies the chosen methodology since the amount of CLA as a percentage of the total 
diet was accurately reflected in values of CLA obtained in the FAME as a percentage of 
total fatty acid.  It was also noteworthy that the data in Table 3.2 showed a 1:1 ratio of 
c9t11 and t10c12 CLA, concurring with the manufacturers formulation and thus suggesting 
that little to no isomersation had taken place. 
3.2.5 Statistical Analysis 
All data presented are as means ± SD (n value as stated). The effects of dietary 
CLA and oil content and any interaction thereof were determined by two-way analysis of 
variance (ANOVA) with Bonferroni post-tests to determine significance of differences 
(Prism 3, Graphpad Software, Inc., San Diego, USA).  Percentage data and data that were 
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identified as non-homogenous were subjected to arcsine transformation before analysis.  
Differences were regarded as significant when P < 0.05 (Zar, 1984). 
3.3 Results 
3.3.1 Diets 
There was no significant difference in the proximate composition of the 
experimental diets (Table 3.1).  Inclusion of CLA in the low oil diets resulted in levels of 
total CLA of 5.9 % and 9.5 % of total fatty acids at the 1 % and 2 % inclusion levels, 
respectively (Table 3.2).  The high oil diets reduced the amount of total CLA at the 1 % 
and 2 % inclusion levels, to 3.3 % and 5.8 % of total fatty acids, respectively. The levels of 
CLA in relative terms were identical in the L1 and H2 diets with an overall rank order for 
CLA content of L2 > L1 = H2 > H1 > L0/H0. 
3.3.2 Growth and Biometry 
There were no effects of diet on growth parameters, with no significant effects of 
CLA or oil content on final weights, specific growth rates (SGR) or feed efficiency as 
measured by feed conversion ratio (FCR) (Table 3.3).  Both the viscero-somatic (VSI) and 
hepato-somatic (HSI) indices were significantly increased in fish fed high fat diets, 
however dietary CLA had no effect on these parameters (Table 3.3).   
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Table 3.3 Growth and biometric parameters for Atlantic salmon fed the experimental diets for 3 months 
ANOVA
CLA Oil Interact
Initial weight (g)1 87.80 ± 1.50 87.4 ± 0.5 87.9 ± 1.5 85.5 ± 1.5 89.3 ± 0.9 86.9 ± 0.6 0.1301 0.4740 0.0506
Final weight (g)1 203.2 ± 7.10 199.7 ± 1.8 195.1 ± 12.3 196.1 ± 4.7 201.0 ± 10.1 199.5 ± 1.8 0.7631 0.8964 0.4108
SGR2 1.02 ± 0.10 1.01 ± 0.01 0.97 ± 0.05 1.01 ± 0.05 0.99 ± 0.05 1.01 ± 0.02 0.6236 0.8749 0.4712
FCR2 1.24 ± 0.10 1.26 ± 0.03 1.32 ± 0.13 1.27 ± 0.07 1.29 ± 0.10 1.28 ± 0.03 0.6547 0.8681 0.7100
VSI4 9.20 ± 0.61 9.20 ± 0.80 9.42 ± 0.43 10.87 ± 0.33 10.66 ± 0.52 10.63 ± 0.48 0.9356 0.0001 0.7722
HSI4 1.09 ± 0.09 1.12 ± 0.09 1.11 ± 0.06 1.13 ± 0.05 1.20 ± 0.03 1.2 ± 0.02 0.3543 0.0372 0.7742
H2L0 L1 L2 H0 H1
 
Data are presented as means ± SD (n=3). FCR= feed conversion ratio; HSI = hepato-somatic index; SGR = specific growth rate; VSI = 
viscero-somatic index; L0, L1 and L2, low lipid diets with 0 %, 1 % and 2 % CLA; H0, H1 and H2, high lipid diets with 0 %, 1 % and 2 % 
CLA. Significance (P values) of effects of CLA, oil content and their interaction were determined by two-way ANOVA as described in the 
Materials and methods. 
 
Chapter 3  
 65
3.3.3 Whole Body Proximate Compositions 
Whole body proximate composition was analysed at 1, 2 and 3 (end point) months 
post trial initiation.  Whole body proximate composition of the fish was unaffected by CLA 
content at both 1 and 2 % inclusion levels at all time points analysed.  Oil content 
significantly affected the proximate composition of the fish at all time points, with high oil 
diets significantly increasing whole body lipid levels and, as such, decreasing the protein, 
moisture and ash contents  (Tables 3.4 - 3.6) 
Table 3.4 Proximate composition of Atlantic salmon after 1 month of dietary treatment. 
Diet
L0 70.9 ± 1.5 61.1 ± 1.5 29.6 ± 1.6 7.3 ± 0.2
L1 71.2 ± 0.9 62.5 ± 1.4 29.8 ± 1.0 7.5 ± 0.4
L2 70.9 ± 1.1 60.1 ± 2.3 29.3 ± 1.8 7.6 ± 0.5
H0 69.6 ± 1.0 56.8 ± 1.7 33.8 ± 1.3 7.1 ± 0.2
H1 69.8 ± 1.2 56.3 ± 1.7 34.0 ± 2.3 7.1 ± 0.3
H2 69.0 ± 2.2 55.3 ± 3.9 34.3 ± 3.8 7.4 ± 0.6
ANOVA
CLA
Oil
Interact.
0.7931
0.0371
0.9231 0.5701 0.8733
0.0303<0.0001 <0.0001
Moisture Protein Lipid Ash
0.27700.1775 0.9748
0.8267
 
Values are means ± SD of 12 fish. Significance (P values) of effects of CLA, 
oil content and their interaction were determined by two-way ANOVA as 
described in the Materials and methods. H0, H1 and H2, diets containing FO at 
34 % and supplemented with 0 %, 1 % and 2 % CLA; L0, L1 and L2, diets 
containing FO at 17 % and supplemented with 0 %, 1 % and 2 % CLA. 
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Table 3.5 Proximate composition of whole Atlantic salmon after 2 months of 
dietary treatment  
Diet
L0 71.4 ± 1.3 61.3 ± 3.7 28.7 ± 2.7 7.4 ± 0.2
L1 71.2 ± 0.7 60.7 ± 3.7 29.4 ± 1.5 7.3 ± 0.3
L2 70.7 ± 0.5 59.7 ± 1.6 31.8 ± 1.5 7.4 ± 0.4
H0 69.4 ± 0.2 53.7 ± 1.1 36.2 ± 1.1 6.8 ± 0.6
H1 69.4 ± 0.8 54.7 ± 2.4 36.4 ± 1.6 7.2 ± 0.7
H2 69.1 ± 1.7 54.5 ± 1.0 35.7 ± 2.0 7.1 ± 0.9
ANOVA
CLA
Oil
Interact.
0.8646
<0.0001
0.3824 0.56350.9420 0.0430
0.0024 <0.0001
0.76000.6663 0.2178
0.0896
Moisture Protein Lipid Ash
 
Values are means ± SD of 12 fish. Significance (P values) of effects of 
CLA, oil content and their interaction were determined by two-way 
ANOVA as described in the Materials and methods. H0, H1 and H2, 
diets containing FO at 34 % and supplemented with 0 %, 1 % and 2 % 
CLA; L0, L1 and L2, diets containing FO at 17 % and supplemented 
with 0 %, 1 % and 2 % CLA. 
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Table 3.6 Proximate composition of whole Atlantic salmon after 3 months of 
dietary treatment (end of trial). 
Diet
L0 69.8 ± 1.1 61.2 ± 2.0 29.7 ± 3.1 7.3 ± 0.6 2.06 ± 0.20
L1 70.0 ± 0.6 62.1 ± 2.1 29.4 ± 1.9 7.3 ± 0.7 2.11 ± 0.16
L2 69.9 ± 1.1 61.5 ± 1.7 29.4 ± 2.7 7.2 ± 0.7 2.09 ± 0.17
H0 68.1 ± 0.9 54.9 ± 1.7 35.1 ± 2.1 6.4 ± 0.6 1.56 ± 0.15
H2 68.0 ± 1.3 54.0 ± 1.8 37.3 ± 2.2 6.7 ± 0.9 1.45 ± 0.16
H3 67.5 ± 0.7 53.4 ± 1.4 37.8 ± 1.3 5.9 ± 0.5 1.41 ± 0.11
ANOVA
CLA
Oil
Interact.
<0.0001
0.4674 0.1428 0.0589 0.2215 0.1118
<0.0001 <0.0001 <0.0001 <0.0001
0.5281 0.4150 0.1676 0.0799 0.4372
P:L ratioMoisture Protein Lipid Ash
 
Values are means ± SD of 12 fish. Significance (P values) of effects of CLA, oil content 
and their interaction were determined by two-way ANOVA as described in the Materials 
and methods. P:L, protein:lipid ratio; H0, H1 and H2, diets containing FO at 34 % and 
supplemented with 0 %, 1 % and 2 % CLA; L0, L1 and L2, diets containing FO at 17 % 
and supplemented with 0 %, 1 % and 2 % CLA. 
 
3.3.4 Lipid Contents and Class Compositions of Liver and Flesh 
 
Neither CLA nor dietary oil content influenced lipid class composition in liver (Table 3.7) 
or muscle (Table 3.8) after 1 month of dietary treatment.  However, total neutral lipid and, 
particularly, TAG levels, increased over time in both liver (Table 3.9) and muscle (Table 
3.10) in fish fed the high fat diets in comparison with fish fed the low fat diets.  These 
changes in TAG, and total neutral lipids reached statistical significance after 2 months of 
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dietary treatment (Table 3.9 & 3.10).  Similarly, after 3 months, liver and flesh (muscle) 
lipid contents were significantly increased in fish fed the diets containing the higher oil 
content (Tables 3.11 & 3.12).  The increased lipid contents in fish fed the high oil diets 
were reflected in increased proportions of TAG and total neutral lipids in both the liver 
(Table 3.11) and flesh (Table 3.12).  Dietary CLA also had an effect on the lipid content of 
liver and flesh with increasing CLA leading to increased lipid content (Table 3.11).  This 
effect was more pronounced in fish fed the high oil diets and was significant in the case of 
flesh although it was just short of statistical significance in the liver (Table 3.11).  The 
increased lipid content in the liver in response to dietary CLA was also reflected in 
increased proportions of TAG and total neutral lipids particularly in the high oil diets.  
Similarly, increased lipid contents in the flesh in response to dietary CLA were reflected in 
increased proportions of TAG and total neutral lipids (Table 3.12).  The effects of CLA and 
oil content on liver and flesh lipid contents and class compositions as described above were 
statistically significant except for TAG levels in the liver (Table 3.11).  
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Table 3.7 Lipid content (percentage of tissue wet weight) and class composition (percentage of total lipid) of liver of Atlantic 
salmon fed CLA for 1 month. 
Lipid Content 3.4 ± 0.4 3.4 ± 0.6 3.7 ± 0.1 3.8 ± 0.4 3.8 ± 0.4 4.3 ± 1.5
PC 27.0 ± 0.4 27.6 ± 1.3 27.2 ± 0.7 25.5 ± 1.2 23.9 ± 1.1 26.2 ± 2.2
PE 15.5 ± 0.3 16.2 ± 0.4 16.0 ± 0.6 16.4 ± 0.3 15.8 ± 1.0 16.0 ± 0.6
PS 3.7 ± 0.3 3.9 ± 0.4 3.8 ± 0.4 3.6 ± 0.3 3.9 ± 0.6 3.7 ± 0.2
PI 5.5 ± 0.3 5.7 ± 0.9 5.6 ± 0.8 5.8 ± 0.9 5.3 ± 0.3 6.0 ± 0.5
PG/CL 3.7 ± 0.0 3.9 ± 0.1 3.6 ± 0.1 3.3 ± 1.0 3.5 ± 0.2 3.2 ± 0.9
Sphingomyelin 3.9 ± 0.4 3.9 ± 0.5 4.3 ± 0.3 3.0 ± 0.5 4.0 ± 1.0 3.2 ± 0.3
Lyso-PC 1.8 ± 0.3 1.7 ± 0.4 1.9 ± 0.4 2.1 ± 0.3 2.4 ± 0.4 1.9 ± 0.0
Total Polar 61.2 ± 1.4 63.0 ± 2.5 62.4 ± 0.8 59.8 ± 1.4 58.8 ± 1.6 60.2 ± 3.8
Total Neutral 38.8 ± 1.4 37.0 ± 2.5 37.6 ± 0.8 40.2 ± 1.4 41.2 ± 1.6 39.8 ± 3.8
Cholesterol 17.1 ± 0.9 17.1 ± 0.3 16.6 ± 0.2 16.9 ± 0.6 17.7 ± 1.0 16.8 ± 2.1
Triacylglycerol 15.9 ± 1.9 14.4 ± 0.7 14.1 ± 0.3 17.9 ± 1.4 18.5 ± 1.3 16.1 ± 0.7
Free fatty acid 5.8 ± 1.3 5.6 ± 2.7 6.9 ± 0.9 5.4 ± 0.6 4.9 ± 1.2 7.0 ± 5.2
Steryl ester -tr tr - -tr tr tr tr
0.0529 0.0004 0.2444
0.4928 0.7852 0.9628
0.8158 0.0249 0.5284
0.5338 0.6953 0.8099
0.7334 0.0544 0.2271
0.8158 0.0249 0.5284
0.6484 0.1544 1.0000
0.3242 0.032 0.1751
0.5477 0.7214 0.9673
0.7454 0.7568 0.5465
0.4608 0.005 0.1935
0.9856 0.5575 0.1866
0.5546 0.1936 0.9621
CLA Oil Interact.
H1 H2 ANOVAL0 L1 L2 H0
 
Values are means ± SD of 6 samples. CL, cardiolipin; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PG, 
phosphatidylglycerol; PI, phosphatidylinositol; PS, phosphatidylserine; tr, trace < 0.5%. 
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Table 3.8 Lipid content (percentage of tissue wet weight) and class composition (percentage of total lipid) of flesh of Atlantic 
salmon fed CLA for 1 month. 
Lipid Content 3.5 ± 0.9 2.1 ± 0.9 3.8 ± 0.7 3.2 ± 1.3 2.8 ± 0.3 3.6 ± 1.1
PC 12.6 ± 2.6 14.3 ± 1.7 11.4 ± 2.3 12.3 ± 3.5 14.0 ± 1.7 12.3 ± 1.1
PE 8.8 ± 1.0 9.9 ± 1.7 7.9 ± 1.8 7.9 ± 2.0 9.3 ± 0.8 7.4 ± 1.3
PS 0.9 ± 0.2 1.2 ± 0.5 0.6 ± 0.2 0.7 ± 0.3 0.7 ± 0.1 0.6 ± 0.3
PI 2.5 ± 0.3 3.0 ± 0.5 2.2 ± 0.6 2.2 ± 0.8 2.3 ± 0.2 1.8 ± 0.5
PG/CL 2.2 ± 0.0 2.2 ± 0.2 2.0 ± 0.1 1.9 ± 0.5 2.1 ± 0.3 1.6 ± 0.3
Sphingomyelin 0.9 ± 0.3 1.2 ± 0.2 0.7 ± 0.2 0.6 ± 0.3 0.7 ± 0.1 0.6 ± 0.2
Lyso-PC 0.5 ± 0.2 1.0 ± 0.4 0.5 ± 0.2 0.6 ± 0.5 0.4 ± 0.0 0.4 ± 0.1
Total Polar 28.3 ± 4.3 32.8 ± 4.7 25.3 ± 5.2 26.1 ± 7.6 29.5 ± 2.4 24.7 ± 3.4
Total Neutral 71.7 ± 4.3 67.2 ± 4.7 74.7 ± 5.2 73.9 ± 7.6 70.5 ± 2.4 75.3 ± 3.4
Cholesterol 10.7 ± 1.0 11.6 ± 1.5 10.1 ± 0.8 9.8 ± 0.7 10.4 ± 0.3 9.2 ± 1.2
Triacylglycerol 55.1 ± 5.9 48.5 ± 8.8 58 ± 4.6 58 ± 7.8 54.1 ± 3.1 60.8 ± 6.6
Free fatty acid 5.9 ± 1.2 7.0 ± 2.6 6.7 ± 1.1 5.8 ± 0.7 6.0 ± 0.6 5.3 ± 2.3
0.0480
0.7692
0.1404 0.8642
0.2937 0.7778
0.1282 0.3938 0.8912
0.1014 0.0538 0.9555
0.3521 0.1674 0.1386
0.1282 0.3938 0.8912
0.1293 0.0687 0.6555
0.1069 0.0161 0.3459
0.1610 0.1185 0.3654
0.1389 0.0818 0.7909
0.2351 0.9275 0.8724
0.1145 0.3637 0.9715
0.0917 0.8806 0.5988
CLA Oil Interact.
H1 H2 ANOVAL0 L1 L2 H0
 
Values are means ± SD of 6 samples. CL, cardiolipin; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PG, 
phosphatidylglycerol; PI, phosphatidylinositol; PS, phosphatidylserine.  
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Table 3.9 Lipid content (percentage of tissue wet weight) and class composition (percentage of total lipid) of liver of Atlantic 
salmon fed CLA for 2 months. 
Lipid Content 3.5 ± 0.3 3.6 ± 0.1 3.3 ± 0.3 3.3 ± 0.2 3.7 ± 0.3 3.7 ± 0.5
PC 26.8 ± 1.2 24.9 ± 2.4 24.9 ± 1.1 26.1 ± 0.6 23.4 ± 0.7 25.3 ± 0.2
PE 16.2 ± 0.7 16.0 ± 0.9 15.2 ± 0.7 16.5 ± 1.3 13.7 ± 0.0 16.0 ± 0.7
PS 3.7 ± 0.1 3.7 ± 0.7 3.9 ± 0.7 4.1 ± 0.3 2.9 ± 0.3 4.0 ± 0.3
PI 5.8 ± 0.5 5.8 ± 0.6 5.4 ± 2.0 6.0 ± 0.9 4.5 ± 0.7 5.4 ± 0.9
PG/CL 3.8 ± 0.6 3.6 ± 0.2 3.9 ± 1.8 4.3 ± 0.8 3.0 ± 0.3 3.8 ± 0.3
Sphingomyelin 3.8 ± 0.8 3.2 ± 0.9 4.2 ± 1.1 4.0 ± 1.0 2.6 ± 0.0 3.9 ± 0.5
Lyso-PC 1.3 ± 0.2 1.3 ± 0.4 1.5 ± 0.8 1.5 ± 0.3 1.6 ± 0.8 1.6 ± 0.2
Total Polar 61.5 ± 1.6 58.5 ± 4.7 58.8 ± 8.3 62.5 ± 4.2 51.7 ± 0.7 60.0 ± 2.3
Total Neutral 38.5 ± 1.6 41.5 ± 4.7 41.2 ± 8.3 37.5 ± 4.2 48.3 ± 0.7 40.0 ± 2.3
Cholesterol 17.6 ± 1.8 17.3 ± 3.0 16.8 ± 2.9 17.2 ± 2.0 16.4 ± 0.7 17.8 ± 1.6
Triacylglycerol 14.2 ± 0.8 13.4 ± 2.6 14.3 ± 1.3 14.5 ± 2.2 15.5 ± 2.0 15.3 ± 2.9
Free fatty acid 6.7 ± 0.8 10.7 ± 9.3 10.0 ± 4.2 5.8 ± 0.9 16.4 ± 3.4 6.8 ± 2.2
Steryl ester tr tr tr tr tr tr
0.0547 0.4755 0.2418
- - -
0.9270 0.2736 0.7596
0.0426 0.8061 0.2470
0.0547 0.4755 0.2418
0.8954 0.9230 0.7355
0.0597 0.5512 0.6944
0.8789 0.4287 0.9459
0.4798 0.4765 0.4367
0.3301 0.8724 0.5583
0.0136
0.0547 0.6517 0.1014
Oil Interact.
0.5044 0.2793
0.3268 0.4397
CLA
0.3966
0.0240
H1 ANOVA
0.0249 0.3174
H2L0 L2 H0L1
 
Values are means ± SD of 6 samples. CL, cardiolipin; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PG, 
phosphatidylglycerol; PI, phosphatidylinositol; PS, phosphatidylserine. tr, trace < 0.5%. 
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Table 3.10 Lipid content (percentage of tissue wet weight) and class composition (percentage of total lipid) of flesh of Atlantic 
salmon fed CLA for 2 months 
Lipid Content 3.9 ± 0.2 4.5 ± 0.0 8.1 ± 1.9 5.2 ± 0.7 6.2 ± 0.7 7.3 ± 0.9
PC 12.0 ± 0.1 11.3 ± 0.0 8.9 ± 1.7 10.9 ± 1.8 10.0 ± 0.2 8.0 ± 0.1
PE 7.5 ± 0.2 6.5 ± 0.3 5.0 ± 1.3 6.3 ± 1.4 5.7 ± 0.1 5.0 ± 0.5
PS 0.6 ± 0.1 0.8 ± 0.0 0.5 ± 0.1 0.6 ± 0.2 0.5 ± 0.2 0.5 ± 0.2
PI 2.0 ± 0.3 1.8 ± 0.2 1.6 ± 0.7 2.0 ± 0.6 1.3 ± 0.2 1.5 ± 0.2
PG/CL 1.8 ± 0.1 0.9 ± 0.5 0.8 ± 0.4 1.0 ± 0.7 1.1 ± 0.2 1.1 ± 0.1
Sphingomyelin 0.4 ± 0.1 0.6 ± 0.2 0.4 ± 0.0 0.5 ± 0.1 0.3 ± 0.1 0.3 ± 0.1
Lyso-PC 0.6 ± 0.1 0.4 ± 0.2 0.3 ± 0.1 0.5 ± 0.1 0.3 ± 0.0 0.5 ± 0.1
Total Polar 24.9 ± 0.4 22.3 ± 0.3 17.5 ± 4.3 21.8 ± 4.5 19.3 ± 0.1 16.8 ± 0.7
Total Neutral 75.1 ± 0.4 77.7 ± 0.3 82.5 ± 4.3 78.2 ± 4.5 80.7 ± 0.1 83.2 ± 0.7
Cholesterol 3.4 ± 0.5 2.7 ± 0.9 3.1 ± 0.8 3.6 ± 0.5 2.1 ± 0.7 3.9 ± 0.6
Triacylglycerol 62.2 ± 0.5 65.0 ± 0.4 70.9 ± 3.8 66.0 ± 5.0 70.7 ± 0.7 71.5 ± 1.2
Free fatty acid 9.5 ± 0.4 10.0 ± 1.5 8.5 ± 0.6 8.6 ± 0.3 7.9 ± 0.1 7.8 ± 0.1
0.1104
0.002 0.0191 0.2771
0.0854 0.0026 0.2085
0.0043 0.0854 0.6663
0.0238 0.6861 0.2449
0.0282 1.0000 0.0687
0.0043 0.0854 0.6663
0.1447 0.6056 0.0647
0.2621 0.0911 0.0348
0.1878
0.1435 0.3327 0.5674
0.9438
0.0059 0.4589
0.0796
CLA Oil Interact.
ANOVA
0.0002 0.1134
0.0007 0.0404
0.2621 0.1902
H1 H2L0 L1 L2 H0
 
 
Values are means ± SD of 6 samples. CL, cardiolipin; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PG, 
phosphatidylglycerol; PI, phosphatidylinositol; PS, phosphatidylserine. 
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Table 3.11 Lipid content (percentage of tissue wet weight) and class composition (percentage of total lipid) of liver of Atlantic 
salmon fed CLA for 3 months 
 
Lipid Content 3.3 ± 0.3 3.4 ± 0.1 3.5 ± 0.2 3.5 ± 0.2 3.6 ± 0.2 3.8 ± 0.2
PC 29.8 ± 0.9 28.2 ± 3.8 30.1 ± 2.4 28.2 ± 2.1 25.3 ± 2.2 24.7 ± 1.2
PE 17.1 ± 0.4 17.7 ± 1.0 17.5 ± 0.9 17.5 ± 0.9 15.0 ± 0.6 14.4 ± 0.9
PS 4.1 ± 0.5 4.1 ± 0.8 4.1 ± 0.8 3.6 ± 0.5 3.2 ± 0.2 3.2 ± 0.1
PI 5.8 ± 0.8 6.0 ± 0.7 5.7 ± 0.8 5.6 ± 0.4 5.4 ± 0.3 4.9 ± 0.6
PG/CL 4.7 ± 0.2 4.8 ± 0.4 4.5 ± 0.4 4.5 ± 0.2 3.9 ± 0.3 3.5 ± 0.3
Sphingomyelin 4.8 ± 0.8 4.7 ± 0.9 4.8 ± 0.8 4.2 ± 0.6 3.7 ± 0.3 3.8 ± 0.3
Lyso-PC 0.9 ± 0.6 0.7 ± 0.3 0.8 ± 0.2 0.9 ± 0.4 0.7 ± 0.2 0.7 ± 0.1
Total Polar 67.2 ± 3.9 66.2 ± 6.6 67.4 ± 5.8 64.5 ± 3.4 57.2 ± 3.2 55.3 ± 2.2
Total Neutral 32.8 ± 3.9 33.8 ± 6.6 32.6 ± 5.8 35.5 ± 3.4 42.8 ± 3.3 44.7 ± 2.2
Cholesterol 18.3 ± 0.9 18.2 ± 1.5 18.8 ± 0.3 18.0 ± 0.6 15.4 ± 1.8 15.1 ± 1.2
Triacylglycerol 12.3 ± 4.7 13.4 ± 8.5 11.9 ± 5.8 15.4 ± 3.8 25.7 ± 4.7 27.3 ± 3.8
Free fatty acid 2.2 ± 0.6 2.1 ± 0.5 1.9 ± 1.0 2.1 ± 1.2 1.7 ± 0.6 2.3 ± 0.7
Steryl ester - -
0.0341 <0.0001 0.0441
tr tr tr tr tr tr -
0.4793
CLA Oil Interact.
0.7264 0.9021
0.0154 <0.0001 0.0036
0.0212 <0.0001 0.0263
0.0341 <0.0001 0.0441
0.5350 0.0005 0.6972
0.3414 0.7717 0.9181
0.2160 0.0165 0.5017
0.0002 <0.0001 0.0069
0.0008 <0.0001 <0.0001
0.5971 0.0002 0.5971
0.0625 0.0002 0.1379
0.0636 0.0008 0.8762
L0 L1 L2 H0 H1 H2 ANOVA
 
Values are means ± SD of 6 samples pooled from 3 fish each. CL, cardiolipin; PC, phosphatidylcholine; PE, 
phosphatidylethanolamine; PG, phosphatidylglycerol; PI, phosphatidylinositol; PS, phosphatidylserine; tr, trace, < 0.5%. 
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Table 3.12 Lipid content (percentage of tissue wet weight) and class composition (percentage of total lipid) of flesh of Atlantic 
salmon fed CLA for 3 months 
Lipid Content 3.1 ± 0.4 3.2 ± 0.5 3.2 ± 0.4 3.9 ± 0.8 4.5 ± 0.5 5.0 ± 0.2
PC 8.6 ± 1.0 8.2 ± 0.6 8.1 ± 1.0 8.0 ± 0.5 7.4 ± 0.5 7.3 ± 0.9
PE 6.9 ± 0.9 6.5 ± 0.9 6.0 ± 0.6 5.6 ± 0.7 5.3 ± 0.5 5.0 ± 0.5
PS 0.8 ± 0.2 0.7 ± 0.2 0.6 ± 0.2 0.5 ± 0.1 0.5 ± 0.1 0.6 ± 0.2
PI 3.4 ± 0.5 3.0 ± 0.5 2.7 ± 0.6 2.2 ± 0.3 2.0 ± 0.2 1.8 ± 0.2
PG/CL 1.4 ± 0.4 1.5 ± 0.5 1.4 ± 0.3 1.2 ± 0.2 1.1 ± 0.2 1.1 ± 0.1
Sphingomyelin 0.6 ± 0.2 0.6 ± 0.2 0.5 ± 0.1 0.4 ± 0.1 0.4 ± 0.0 0.4 ± 0.1
Lyso-PC 2.6 ± 0.4 1.7 ± 0.4 1.6 ± 0.5 1.4 ± 0.4 1.1 ± 0.3 1.0 ± 0.1
Total Polar 24.3 ± 2.7 22.3 ± 2.4 20.9 ± 2.8 19.3 ± 1.7 17.6 ± 1.4 17.2 ± 1.7
Total Neutral 75.7 ± 2.7 77.7 ± 2.4 79.1 ± 2.8 80.7 ± 1.7 82.4 ± 1.4 82.8 ± 1.7
Cholesterol 9.3 ± 0.3 8.8 ± 0.5 8.7 ± 0.5 8.5 ± 0.7 8.4 ± 0.4 8.3 ± 0.3
Triacylglycerol 53.4 ± 3.0 56.4 ± 3.0 59.5 ± 3.9 62.0 ± 3.4 65.4 ± 2.5 66.0 ± 2.0
Free fatty acid 13.0 ± 1.3 12.5 ± 1.1 11.0 ± 1.1 10.2 ± 2.8 8.6 ± 0.8 8.5 ± 0.4
0.0012 <0.0001 0.5606
0.0148 <0.0001 0.4733
0.0139 <0.0001 0.7494
0.1131 0.0019 0.4941
0.0001 <0.0001 0.0907
0.0139 <0.0001 0.7494
0.9036 0.0075 0.7393
0.5852 0.0009 0.5852
0.7192 0.0072 0.1143
0.0107 <0.0001 0.6688
0.1493 0.0086 0.9368
0.0461 <0.0001 0.8687
0.0231 <0.0001 0.0676
CLA Oil Interact.
H1 H2 ANOVAL0 L1 L2 H0
 
Values are means ± SD of 6 samples pooled from 3 fish each. CL, cardiolipin; PC, phosphatidylcholine; PE, 
phosphatidylethanolamine; PG, phosphatidylglycerol; PI, phosphatidylinositol; PS, phosphatidylserine. 
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3.3.5 Fatty Acid Compositions of Liver and Flesh 
 
Similar to the lipid class data, the effects of diet on fatty acid compositions changed over time 
(see Tables 3.13 – 3.18). Therefore, the amount of CLA deposited in both liver and flesh of 
salmon increased with duration of feeding, and after 2 months, 22:6n-3 and total n-3 PUFA 
levels began to be significantly depressed in muscle particularly in fish fed 2 % dietary CLA 
incorporated into both low and high fat diets (Table 3.16).  The details of dietary effects on fatty 
acid compositions are described in relation to the data at the end of the trial, after the fish had 
been fed the diets for 3 months.  After 3 months, the fatty acid compositions of total lipid from 
liver (Table 3.17) and flesh (Table 3.18) reflected the fatty acid composition of the diets.  Dietary 
CLA resulted in the deposition of CLA in both tissues with the rank order for total CLA in both 
liver and flesh being L2 > H2 > L1 > H1 > L0/H0 (Tables 3.17 & 3.18).  Accumulation of CLA 
was 2-fold higher in the flesh, with total CLA in fish fed the L2 diet reaching 3.4 % in the liver 
(Table 3.17), and 6.9 % in the flesh (Table 3.18).  CLA deposition in the liver was not at the 
expense of any one particular fatty acid, but tended to be spread across several saturated and 
monounsaturated fatty acids (Table 3.17).  In contrast, in the flesh, CLA deposition appeared to 
be primarily at the expense of 20:5n-3 and 22:6n-3 rather than saturated and monounsaturated 
fatty acids (Table 3.18).  It was noteworthy that dietary CLA had no significant effect on the 
proportions of n-6 fatty acids 18:2n-6 or 20:4n-6 in either liver or flesh (Tables 3.17 & 3.18).  
Oil content also had an effect on tissue fatty acid compositions with most fatty acids being 
significantly affected, with fatty acids derived from the plant (meal) sources, such as 18:0, 18:1n-
9 and 18:2n-6, being reduced and generally all the other fatty acids being increased in liver and 
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flesh of fish fed the high oil diets (Tables 3.17 & 3.18). The statistical significance of dietary oil 
level and CLA is shown in Tables 3.19 – 3.21. 
 
Table 3.13 Fatty acid composition (percentage of weight) of total lipid from liver of Atlantic 
salmon fed CLA for 1 month. 
18:0 6.6 ± 0.9 7.2 ± 0.3 7.0 ± 0.8 6.5 ± 1.3 6.8 ± 0.5 6.6 ± 0.9
Total saturated1 30.0 ± 1.5 29.3 ± 1.2 28.0 ± 0.8 28.8 ± 1.4 28.8 ± 1.2 30.5 ± 0.4
18:1n-9 8.9 ± 0.4 8.9 ± 0.2 8.4 ± 0.5 9.4 ± 0.5 7.7 ± 0.1 8.6 ± 1.1
Total monoenes 16.5 ± 0.6 16.4 ± 1.4 14.6 ± 0.2 18.9 ± 1.8 15.4 ± 0.1 16.0 ± 0.1
CLA (9c,11t) 0.0 ± 0.0 0.4 ± 0.3 1.3 ± 0.3 0.0 ± 0.0 0.2 ± 0.2 0.3 ± 0.1
CLA (10t,12c) 0.0 ± 0.0 0.3 ± 0.3 1.2 ± 0.2 0.0 ± 0.0 0.3 ± 0.0 0.2 ± 0.1
Total n-6 PUFA2 7.1 ± 1.0 7.3 ± 0.5 7.9 ± 0.8 6.7 ± 0.7 6.5 ± 0.2 6.7 ± 0.5
20:5n-3 7.4 ± 1.2 7.0 ± 1.3 6.6 ± 0.3 8.4 ± 1.0 10.0 ± 0.4 6.6 ± 1.4
22:6n-3 35.7 ± 2.0 35.5 ± 2.7 36.4 ± 2.5 32.8 ± 1.0 34.4 ± 0.3 34.2 ± 0.1
Total n-3 PUFA3 46.4 ± 2.1 45.7 ± 1.9 46.4 ± 1.9 45.6 ± 0.8 48.8 ± 0.9 45.2 ± 3.7
H1 H2L0 L1 L2 H0
Values are means ± SD of 6 samples. 1, contains 15:0, 20:0 and 22:0, present in some samples at 
up to 0.4 % 2, totals include 18:3n-6, 20:2n-6, 20:3n-6 and 22:4n-6 and 22:5n-6 present in some 
samples at up to 0.6 % 3, contains 20:3n-3 present at up to 0.1 %.  H0, H1 and H2, diets 
containing FO at 34 % and supplemented with 0, 1 and 2 % CLA; L0, L1 and L2, diets 
containing FO at 17 % and supplemented with 0, 1 and 2 % CLA. 
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Table 3.14 Fatty acid composition (percentage of weight) of total lipid from muscle of Atlantic 
salmon fed CLA for1 month 
18:0 3.9 ± 0.4 4.0 ± 0.2 4.0 ± 0.3 3.9 ± 0.9 3.7 ± 0.2 3.8 ± 0.1
Total saturated1 25.3 ± 1.7 24.9 ± 1.5 24.5 ± 1.6 25.4 ± 3.7 24.7 ± 0.5 25.2 ± 0.2
18:1n-9 14.7 ± 0.9 14.2 ± 0.8 15.5 ± 0.8 14.3 ± 1.0 13.5 ± 1.1 14.6 ± 1.2
Total monoenes 37.9 ± 3.3 36.0 ± 1.7 38.7 ± 2.3 36.5 ± 3.7 35.3 ± 2.5 37.1 ± 3.8
CLA (9c,11t) 0.0 ± 0.0 0.5 ± 0.3 1.5 ± 0.3 0.0 ± 0.0 0.5 ± 0.1 1.0 ± 0.5
CLA (10t,12c) 0.0 ± 0.0 0.4 ± 0.2 1.3 ± 0.3 0.0 ± 0.0 0.4 ± 0.1 0.9 ± 0.4
Total n-6 PUFA2 5.7 ± 0.5 5.5 ± 0.4 5.9 ± 0.2 5.1 ± 0.5 5.0 ± 0.2 5.1 ± 0.2
20:5n-3 6.2 ± 0.9 6.5 ± 0.9 5.5 ± 0.1 6.8 ± 0.7 7.1 ± 0.5 6.4 ± 0.5
22:6n-3 18.8 ± 1.1 20.8 ± 3.3 16.8 ± 2.0 20.1 ± 0.1 20.8 ± 2.6 18.4 ± 2.9
Total n-3 PUFA3 31.1 ± 1.7 32.6 ± 3.7 28.1 ± 1.8 33.1 ± 0.6 34.2 ± 2.9 30.8 ± 3.2
H1 H2L0 L1 L2 H0
 
Values are means ± SD of 6 samples. 1, contains 15:0, 20:0 and 22:0, present in some samples at 
up to 0.4 % 2, totals include 18:3n-6, 20:2n-6, 20:3n-6 and 22:4n-6 and 22:5n-6 present in some 
samples at up to 0.6 % 3, contains 20:3n-3 present at up to 0.1 %.  H0, H1 and H2, diets 
containing FO at 34 % and supplemented with 0, 1 and 2% CLA; L0, L1 and L2, diets 
containing FO at 17 % and supplemented with 0, 1 and 2 % CLA. 
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Table 3.15 Fatty acid composition (percentage of weight) of total lipid from liver of Atlantic 
salmon fed CLA for 2 months 
18:0 6.9 ± 0.5 6.1 ± 1.3 8.7 ± 1.5 5.2 ± 0.6 6.0 ± 0.7 5.5 ± 1.0
Total saturated1 27.0 ± 0.5 27.1 ± 1.0 28.1 ± 1.1 27.9 ± 1.5 27.6 ± 0.5 27.1 ± 2.8
18:1n-9 9.9 ± 1.5 9.5 ± 1.7 8.8 ± 0.9 8.4 ± 0.3 8.5 ± 0.8 8.9 ± 2.1
Total monoenes 17.8 ± 1.9 18.8 ± 4.6 15.8 ± 2.2 16.2 ± 0.8 16.8 ± 2.4 17.8 ± 4.5
CLA (9c,11t) 0.0 ± 0.0 0.8 ± 0.3 1.6 ± 0.2 0.0 ± 0.0 0.6 ± 0.1 1.1 ± 0.3
CLA (10t,12c) 0.0 ± 0.0 0.5 ± 0.3 1.4 ± 0.2 0.0 ± 0.0 0.4 ± 0.1 0.8 ± 0.1
Total n-6 PUFA2 7.8 ± 0.3 7.0 ± 1.6 7.8 ± 0.4 6.2 ± 0.2 6.1 ± 0.2 6.3 ± 0.5
20:5n-3 9.1 ± 0.5 8.2 ± 0.9 7.5 ± 0.8 9.9 ± 0.6 9.8 ± 0.3 10.2 ± 0.9
22:6n-3 34.2 ± 2.0 33.6 ± 1.5 34.8 ± 2.5 35.5 ± 2.2 34.4 ± 2.9 32.2 ± 2.1
Total n-3 PUFA3 47.4 ± 2.3 45.8 ± 2.1 45.3 ± 2.5 49.5 ± 2.5 48.3 ± 2.4 46.9 ± 2.1
H1 H2L0 L1 L2 H0
 
Values are means ± SD of 6 samples. 1, contains 15:0, 20:0 and 22:0, present in some samples at 
up to 0.4 % 2, totals include 18:3n-6, 20:2n-6, 20:3n-6 and 22:4n-6 and 22:5n-6 present in some 
samples at up to 0.6 % 3, contains 20:3n-3 present at up to 0.1 %.  H0, H1 and H2, diets 
containing FO at 34 % and supplemented with 0, 1 and 2 % CLA; L0, L1 and L2, diets 
containing FO at 17 % and supplemented with 0, 1 and 2 % CLA.. 
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Table 3.16 Fatty acid composition (percentage of weight) of total lipid from muscle of Atlantic 
salmon fed CLA for 2 months 
18:0 4.2 ± 0.1 4.2 ± 0.3 5.0 ± 0.9 3.7 ± 0.3 4.0 ± 0.3 4.1 ± 0.2
Total saturated1 26.1 ± 0.6 24.5 ± 1.4 26.3 ± 1.2 25.0 ± 1.1 25.2 ± 0.9 25.9 ± 1.4
18:1n-9 15.3 ± 0.8 15.2 ± 1.0 16.7 ± 0.4 14.9 ± 1.0 14.8 ± 0.6 15.5 ± 1.3
Total monoenes 37.1 ± 1.7 37.3 ± 4.2 37.3 ± 5.0 38.1 ± 2.8 36.3 ± 1.8 37.8 ± 2.1
CLA (9c,11t) 0.0 ± 0.0 0.9 ± 0.3 2.9 ± 0.3 0.0 ± 0.0 0.7 ± 0.2 1.7 ± 0.1
CLA (10t,12c) 0.0 ± 0.0 0.8 ± 0.3 2.6 ± 0.2 0.0 ± 0.0 0.6 ± 0.2 1.6 ± 0.1
Total n-6 PUFA2 6.7 ± 0.3 6.1 ± 0.3 6.2 ± 0.9 5.1 ± 0.1 5.1 ± 0.2 5.1 ± 0.2
20:5n-3 6.8 ± 0.5 6.7 ± 0.8 5.4 ± 0.6 6.6 ± 0.7 7.0 ± 0.4 6.9 ± 1.3
22:6n-3 16.0 ± 1.9 17.5 ± 1.6 13.8 ± 1.1 18.2 ± 1.5 18.1 ± 1.0 14.2 ± 1.9
Total n-3 PUFA3 29.5 ± 1.6 30.5 ± 2.0 24.8 ± 1.0 31.6 ± 2.3 32.1 ± 1.1 27.8 ± 3.8
H1 H2L0 L1 L2 H0
 
Values are means ± SD of 6 samples. 1, contains 15:0, 20:0 and 22:0, present in some samples at 
up to 0.4 % 2, totals include 18:3n-6, 20:2n-6, 20:3n-6 and 22:4n-6 and 22:5n-6 present in some 
samples at up to 0.6 % 3, contains 20:3n-3 present at up to 0.1 %.  H0, H1 and H2, diets 
containing FO at 34 % and supplemented with 0, 1 and 2% CLA; L0, L1 and L2, diets 
containing FO at 17 % and supplemented with 0, 1 and 2 % CLA
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Table 3.17  Fatty acid composition (percentage of weight) of total lipid from liver of Atlantic 
salmon fed CLA for 3 months 
14:0 1.6 ± 0.1 1.5 ± 0.1 1.3 ± 0.2 2.3 ± 0.5 1.8 ± 0.2 1.9 ± 0.2
16:0 18.5 ± 1.3 17.8 ± 0.2 17.1 ± 0.9 19.4 ± 0.9 18.7 ± 0.9 18.4 ± 0.7
18:0 8.3 ± 1.0 8.8 ± 1.1 8.9 ± 0.8 6.3 ± 0.3 7.1 ± 0.4 7.4 ± 0.5
Total saturated1 29.0 ± 1.3 28.8 ± 1.3 27.8 ± 0.7 28.6 ± 1.1 28.2 ± 1.2 28.3 ± 1.2
16:1n-72 2.3 ± 0.1 2.2 ± 0.3 2.0 ± 0.2 3.2 ± 0.5 2.6 ± 0.3 2.6 ± 0.3
18:1n-9 9.6 ± 1.0 8.8 ± 0.4 9.4 ± 0.6 9.4 ± 1.0 8.2 ± 0.8 8.9 ± 0.8
18:1n-7 2.4 ± 0.1 2.3 ± 0.1 2.3 ± 0.1 2.6 ± 0.2 2.5 ± 0.2 2.5 ± 0.1
20:1n-93 1.8 ± 0.2 1.8 ± 0.1 1.6 ± 0.2 2.1 ± 0.4 1.6 ± 0.3 2.0 ± 0.2
22:1n-114 0.5 ± 0.1 0.4 ± 0.3 0.6 ± 0.2 1.0 ± 0.4 0.7 ± 0.2 8.0 ± 0.2
24:1n-9 1.1 ± 0.1 1.0 ± 0.2 0.8 ± 0.1 1.1 ± 0.2 0.9 ± 0.0 0.9 ± 0.1
Total monoenes 17.7 ± 0.5 16.7 ± 1.0 16.6 ± 1.4 19.3 ± 2.4 16.4 ± 1.0 17.6 ± 1.6
18:2n-6 2.8 ± 0.2 2.9 ± 0.2 3.0 ± 0.2 1.9 ± 0.2 1.7 ± 0.2 1.8 ± 0.1
20:4n-6 3.6 ± 0.4 3.7 ± 0.2 3.7 ± 0.2 3.5 ± 0.4 3.9 ± 0.3 3.8 ± 0.3
CLA (9c,11t) 0.0 ± 0.0 0.9 ± 0.2 1.8 ± 0.2 0.0 ± 0.0 0.6 ± 0.1 1.2 ± 0.2
CLA (10t,12c) 0.0 ± 0.0 0.7 ± 0.1 1.6 ± 0.2 0.0 ± 0.0 0.5 ± 0.1 1.0 ± 0.2
Total n-6 PUFA5 7.9 ± 0.4 8.3 ± 0.3 8.3 ± 0.4 6.5 ± 0.3 6.7 ± 0.3 6.7 ± 0.3
18:3n-3 0.4 ± 0.0 0.3 ± 0.1 0.3 ± 0.1 0.5 ± 0.1 0.5 ± 0.1 0.4 ± 0.0
18:4n-3 0.2 ± 0.1 0.2 ± 0.1 0.2 ± 0.1 0.5 ± 0.2 0.3 ± 0.1 0.3 ± 0.1
20:4n-3 0.6 ± 0.1 0.6 ± 0.1 0.6 ± 0.1 1.0 ± 0.1 1.0 ± 0.1 0.9 ± 0.1
20:5n-3 8.4 ± 0.7 8.3 ± 0.6 7.9 ± 0.3 10.2 ± 0.6 10.6 ± 0.3 10.0 ± 0.5
22:5n-3 2.7 ± 0.2 2.5 ± 0.3 2.4 ± 0.1 3.0 ± 0.2 3.1 ± 0.2 2.8 ± 0.1
22:6n-3 33.0 ± 1.3 32.6 ± 0.8 32.5 ± 1.3 30.0 ± 2.3 31.9 ± 1.9 30.7 ± 0.1
Total n-3 PUFA6 45.4 ± 2.0 44.7 ± 0.9 43.9 ± 1.3 45.6 ± 2.5 47.6 ± 1.6 45.3 ± 0.3
H1 H2L0 L1 L2 H0
 
Values are means ± SD of 6 samples. 1, contains 15:0, 20:0 and 22:0, present in some samples at 
up to 0.4 %; 2, contains n-9 isomer; 3,contains n-7 isomer; 4, contains n-9 isomer; 5, totals include 
18:3n-6, 20:2n-6, 20:3n-6 and 22:4n-6 and 22:5n-6 present in some samples at up to 0.6 %; 6, 
contains 20:3n-3 present at up to 0.1 %.  H0, H1 and H2, diets containing FO at 34 % and 
supplemented with 0, 1 and 2 % CLA; L0, L1 and L2, diets containing FO at 17 % and 
supplemented with 0, 1 and 2 % CLA. 
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Table 3.18 Fatty acid composition (percentage of weight) of total lipid from muscle of Atlantic 
salmon fed CLA for 3 months. 
14:0 3.8 ± 0.2 3.7 ± 0.6 3.3 ± 0.2 4.2 ± 0.3 4.3 ± 0.3 4.2 ± 0.2
16:0 18.4 ± 0.3 18.1 ± 1.4 16,7 ± 0.4 17.3 ± 0.6 17.5 ± 0.7 16.7 ± 0.5
18:0 5.2 ± 0.2 5.4 ± 0.5 5.3 ± 0.2 4.1 ± 0.2 4.4 ± 0.2 4.3 ± 0.1
Total saturated1 28.2 ± 0.5 28.1 ± 2.5 26.2 ± 0.7 26.3 ± 0.9 26.9 ± 1.1 25.9 ± 0.7
16:1n-72 5.2 ± 0.2 5.2 ± 0.3 4.7 ± 0.1 6.3 ± 0.2 6.2 ± 0.2 6.0 ± 0.2
18:1n-9 14.9 ± 0.4 15.6 ± 0.7 16.0 ± 0.4 14.2 ± 0.8 14.4 ± 0.4 15.0 ± 0.4
18:1n-7 3.3 ± 0.1 3.3 ± 0.2 3.0 ± 0.0 3.4 ± 0.1 3.4 ± 0.2 3.3 ± 0.1
20:1n-93 4.6 ± 0.4 4.8 ± 0.5 4.4 ± 0.2 4.8 ± 0.3 4.5 ± 0.4 4.8 ± 0.5
22:1n-114 3.9 ± 0.4 4.2 ± 0.4 3.8 ± 0.2 4.1 ± 0.3 3.9 ± 0.2 4.0 ± 0.3
24:1n-9 0.7 ± 0.2 0.7 ± 0.2 0.7 ± 0.1 0.8 ± 0.1 0.7 ± 0.1 0.6 ± 0.1
Total monoenes 32.7 ± 1.5 34.0 ± 2.2 32.6 ± 0.8 33.7 ± 1.5 33.1 ± 1.3 33.6 ± 1.1
18:2n-6 5.2 ± 0.2 5.2 ± 0.2 4.9 ± 0.2 3.4 ± 0.1 3.3 ± 0.1 3.4 ± 0.0
20:4n-6 0.8 ± 0.1 0.7 ± 0.1 0.7 ± 0.0 0.8 ± 0.1 0.8 ± 0.1 0.8 ± 0.2
CLA (9c,11t) 0.0 ± 0.0 1.9 ± 0.2 3.7 ± 0.4 0.0 ± 0.0 1.1 ± 0.1 2.2 ± 0.2
CLA (10t,12c) 0.0 ± 0.0 1.6 ± 0.2 3.2 ± 0.4 0.0 ± 0.0 1.0 ± 0.1 2.0 ± 0.2
Total n-6 PUFA5 7.2 ± 0.3 7.0 ± 0.7 6.7 ± 0.3 5.2 ± 0.3 5.2 ± 0.4 5.3 ± 0.3
18:3n-3 1.0 ± 0.0 0.9 ± 0.1 0.8 ± 0.0 1.1 ± 0.0 1.0 ± 0.1 1.0 ± 0.1
18:4n-3 1.4 ± 0.0 1.3 ± 0.1 1.2 ± 0.1 1.8 ± 0.1 1.8 ± 0.1 1.6 ± 0.0
20:4n-3 1.1 ± 0.1 0.9 ± 0.1 0.9 ± 0.0 1.2 ± 0.1 1.2 ± 0.1 1.1 ± 0.0
20:5n-3 7.2 ± 0.3 6.1 ± 1.0 5.9 ± 0.1 8.5 ± 0.5 8.3 ± 0.4 7.6 ± 0.3
22:5n-3 0.8 ± 0.1 2.3 ± 0.4 2.4 ± 0.1 3.2 ± 0.2 3.1 ± 0.2 2.9 ± 0.1
22:6n-3 18.2 ± 1.4 15.5 ± 0.5 16.0 ± 1.3 18.6 ± 1.5 17.0 ± 1.2 16.6 ± 0.5
Total n-3 PUFA6 31.9 ± 1.8 27.4 ± 4.1 27.5 ± 1.2 34.8 ± 2.2 32.6 ± 1.6 31.0 ± 0.8
H1 H2L0 L1 L2 H0
 
Values are means ± SD of 6 samples. 1, contains 15:0, 20:0 and 22:0, present in some samples at 
up to 0.5 %; 2, contains n-9 isomer; 3,contains n-7 isomer; 4, contains n-9 isomer; 5, totals include 
18:3n-6, 20:2n-6, 20:3n-6 and 22:4n-6 and 22:5n-6 present in some samples at up to 0.5 %; 6, 
contains 20:3n-3 present at up to 0.5 %.  H0, H1 and H2, diets containing FO at 34 % and 
supplemented with 0, 1 and 2 % CLA; L0, L1 and L2, diets containing FO at 17 % and 
supplemented with 0, 1 and 2 % CLA. 
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Table 3.19 Significance (P values) of effects of dietary conjugated linoleic acid (CLA) and oil 
content (Oil), and their interaction (Interact.) on tissue fatty acid compositions after feeding the 
diets for 1 month, as determined by two-way ANOVA. 
Liver Muscle
18:0
Total saturated
18:1n-9
Total monoenes
CLA (9c,11t)
CLA (10t,12c)
Total n-6 PUFA 
20:5n-3
22:6n-3
Total n-3 PUFA
0.2299 0.2421
Interact CLA
<0.0001 <0.0001 <0.0001 <0.0001
Oil InteractCLA Oil
0.6623 0.4662 0.9393 0.9743
0.0367 0.8593
0.4351 0.8354
0.8271 0.91710.8702 0.6307
0.0559 0.5437 0.0508 0.1466 0.1738 0.9062
0.0280 0.4350 0.3979 0.96320.0028 0.0633
0.0005 <0.0001 0.2162 0.2231
0.5070 0.0257 0.5966 0.5018 0.0029 0.7685
<0.0001 <0.0001
0.0217 0.0176 0.0715 0.1191
0.6805 0.0758
0.0442 0.9029
<0.0001 0.0020
0.4594 0.7191 0.1923 0.0541 0.1054 0.9311
0.5897 0.0286
 
Chapter 3  
 83
 
 
 
 
 
 
 
 
Table 3.20 Significance (P values) of effects of dietary conjugated linoleic acid (CLA) and oil 
content (Oil), and their interaction (Interact.) on tissue fatty acid compositions after feeding the 
diets for 2 months, as determined by two-way ANOVA. 
Liver Muscle
18:0
Total saturated
18:1n-9
Total monoenes
CLA (9c,11t)
CLA (10t,12c)
Total n-6 PUFA 
20:5n-3
22:6n-3
Total n-3 PUFA
Interact CLA Oil InteractCLA Oil
0.1546 0.0042 0.0603 0.0818
0.5133 0.2031
0.0229 0.4026
0.6274 0.41140.9566 0.8497
0.9300 0.2357 0.5942 0.1042 0.1417 0.6816
0.4500 0.8893 0.9136 0.85410.8237 0.7052
<0.0001 0.0265 0.1256 <0.0001
<0.0001 0.0087 0.0141 <0.0001
0.6721 0.4472
0.0003 0.0004
0.0004 0.0007
<0.0001 0.44720.4440 0.0021
0.2821 0.0002 0.1028 0.2930
0.5876 0.8773 0.2974 0.0025
0.9453 0.0038
0.1693 0.1900
0.1676 0.5568
0.0505 0.85480.2511 0.0835
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Table 3.21 Significance (P values) of the effects of dietary conjugated linoleic acid (CLA) and 
oil content (Oil), and their interaction (Interact.) on tissue fatty acid compositions after feeding 
the diets for 3 months, as determined by two-way ANOVA.  
Liver Muscle
14:0
16:0
18:0
Total saturated
16:1n-7
18:1n-9
18:1n-7
20:1n-9
22:1n-11
24:1n-9
Total monoenes
18:2n-6
20:4n-6
CLA (9c,11t)
CLA (10t,12c)
Total n-6 PUFA
18:3n-3
18:4n-3
20:4n-3
20:5n-3
22:5n-3
22:6n-3
Total n-3 PUFA
0.0561 <0.0001 0.7055 0.4984 <0.0001 0.2065
Oil InteractCLA Oil Interact CLA
0.0042 <0.0001 0.1530 0.1205
0.0224 0.0043 0.8450 0.0008
0.7143 0.0825
<0.0001 0.1950
0.0293 0.2091
<0.0001 0.8675
0.2904 0.6673 0.4691 0.0187 0.0112 0.3098
0.0238 <0.0001
0.0031 <0.0001 0.1530 <0.0001
0.8156 0.0008
<0.0001 0.0649
<0.0001 0.5323
0.1530 0.0002 1.0000 0.0010 0.0009 0.1304
0.0146 0.1128
0.0649 0.0561 0.0145 0.8284
0.1460 0.0004 0.3442 0.1296
0.1229 0.2394
0.4568 0.1022
0.0979 0.0061
1.0000 0.2394
0.0206 0.1747 0.3679 0.7342 0.4586 0.2031
<0.0001 1.0000
0.4345 <0.0001 0.0932 0.0649
0.4930 0.4810
<0.0001 0.0088
0.0935 0.4810
<0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
0.1315 0.5249
<0.0001 <0.0001<0.0001 <0.0001 <0.0001 <0.0001
0.0195 <0.0001 0.2394 <0.0001
0.0859 <0.0001
<0.0001 0.1530
<0.0001 0.2394
0.3798 <0.0001 0.3798 0.0003 <0.0001 0.0195
0.0859 0.0003
0.0851 <0.0001 0.5323 <0.0001
0.1785 <0.0001 0.1785 0.0006
0.3651 0.0018
<0.0001 0.1190
<0.0001 0.0712
0.1102 0.6440
0.1380 0.0214 0.2188 0.0002 <0.0001 0.4302
0.5863 0.0046
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3.4 Discussion 
The principal aim of this trial was to determine if dietary CLA had any important 
effects on lipid metabolism and growth parameters in Atlantic salmon.  Collectively there 
was little evidence from preceding studies that dietary CLA can influence proximate 
composition, growth, feed efficiency or biometry of salmonids (Berge et al, 2004; 
Figueiredo-Silva et al., 2005; Bandarra et al., 2006; Valente et al, 2007a).  This is in 
agreement with the results of the present study, which also show that dietary CLA, at 
levels up to 2 % of total diet, does not influence SGR, FCR, VSI and HSI.  However, 
dietary CLA was shown to significantly increase HSI in striped bass (Twibell et al., 
2000) and yellow perch (Twibell et al., 2001).  Although HSI was not influenced by 
dietary CLA in the present trial, it was increased in fish fed high dietary oil.  The 
increased HSI was associated with increased lipid and TAG content in the liver, whereas 
in the studies on yellow perch and tilapia, increased HSI was not associated with 
increased lipid content and, indeed, liver lipid content was reduced by CLA in striped 
bass (Twibell et al., 2001; Yasmin et al., 2004).  The effects of dietary CLA on lipid 
content and composition were more prevalent towards the end of the study, with 
significant increases in flesh TAG associated with significant increases in lipid content.  
These data are as expected of course, and are consistent with the changes in lipid content, 
composition and fatty acid composition in salmon fed CLA being gradual and 
progressive with time.  
Dietary CLA has been shown to have some beneficial effects on body 
composition in mammals, with decreased body fat and increased lean body mass having 
been shown in mice, rats and pigs (Ohnuki et al., 2001; Thiel-Cooper et al., 2001; 
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Terpstra et al., 2002; Tischendorf et al., 2002; Yamasaki et al., 2003).  CLA also 
decreased whole body TAG accumulation in hamsters (Bouthegourd et al., 2002) and 
reduced hepatic TAG levels in rats (Rahman et al., 2002).  In contrast, similar effects 
have rarely been observed in fish.  No significant effects of CLA on carcass lipid, intra-
peritoneal fat or liver lipid content were reported in catfish (Twibell and Wilson, 2003), 
or on tissue lipid contents in tilapia (Yasmin et al., 2004).  However, intra-peritoneal fat 
and liver lipid content were decreased by dietary CLA in striped bass (Twibell et al., 
2001).  Whole body proximate composition remained unchanged throughout the course 
of the trial, even when fed in combination with high fat diets, in line with previous 
studies on salmon and trout fed CLA (Berge et al., 2004; Figuredo-Silva et al., 2005; 
Valente et al., 2007a).  Thus, in this instance, high dietary oil level does not greatly 
enhance the effects of dietary CLA in Atlantic salmon as hypothesised.  Indeed, overall 
the data suggest that dietary CLA does not have any beneficial effects on growth 
performance or body composition in salmon smolts that can tolerate higher levels of lipid 
in their diet.  However, as expected dietary oil level significantly increased the amount of 
lipid in salmon as a percentage of total carcass composition consistent with higher dietary 
oil leading to higher deposition of fat in the tissues of fish in general (Sargent et al., 
2002; Tocher, 2003).   
In the present trial we also aimed to determine if absolute content of CLA in the 
diet or the level of CLA relative to other fatty acids in the diets were more important in 
eliciting effects, and the diets were specifically formulated to this end.  The appropriate 
formulations were largely achieved and the diets provided a graded amount of CLA 
relative to total fatty acids with diets L1 and H2 supplying around the same amount of 
CLA relative to other fatty acids, but at two levels of dietary inclusion, 1 % and 2 %.  The 
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few significant effects observed made it difficult to be conclusive on the comparative 
importance of absolute or relative amount of dietary CLA.  However, the effects of 
dietary CLA were generally more pronounced in salmon fed the high oil diets suggesting 
that oil content in the diet was important in determining some of the effects of CLA 
although, as alluded to above, probably not to a level that would be physiologically 
significant.  
Taking all these studies together, it is becoming increasingly appreciated that 
dietary CLA has few effects on lipid homeostasis in salmonids.  However, the effects are 
not consistent and may vary with species, dependant on the pattern of lipid metabolism 
which itself varies with species (Tocher, 2003).  In addition, patterns of lipid metabolism 
may also vary with developmental stage of the fish so this may also be important 
(Tocher, 2003).  Thus, as the salmon used in the present trial were smolts in seawater, 
this is arguably more relevant than the earlier published trial on salmon that used fry in 
freshwater (Berge et al., 2004).  However, ideally, even larger and older Atlantic salmon 
that are known to actively deposit lipid at a much greater rate would have been the 
preferred candidates for study in this instance.  It is possible that the results obtained may 
also be dependant upon other dietary factors such as CLA isomer mix, and duration of the 
feeding trial.  Levels of oil used in the trials investigating the effects of CLA in fish have 
varied between 5 % and 12 % of diet for all species other than salmon, or up to 24 % and 
34 % (the present trial) of the diet in salmon.  The diets have generally been based on FO 
although the exact type has varied, and two trials also used diets including a mix of FO 
and VOs such as corn and soybean oil (Twibell et al., 2000, 2001; Twibell and Wilson, 
2003; Berge et al., 2004; Yasmin et al., 2004).  A diet containing exclusively VO could 
possibly be interesting to investigate, to determine if CLA could have more pronounced 
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effects when the basal diet had such a substantial difference in dietary fatty acid 
composition that a diet rich in VO would have.  Although the influence of individual 
CLA isomer preparations as dietary supplements have yet to be investigated in fish, it can 
be surmised from studies in rodents that each isomer may have different metabolic effects 
in salmon and that c9t11 and t10c12 CLA may even have acted antagonistically (Brown 
et al., 2003a; Brandebourg and Hu, 2005).  Many of the previous trials in fish also failed 
to define the precise chemical from of the CLA (free fatty acid, methyl esters or TAG).  
Thus, the effects of dietary CLA on lipid metabolism in the present trial may have been 
masked by the type of CLA preparation used. 
In mammals, CLA is also known to decrease the activity and gene expression of 
SCD and may also suppress ∆5 and ∆6 desaturases, and elongase (Choi et al., 2001, 
2002; Chuang et al., 2001a,b; Eder et al., 2002).  Dietary CLA increased saturated fatty 
acids and decreased 18:1 and C18 PUFA in pig muscle and fat (Ramsay et al., 2001), 
indicating a suppression in SCD activity.  In chicken, dietary CLA decreased 22:6n-3 in 
all tissues (Yang et al., 2003) and increased saturates and decreased monoenes and PUFA 
in eggs (Szymczyk and Pisulewski, 2003).  The tissue fatty acid composition data in the 
present study indicated that dietary CLA might have some similar effects in salmon.  In 
support of the above findings, dietary CLA has also been reported to significantly alter 
the ratio of 18:0/18:1n-9 in tissues of related studies involving rainbow trout (see section 
6.3.4; Bandarra et al., 2006; Valente et al., 2007a), striped bass (Twibell et al., 2000), 
yellow perch (Twibell et al., 2001), salmon (Berge et al., 2004) and sea bass (Valente et 
al., 2007b).  Dietary CLA has had rather diverse effects on tissue fatty acid compositions 
in fish.  For example, lower 16:1n-7 was reported in striped bass, and lower monoenes 
were reported in liver and muscle of yellow perch and in tilapia tissues (Twibell et al., 
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2000, 2001; Yasmin et al., 2004).  In striped bass, CLA increased PUFA, including 
20:5n-3, 22:6n-3 and 18:2n-6, in liver, but decreased PUFA in muscle (Twibell et al., 
2000).  Total n-3 PUFA, especially 22:6n-3, were increased in salmon fry fed CLA 
(Berge et al., 2004), however 22:6n-3 was significantly decreased in muscle of rainbow 
trout fed up to 2 % CLA (Bandarra et al., 2006).  No effect on 22:6n-3 levels were 
reported in a similar trial by the same laboratory using larger sized trout (Valente et al., 
2007a).  In the present study, it was noteworthy that deposition of CLA in flesh was at 
the expense of n-3 HUFA whereas in liver it was at the expense of saturated and 
monounsaturated fatty acids.  Clearly, the benefits of CLA-fed fish would be greater if 
this was the other way around and CLA replaced saturated and monounsaturated fatty in 
the flesh.  One potential consequence of feeding dietary CLA to oily fish such as salmon, 
is that they can incorporate an appreciable quantity of the bioactive fatty acid in their 
flesh, thus potentially providing a source of CLA to the human diet.  In line with previous 
studies in salmonids, results indicate that CLA is preferentially incorporated into flesh 
tissue with levels reaching approximately 7 % of the two CLA isomers, c9t11 is retained 
in both liver and flesh somewhat more than t10c12 CLA.  This finding may have 
commercial impact if CLA is ever to be incorporated into mainstream aquafeeds 
considering the potential physiological differences each isomer elicits in other animal 
models.  This trial was unable to elucidate at which point maximal deposition of CLA 
was attained in flesh.  This was due to the fact that levels of this bioactive fatty acid 
continued to increase steadily in both liver and flesh during the entire duration of the trial.  
However, it is possible this time could be reduced if relatively larger and older fish, 
actively depositing lipid, were fed dietary CLA although this has to be balanced with the 
fact that it can take longer to effect changes in tissue fatty acid compositions in larger 
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animals.  Indeed, near market-sized rainbow trout incorporated a maximum CLA level of 
2.4 % of total fatty acids after only six weeks of a twelve week trial in fish diets 
containing 1 % CLA (Ramos et al., 2006).  
In summary, CLA had no effect on growth parameters, but there was a clear but 
gradual trend of increased total lipid and TAG contents in both liver and flesh in fish fed 
CLA, particularly in fish fed high oil diets.  CLA was incorporated into tissue lipids, with 
levels in flesh being 2-fold higher than in liver, but importantly, incorporation in flesh 
was at the expense of n-3 HUFA.  In conclusion however, the results of the present study 
generally do not support the hypothesis that dietary CLA elicits beneficial changes in 
Atlantic salmon smolts in terms of enhanced growth parameters or improved body 
composition and flesh quality through decreased adiposity or lipid deposition.  However, 
salmon fed CLA could be beneficial in the human diet through provision of CLA with 
minimal effect on n-3 HUFA levels.   
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CHAPTER 4. INFLUENCE OF DIETARY CLA ON LIPID 
METABOLISM AND IMMUNE FUNCTION IN 
ATLANTIC SALMON 
4.1 Introduction 
Evidence suggests that CLA could affect lipid accumulation both by decreasing 
synthesis and increasing oxidation in mammals (Pariza et al., 2001). Although the exact 
biochemical mechanism of action of CLA is yet to be elucidated, CLA has been proven 
to alter the gene expression of an array of transcription factors known to be pivotal in the 
control of lipid metabolism.  The most extensively studied of these with regard to studies 
involving CLA in mammals includes the family of nuclear transcription factors named 
peroxisome proliferator-activated receptors or PPARs.  As outlined previously, there are 
three main isoforms of PPAR in mammals named PPARα, PPARβ and PPARγ.  CLA 
isomers are ligands and activators of PPARα/PPARβ (Moya-Camarena; et al., 1999a,b) 
and PPARγ (Belury, 2002) that in mammals are, in turn, known to regulate the expression 
of genes of fatty acid oxidation and lipid deposition in liver/skeletal muscle 
(PPARα/PPARβ) and adipose tissue (PPARγ), respectively.  Generally, increased 
expression and activity of PPARα stimulates fatty acid oxidation through activation of a 
comprehensive set of target genes, including CPT-1 and ACO, primarily in liver 
(Desvergne et al., 2006).  Similarly, activation of PPARβ leads to increased fatty acid 
oxidation, however, principally in muscle (Tanaka et al., 2003).  Activation of PPARγ is 
known to enhance adipogenenis and steatosis in murine models (Desvergne et al., 2006) 
and deletion of this transcription factor results in reduced lipid distribution in muscle 
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(Norris et al., 2003).  However, to date only gross effects have been measured in fish 
administered dietary CLA, and the biochemical pathways have not been directly studied. 
The influence of PPARα is not restricted to effects on fatty acid catabolism given 
that this transcription factor is also implicated in the regulation of fatty acid desaturation.  
Indeed, it has been elucidated that PPARα can directly activate ∆6 desaturase gene 
transcription in rodents (Nakamura and Nara, 2004).  Moreover, PPARs may also be 
implicated in immunological function and have been shown to mediate the expression of 
various genes involved in proliferation of lymphocytes, macrophages, apoptosis and 
inflammation (O’Shea et al., 2003). In addition, other studies have also recently shown 
that CLA confers an anti-inflammatory response in human vascular smooth cells 
(Ringseis et al., 2006) and decreases production of pro-inflammatory products in 
macrophages (Yu et al., 2002), via a PPARγ-dependant mechanism.  
Accordingly, the overall objective was to test the hypothesis that CLA has 
beneficial effects on the biochemistry and physiology of Atlantic salmon through 
affecting lipid and fatty acid metabolism as well as immune function.  The specific aims 
of the present study were to determine the effects of CLA on some key pathways of fatty 
acid metabolism including fatty acid oxidation and HUFA synthesis via fatty acyl 
desaturation and elongation, and in addition, to determine the influence of dietary CLA 
on the innate immunological response of Atlantic salmon.  To this end, salmon smolts 
were fed diets containing two levels of FO (low, ~17 % and high, ~34 %) containing 
three levels of CLA (a 1:1 mixture of the two main isomers present in nature, c9t11 and 
t10c12 at 0, 1 and 2 % of diet) for 3 months.  The effects of dietary CLA on the 
expression of key genes of fatty acid oxidation and HUFA synthesis, and on the enzymic 
activities of the respective pathways were determined. In addition, the effect of CLA on 
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the expression of the potentially important transcription factors, PPARs, was determined 
in selected tissues. Finally, the influence of dietary CLA on some basic haematology and 
non-specific immune response parameters were measured.  
 
4.2 Materials and Methods 
4.2.1 Experimental Fish and Diets 
This experiment was an extension of the work described in Chapter 3.  
Photoperiod adapted Atlantic Salmon smolts (S1/2) were obtained from a commercial 
salmonid farm (Howietoun Fish Farm, Sauchieburn, Scotland) in late October 2003 and 
transported to the Machrihanish, Marine Environmental Research Laboratory, 
Machrihanish, Scotland.  General fish husbandry was followed as described in section 
3.2.2. The formulations and fatty acid compositions of the diets are also presented in 
section 3.2.2. 
4.2.2 Sampling and Analysis 
Sampling of the fish was carried out essentially as described in section 3.2.3.  In 
addition though, 0.5 g samples of liver, white and red muscle, intended for molecular 
analysis, were rapidly dissected from six fish (two per tank) and immediately frozen in 
liquid nitrogen prior to storage at -80 oC .  Samples of 1-2 g of liver, white and red 
muscle for biochemical analyses were also collected and immediately frozen in liquid 
nitrogen prior to storage at -80 oC.  Blood and head kidney was extracted from the 
remaining sampled fish prior to being assayed for basic haematology and non-specific 
immune response parameters as detailed in section 2.4. 
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For biochemical analyses (enzyme and pathway assays), homogenates of liver, 
red and white muscle, and liver microsomes were prepared as described in sections 2.3.1 
and 2.3.2. Peroxisomal β-oxidation capacity and CPT-1 activity were measured in 
homogenates of liver, red and white muscle as described in sections 2.3.3 and 2.3.4, 
respectively.  HUFA synthesis in liver microsomes was determined as described in detail 
in section 2.3.2.  
For gene expression studies, the PCR primers were designed according to the salmon 
cDNA sequences for ∆6 desaturase (accession no. AY458652), ∆5 desaturase (accession 
no: AF478472), CPT-1 and PPARα (M.J. Leaver, personal communication), PPARβ1 
(accession no: AJ416953) and PPARγ (accession no: AJ416951).  Primer sequences and 
PCR product sizes are given in Table 4.1.  
Table 4.1 Forward (sense) and reverse (antisense) primers used for QPCR. 
Gene PCR product length Forward primer Reverse primer
∆5 Desaturase 192 5’-GTGAATGGGGATCCATAGCA-3’ 5’-AAACGAACGGACAACCAGA-3’.
∆6 Desaturase 181 5'-CCCCAGACGTTTGTGTCAG-3’ 5’-CCTGGATTGTTGCTTTGGAT-3’
CPT-1 161 5'-GAGAGAGCTGCGACTGAAAC-3' 5'-GACAGCACCTCTTTGAGGAA-3'
PPARα 204 5'-ATCTTCCACTGCTGCCAGTGC-3' 5'-GATGAAGCCCGATCCGTAGGCCACCAGG-3'
PPARβ1 517 5'-TACCGCTGCCAGTGCACCACGGTG-3' 5'-TTCTGGACCAAGCTGGCGTTCTCA-3'
PPARγ 266 5'-TATCTCCCCTCTCTAGAGTA-3' 5'-AGGGCTTATCGTTTACTGAACCTTGATACACGC-3'
 
The linearised plasmid DNA containing the target sequence for each gene was 
quantified to generate a standard curve of known copy number as described in section 
2.5.4.  Amplification and quantification of cDNA samples and DNA standards was 
carried out by quantitative real-time PCR (Q-PCR) essentially as described in section 
2.5.5, with the modifications noted below.  Expression of target genes was normalised to 
total cDNA (i.e. tissue RNA) using Quant-iTTM High Sensitivity DNA Assay kit 
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containing PicoGreen reagent, (Molecular Probes, Rijinsburgerweg, The Netherlands) 
using a modified version of the manufacturers protocol as reported previously (Whelan et 
al., 2003).  Twelve µl of the total cDNA from each of the reverse transcribed tissue RNA 
samples was added to individual wells of a 96-well plate along with 200 µl of a reaction 
mix containing a 1:200 dilution of Quant-iTTM DNA HS reagent in Quant-iTTM DNA 
HS Buffer.  A lid was fixed and the plate vortexed for three bursts of 1 s before flicking 
the plate downward to force the liquid to the bottom of the wells.  The plate was wrapped 
in aluminium foil to prevent light degradation of the PicoGreen Reagent and left for 30 
mins at room temperature.  All reactions were carried out in duplicate.  The plate was 
read using a Wallac Victor2 1420 Multilabel Counter (PerkinElmerTM) using an 
absorbance spectrum for PicoGreen standard of 480 nm for excitation with measurement 
at 520 nm. A linear standard curve was drawn, plotting the average absorbance values 
obtained for M13 cDNA standard values against the standard DNA concentration.   
4.2.3 Statistical Analysis 
All data presented are as means ± SD (n value as stated).  Percentage data and 
data that were identified as non-homogenous were subjected to arcsine transformation 
before analysis.  The effects of dietary CLA and oil content and any interaction thereof 
was determined by two-way analysis of variance (ANOVA) with Bonferroni post-tests to 
determine significance of differences (Prism 3, Graphpad Software, Inc., San Diego, 
USA).  Differences were regarded as significant when P < 0.05 (Zar, 1984). 
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4.3 Results 
4.3.1 HUFA Synthesis, Peroxisomal β-oxidation Capacity and CPT-1 
Activity 
Microsomal HUFA synthesis, measured as the sum of desaturated and elongated 
products of radiolabelled precursor, 18:3n-3, is presented in Figure 4.1.  HUFA synthesis 
was significantly affected by both dietary oil and CLA content as determined by 2-way 
ANOVA (Table 4.2). However, there was significant interaction between the variables.  
Dietary CLA at the 2 % inclusion level fed in combination with the low oil diet increased 
total HUFA synthesis 3-fold compared to fish fed FO alone whereas CLA decreased 
HUFA synthesis at the high dietary oil level.  Supplementation with high dietary oil 
resulted in a significant decrease in HUFA synthesis.  
Figure 4.1 Effects of dietary oil content and conjugated linoleic acid (CLA) on highly 
unsaturated fatty acid (HUFA) synthesis in the liver microsomes.  
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Specific activities are presented as means ± SD (n = 3) relative to Low Oil / 0 % CLA 
(i.e. diet L0) = 1. 
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Table 4.2 Significance (P values) of effects of dietary conjugated linoeic acid (CLA) and 
oil content (Oil) and there interaction (Interact.) as determined by ANOVA. 
CLA Oil Interact.
Liver
HUFA synthesis activity < 0.0001 < 0.0001 < 0.0001
∆6 desaturase expression 0.0009 <0.0001 0.0156
∆5 desaturase expression 0.0031 0.0009 0.5247
β-oxidation activity 0.2757 0.0136 0.5943
CPT-1 activity 0.8506 0.5573 0.8676
CPT-1 expression 0.0027 0.001 0.0483
PPARα expression 0.0001 0.0347 0.1144
PPARβ expression 0.0004 0.0445 0.1649
PPARγ expression 0.0449 0.2061 0.237
Red muscle
β-oxidation activity 0.8133 0.3457 0.5257
CPT-1 activity 0.0355 0.1511 0.4857
CPT-1 expression 0.0022 0.7695 0.3469
PPARα expression 0.2603 0.0172 0.0034
PPARβ expression 0.1182 <0.0001 0.046
White muscle
β-oxidation activity 0.0795 0.1473 0.8623
CPT-1 activity 0.0075 0.0001 0.1409
CPT-1 expression 0.0077 0.7394 0.2716
PPARα expression 0.0292 0.0518 0.0836
PPARβ expression 0.0032 0.0006 0.0822
P Value
 
CPT-1. carnitine palmitoyltransferase-1, HUFA, highly unsaturated fatty acids; PPAR, 
peroxisome proliferator activated receptor; PUFA, polyunsaturated fatty acid. 
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Peroxisomal β-oxidation, estimated by measuring the recovery of radioactivity in 
acid-soluble products of radiolabelled palmitate, was not significantly changed in red or 
white muscle of fish by either dietary treatment, oil content or CLA (Table 4.2).  
However, there appeared to be a trend that indicated CLA may enhance peroxisomal β-
oxidation in white muscle tissue although the high variability made the observed 
incremental increase non-significant.  In contrast, hepatic peroxisomal β-oxidation was 
significantly reduced at the high dietary oil inclusion level however it was unaffected by 
CLA administration (Figure 4.2).   
Figure 4.2 Effects of dietary oil content and conjugated linoleic acid (CLA) on 
peroxisomal β-oxidation activities in tissue homogenates of red and white muscle, and 
liver. 
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Data are presented as means ± SD (n = 3) relative to diet L0 = 1. 
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The activity of CPT-1, a key enzyme of mitochondrial β-oxidation, was 
significantly increased in white muscle of salmon fed high oil diets (Figure. 4.3, Table 
4.2).   Conversely, dietary oil level did not influence CPT-1 activity in liver or red muscle 
of fish.  CLA significantly increased the CPT-1 activity of both red and white muscle, 
particularly when administered in combination with high dietary oil, however the 
observed incremental trend was not mirrored in liver.  Although not significant, there was 
a clear trend that fish administered CLA decreased hepatic CPT-1 activity when fed in 
conjunction with low fat diets (Figure 4.3). 
Figure 4.3. Effects of dietary oil content and conjugated linoleic acid (CLA) on carnitine 
palmitoyl acyltransferase-1 (CPT-1) activities in tissue homogenates of red and white 
muscle, and liver.  
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Data are presented as means ± SD (n = 3) relative to diet L0 = 1. 
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4.3.2 Tissue Expression of CPT-1, Fatty Acyl Desaturases  and PPARs 
Both dietary oil and CLA affected ∆5 and ∆6 gene expression (Figure. 4.4).  
Specifically, gene expression was significantly decreased in response to high dietary oil 
whereas dietary CLA significantly increased both dietary ∆5 and ∆6 desaturase transcript 
levels (Table 4.2).  Dietary CLA significantly increased the expression of CPT-1 in liver, 
red and white muscle (Figure 4.5; Table 4.2). CPT-1 expression was significantly 
increased in liver of fish fed high dietary oil, at least when fed in combination with CLA.  
In contrast, CPT-1 expression was not affected by dietary oil in either muscle tissue 
examined.   
Figure 4.4 Effects of dietary oil content and conjugated linoleic acid (CLA) on the 
expression of ∆6 and ∆5 fatty acid desaturase genes in liver.   
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Genes were determined by Q-PCR and normalised relative to total RNA, determined by 
fluorescent assay, as described in Materials and Methods.  Results are presented as means 
and SD (n = 3) relative to diet L0 = 1. 
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Figure 4.5 Effects of dietary oil content and conjugated linoleic acid (CLA) on the 
expression of carnitine palmitoyl transferase-I (CPT-I) in the liver, red and white muscle.  
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Genes were determined by Q-PCR and normalised relative to total RNA, determined by 
fluorescent assay, as described in Materials and Methods.  Results are presented as means 
and SD (n = 3) relative to diet L0 = 1. 
The expression of all PPAR subtypes was significantly affected by both dietary CLA and 
oil content (Table 4.2).  PPARα expression was increased by dietary CLA in liver and, to 
a lesser extent, white muscle (Figure 4.6).  In red muscle, there was a strong interaction 
between dietary CLA and oil content such that CLA increased expression at low oil 
contents, but the opposite at high dietary oil content.  High oil content may have induced 
increased expression of PPARα in red muscle although the interaction also made this 
difficult to interpret.  PPARβ expression in the muscle tissues was similar to that for 
PPARα in these tissues.  Thus the expression of PPARβ was increased by dietary CLA in 
white muscle whereas there was a significant interaction between CLA and dietary oil in 
red muscle, which made the effects of CLA difficult to interpret (Table 4.2).  However, 
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PPARβ expression was increased by high dietary oil, but dietary CLA decreased PPARβ 
expression in red muscle in fish fed high dietary oil (Figure 4.7). The expression of 
PPARβ in liver was greatest in fish fed 1 % CLA (Table 4.2, Figure 4.7).  Expression of 
PPARγ in liver was significantly increased by dietary CLA, but dietary oil content had no 
significant effect (Table 4.2, Figure 4.8). PPARγ expression in muscle tissues was too 
low to be reliably determined.  
Figure 4.6 Effects of dietary oil content and conjugated linoleic acid (CLA) on the 
expression of PPARα in the liver, red and white muscle. 
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Genes were determined by Q-PCR and normalised relative to total RNA, determined by 
fluorescent assay, as described in Materials and Methods.  Results are presented as means 
and SD (n = 3) relative to diet L0 = 1. 
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Figure 4.7 Effects of dietary oil content and conjugated linoleic acid (CLA) on the 
expression of PPARβ in the liver, red and white muscle. 
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Genes were determined by Q-PCR and normalised relative to total RNA, determined by 
fluorescent assay, as described in Materials and Methods.  Results are presented as means 
and SD (n = 3) relative to diet L0 = 1. 
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Figure 4.8 Effects of dietary oil content and conjugated linoleic acid (CLA) on the 
expression of PPARγ in the liver.  
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Genes were determined by Q-PCR and normalised relative to total RNA, determined by 
fluorescent assay, as described in Materials and Methods.  Results are presented as means 
and SD (n = 3) relative to diet L0 = 1. 
4.3.3 Basic Haematology and Selected Innate Immunological 
Measurements 
There were no significant differences in blood cell counts in Atlantic salmon fed 
CLA at either 1 or 2 % dietary inclusion levels compared with controls (Table 4.2). In 
contrast, red blood cell counts were significantly decreased in fish fed the high oil diets. 
However, haematocrit value was unaffected by either dietary treatment.  There was a 
tendency for the phagocytic ability of head kidney macrophages, as measured by the 
phagocytic index and ratio, to increase in fish fed dietary CLA, particularly when fed in 
combination with low oil diets however this trend was not significant (Table 4.3).  
Respiratory burst as measured by the reduction of NBT by head kidney macrophages of 
Atlantic salmon in the presence of PMA was not influenced by either CLA or dietary oil 
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level (Table 4.3).  Additionally, lysozyme activity was not altered in response to dietary 
treatment (Table 4.3).  
Table 4.3 Effects of dietary oil content and conjugated linoleic acid (CLA) on basic 
haematology and selected immunological parameters of Atlantic salmon.  
Diet
L0 1.00 ± 0.43 1.00 ± 0.19 62.9 ± 10.6 0.19 ± 0.09 11.43 ± 5.10 2.32 ± 1.01 1503.0 ± 378.4
L1 1.03 ± 0.25 1.07 ± 0.21 61.4 ± 4.7 0.23 ± 0.10 12.12 ± 2.45 2.22 ± 0.67 1456.2 ± 389.2
L2 1.13 ± 0.48 0.89 ± 0.19 61.6 ± 10.4 0.24 ± 0.08 12.70 ± 4.81 2.39 ± 0.15 1477.3 ± 409.9
H0 0.96 ± 0.31 1.24 ± 0.16 57.3 ± 10.6 0.18 ± 0.01 12.96 ± 4.21 2.92 ± 0.33 1402.3 ± 299.8
H1 0.98 ± 0.21 1.02 ± 0.25 57.5 ± 7.8 0.17 ± 0.03 14.11 ± 2.99 2.19 ± 1.10 1555.5 ± 329.0
H2 0.92 ± 0.23 1.15 ± 0.17 67.3 ± 9.0 0.19 ± 0.11 13.23 ± 2.52 2.52 ± 0.34 1493.0 ± 190.2
ANOVA
CLA
Oil
Interact. 0.7723
RB A610
(L0 =1) (L0 =1) (U/min/ml)
0.9286
0.96680.2992 0.3242
0.1225 0.7923 0.2727 0.7179 0.8929 0.5244
Lysozyme
0.4232 0.9412 0.3571 0.6539 0.8206 0.3543
(104 cells)
PR (%)RBC WBC PCV (%) PI
0.0298 0.3836 0.6822 0.14
 
RBC, red blood cell count (relative to L0 diet); WBC, white blood cell count (relative to 
L0 diet); PCV, packed cell volume; PI, phagocytic index; PR, phagocytic ratio; RB, 
respiratory burst. 
 
4.4 Discussion 
CLA has the capacity to exert both agonistic and antagonistic effects on a wide 
variety of lipid metabolic factors. These effects are entirely dependent upon the pattern of 
lipid metabolism (Tocher, 2003), which itself varies with species, tissue type, age, dietary 
factors such as lipid content and oil composition, CLA isomer composition and duration 
of supplementation. Thus, it is hard to define a specific biochemical mechanism of action.  
However, the view that CLA can affect lipid accumulation both by decreasing de novo 
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fatty acid synthesis and increasing oxidation is well established, at least in mammals.  For 
example, CLA has been shown to inhibit fatty acid synthetase activity in rat liver (Oku et 
al., 2003), and can also suppress TAG accumulation and can increase fatty acid oxidation 
in 3T3-L1 adipocytes (Evans et al., 2002). It is hypothesised that CLA exert such effects 
on lipid metabolism at the transcriptional level by altering gene expression of key 
regulatory proteins and enzymes mediated, in part, by PPARs.  However, it was unclear 
whether CLA have the ability to alter lipid metabolism in fish in a manner similar to that 
of mammalian models (Berge et al., 2004).   
In the present study, salmon fed CLA exhibited increased expression of ∆5 and 
∆6 fatty acyl desaturases in liver; particularly evident in the low oil diet, which displayed 
around a 2-fold increase in expression of ∆5 and ∆6 desaturase at 2 % inclusion of CLA 
relative to the control.  This was at least partly reflected in HUFA synthesis activity, 
which increased in fish fed 2 % CLA at the low dietary oil content.  Analogously, ∆5 and 
∆6 fatty acid desaturase expression was shown to increase in mice fed CLA (Takaheshi et 
al., 2002), while the amount of the HUFA, 20:5n-3 and 22:6n-3, increased in hybrid 
striped bass in response to dietary CLA (Twibell et al., 2000). One explanation may be 
that transcription factors equivalent to mammalian PPARα and sterol response element 
binding protein-1c (SREBP-1c, a transcription factor involved in regulating adipogenesis) 
are directly involved in regulating ∆6 and ∆5 fatty acyl desaturases in fish via a feedback 
mechanism.  A similar mechanism for the regulation of fatty acyl desaturase gene 
expression has been proposed in mammals whereby ∆6 desaturase gene expression is 
partly regulated by PPARα (Nakamura and Nara, 2004). Indeed, it has been shown that 
ligand activation of PPARα via peroxisome proliferators can result in up-regulation of ∆5 
and ∆6 desaturases, while high PUFA feeding down-regulated these genes in a SREBP-1-
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dependent mechanism (Nakamura and Nara, 2004).  In salmon liver, CLA feeding was 
associated with increases in ∆5 and ∆6 fatty acyl desaturase expression and HUFA 
synthesis in low oil treatments, which might be indicative of a role for ligand activation 
of PPARα by CLA.  In contrast, in high oil diets, ∆5 and ∆6 expression and HUFA 
synthesis was repressed, even in the presence of similar amounts of CLA, possibly 
indicating a role for SREBP-1 proteins.  Interestingly, CLA feeding also increased the 
levels of PPARα, providing some further support for this mechanism of regulation in 
salmon liver. As previously elucidated however, dietary CLA had no significant effect on 
either liver or flesh (muscle) fatty acid compositions in salmon (Chapter 3), thus it 
appears that the increased fatty acyl desaturase expression and HUFA synthesis activity 
does not have a major physiological consequence in terms of gross fatty acid 
compositions.  That alterations in desaturase gene expression and HUFA synthesis 
activity in liver can have relatively little effect on tissue fatty acid compositions has been 
demonstrated previously in several trials in which salmon have been fed VOs (Bell et al., 
2001, 2002). The data from the present trial also show a clear correlation between 
desaturase expression and HUFA synthesis activity, and dietary oil content, with diets 
containing high oil conferring significantly lower levels of desaturase expression and 
HUFA synthesis activity compared to low oil diets. In addition to effects on HUFA 
synthesis, it is fairly well established that there is a reduction in fatty acid synthesis 
(lipogenesis) as a result of high dietary oil levels, as has previously been demonstrated in 
Atlantic salmon and other fish species (Tocher, 2003). 
Beta-oxidation is the principal means of fatty acid catabolism in vertebrates and 
the basic mechanism of the pathway, and possibly regulation, appear to be highly 
conserved in mammals and fish (Nanton et al., 2003).  Unfortunately, in the present trial, 
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it was not possible to measure mitochondrial and hence total β-oxidation as this would 
require assay of fresh tissue and it was not possible to do radioactive work outwith the 
University laboratory.  Therefore assays had to be performed on frozen tissue samples.  
To estimate mitochondrial β-oxidation in these frozen samples, the activity of a key 
enzyme in mitochondrial β-oxidation, CPT-1, was measured.  However, peroxisomal β-
oxidation can still be measured in tissue samples previously frozen as the peroxisomal 
membranes are not damaged by freezing as the mitochondrial membranes are.  
Nevertheless, in the present trial, peroxisomal β-oxidation capacity was not significantly 
affected in red or white muscle tissue of fish fed dietary CLA.  In contrast, CLA  
significantly increased both CPT-1 expression and activity in these tissues.  It has been 
previously suggested that in rats, CLA can increase mitochondrial β-oxidation in a 
variety of tissues via an increase in CPT-1 activity (Rahman et al., 2001).  Mitochondria 
are the major site of β-oxidation in salmonid muscle and thus are more likely to influence 
total fatty acid catabolism in comparison to peroxisomal β-oxidation in this tissue 
(Frøyland et al., 2000).  Obviously, it would have been advantageous to have measured 
mitochondrial β-oxidation in order to offer a more unequivocal interpretation of these 
results; however the preliminary evidence suggests that CLA may enhance total fatty acid 
catabolism in muscle.  Although red muscle was the site of higher peroxisomal β-
oxidation activity in the present study, in terms of total activity, white muscle actually 
represents the site of the largest proportion of fatty acid oxidation in salmon due to the 
large size of the tissue (Frøyland et al., 2000). There are few studies in fish species to 
compare the present data with.  However, dietary lipid level did not alter β-oxidation 
activity in the muscle of haddock Melanogrammus aeglefinus L. fed graded levels of oil 
(Nanton et al., 2003).  In the present study, dietary oil content had no major effect on 
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peroxisomal β-oxidation activity or CPT-1 mRNA levels in either red or white muscle, or 
CPT-1 activity in red muscle, although CPT-1 activity was increased by dietary oil 
content in white muscle.    
Previous studies in rodents showed that CPT-1 mRNA level was elevated in liver 
in response to dietary CLA (Degrace et al., 2004). In the present study, and similar to 
results in muscle, CPT-1 gene expression was found to be up-regulated in salmon liver in 
response to dietary CLA supplementation, although this was not accompanied by 
increased CPT-1 activity.  Furthermore, CPT-1 expression was increased in salmon liver 
in fish fed the high oil diet, at least when fed in combination with CLA.  Consistent with 
this it appeared that in fish fed CLA, CPT-1 activity was also higher in fish fed the high 
oil diet compared with fish fed the low oil. Previously, it was shown that the in vivo rate 
of fatty acid oxidation was associated with in vitro CPT-I activity (Rasmussen and Wolfe, 
1999).  However, studies determining changes in energy metabolism in hamsters fed 
CLA found disparities between the activity of CPT-1 and lipid oxidation in the liver 
(Bouthegourd et al., 2002).  Pertinent to this lack of correlation between CPT-1 
expression and activity in liver is the fact that, with Atlantic salmon of similar age and 
size, catabolism of fatty acids in liver was reported to be principally due to peroxisomal, 
rather than mitochondrial, β-oxidation (Frøyland et al., 2000).  Consequently, CPT-1 may 
not have a prominent role as a regulatory element of fatty acid oxidation in salmon smolt 
liver, considering it is primarily involved in mitochondrial metabolism (Eaton et al., 
1996).  This may also be relevant in the present study as it provides a mechanism 
whereby changes in CPT-1 expression and/or activity could be unrelated to total β-
oxidation activity in salmon liver.  Clearly, it would have been desirable to have been 
able to measure mitochondrial β-oxidation, and also to have measured ACO activity, the 
Chapter 4  
 110
rate limiting enzyme of peroxisomal β-oxidation, in the present study.  However, the data 
that were obtained suggest that the major fatty acid oxidation pathway (peroxisomal) in 
salmon liver was generally unaffected by dietary CLA, and actually decreased by high 
dietary oil.  In comparison, graded levels of dietary lipid showed no significant 
differences in total β-oxidation activity in liver of haddock (Nanton et al., 2003). 
There is consolidating evidence that lipid homeostasis is, at least in part, 
modulated through the PPAR transcription factors in mammals.  Recent studies suggest 
that CLA could mediate this activation by acting as high-affinity ligands for a number of 
PPAR isotypes, particularly PPARα (Moya-Camarena et al., 1999b,c).  PPARα is 
intimately involved in the regulation of genes involved in mitochondrial fatty acid 
oxidative processes in mammals (Gulick et al., 1994), whereas PPARγ is primarily 
involved in lipid deposition via preadipocyte differentiation and lipogenesis (Gregoire et 
al., 1998).  Very recent work has elucidated that marine fish also share homologous gene 
sequences, with similar phylogenetic characteristics, to the mammalian PPAR 
counterparts, possibly also suggesting similar molecular roles (Boukouvala et al., 2004; 
Leaver et al., 2005, 2007). However, Atlantic salmon may possibly contain up to five 
PPAR genes, as opposed to three in mammals, and therefore the precise roles of piscine 
PPARs have not been conclusively defined (Andersen et al., 2000; Leaver et al., 2005).  
The effects of CLA on mammalian PPAR gene expression are ambiguous and 
seem to be dependant partly on species, partly on tissue type, and partly on CLA isomer. 
The majority of studies describe a decrease in PPARγ mRNA in isolated adipocytes, or in 
adipose tissue from mice treated with t10c12 CLA or a 1:1 mixture of the two 
predominant CLA isomers (Brown et al., 2003a; Granlund et al., 2003; Kang et al., 
2003). Conversely, CLA has also been reported to increase expression of PPARγ in liver 
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of mice, and in white adipose tissue in rats (Clement et al., 2002; Zhou et al., 2004).  
T10c12 CLA down-regulated PPARα in mice (Warren et al., 2003), however there was 
no change in PPARα expression in liver of hamsters fed diets containing t10c12 or c9t11 
CLA (Macarulla et al., 2005).  In the present study, there was a trend for PPARα 
expression to be increased by dietary CLA in liver, red and white muscle of fish fed the 
low oil diets. In addition, up-regulation of PPARα in response to dietary CLA was also 
observed in white muscle and liver in fish fed the high oil diets.  As mentioned above, 
activation of PPARα (via peroxisome proliferators) can induce β-oxidation through up-
regulation of key enzymes such as CPT-1 in mammals (Nakamura and Nara, 2004).  The 
data in the present trial suggest that PPARα may also be implicated in the action of CLA. 
In general CLA increased the levels of both CPT-1 mRNA and PPARα and, in some 
cases, PPARβ mRNA.  The exceptions to this were PPARα and PPARβ expression in 
red muscle from fish fed the high oil diets, which tended to decrease with dietary CLA 
inclusion and at high CLA inclusion liver PPARβ was decreased.  It has been shown in 
PPARα-knockout mice that the effects of CLA on body fat distribution and 
mitochondrial lipid catabolism genes are not mediated by PPARα, but that the 
peroxisomal β-oxidation gene ACO is mediated by a PPARα-dependent mechanism 
(Peters et al., 2001).  If this is true in fish then it is possible that effects on mitochondrial 
lipid catabolic genes such as CPT-1 could be mediated through PPARβ subtypes. 
However, PPARα expression exceeds that of PPARβ1 by an order of magnitude in 
muscle tissues suggesting PPARα would have the predominant regulatory role.  Of the 
tissues investigated in salmon, PPARγ expression was only detected in liver.  However, 
in agreement with work carried out on mice (Clement et al., 2002), PPARγ mRNA levels 
increased in liver of salmon fed CLA, and CLA has been reported to cause ‘fatty liver’ in 
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mice (Tsuboyama-Kasaoka et al., 2000; Clement et al., 2002).  However, fish PPARγ 
does not appear to share the same ligand activation profile as in mammals (Leaver et al., 
2005).  Fish PPARγ does not respond to fatty acids and has specific amino acid 
differences compared to the mammalian form which may explain the lack of activation, 
suggesting that is unlikely, despite increases in liver, that CLA would mediate its effects 
through this transcription factor.  Indeed, neither liver size nor lipid content was 
increased in salmon fed CLA (Chapter 3).   
The extent to which the effects of CLA on immunological status could be 
investigated in the present study was rather limited but the data obtained showed that 
CLA had very little effect on the few parameters measured.  Therefore, the data in the 
present study suggest that dietary CLA does not confer a non-humoral immunological 
response in Atlantic salmon, which is in agreement with similar studies in rainbow trout 
(Clarke, 2003; Marshall, 2003).    
In summary, gene expression and activity of various lipid metabolic factors were 
altered in response to graded levels of CLA and/or dietary oil content in Atlantic salmon 
smolts.  Specifically, some association was observed between dietary CLA, liver HUFA 
synthesis and desaturase gene expression, and liver PPARα expression although this 
varied with dietary oil content.  In addition, some association between dietary CLA, CPT-
1 expression and activity, and PPARα expression was observed in muscle tissues.  
However, the magnitude of the changes in fatty acid metabolism observed were not 
sufficient to bring about major changes in the whole body lipid and fatty acid 
composition of the fish (Chapter 3).  Additionally, dietary CLA does not appear to 
significantly influence the immunological response in Atlantic salmon.  In conclusion, 
this study has presented evidence that dietary CLA may have some effects on fatty acid 
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metabolism in Atlantic salmon, but that there is little evidence of a direct mechanism 
involving PPAR transcription factors. However, considering the importance of dietary 
lipid in aquaculture, further work is required to assess the potential of CLA as a dietary 
supplement, and the role of PPARs in the regulation of lipid metabolism in fish.  
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CHAPTER 5. INFLUENCE OF DIETARY CLA AND TTA 
IN ATLANTIC COD 
5.1 Introduction 
Aquaculture is the fastest growing animal-based agricultural food production 
sector, expanding at more than 9 % per year, and currently contributes over one third of 
all the fish in the human food basket (Tacon, 2003).  Farming of finfish in seawater is 
dominated by Atlantic salmon (Salmo salar L.), but other marine species are becoming 
increasingly important, including temperate species such as gilthead sea bream (Sparus 
aurata), European sea bass (Dicentrarchus labrax) and turbot (Psetta maximus) and, in 
colder waters, halibut (Hippoglossus hippoglossus). Recently, declining catches and high 
market prices have seen Atlantic cod (Gadus morhua L.) emerge as the most promising 
species for culture in the northern Atlantic area (Brown and Puvanendran, 2002; Brown 
et al., 2003b) with production expanding in Norway and Scotland.  A major factor 
influencing the commercial success of cod culture will be the development of diets and 
feeding strategies to maximise growth and feed conversion efficiencies (Morais et al., 
2001; Lall and Nanton, 2002; Hemre et al., 2003, 2004; Rosenlund et al., 2004). One 
major issue pertaining to this is that cod store lipid in the liver and, in early studies, 
farmed fish were reported to have enlarged livers and display a HSI of over 12 % 
compared to values of 2 – 6 % in wild fish (Jobling, 1988). In early feeding trials with 
captive cod, the HSI increased from 9.5 % to an average of 13 %, and liver fat increased 
from around 55 % to 67 – 70 % in cod fed various dietary oils (Lie et al., 1986). Further 
studies have consistently shown that farmed cod have high liver lipid levels that can 
exceed 70 % of wet weight, and have higher HSI and condition factor (K) than their wild 
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counterparts (Dos Santos et al., 1993; Shahidi and Dunajski, 1994; Grant et al., 1998; 
Gildberg, 2004). Dietary formulations in aquaculture have tended to exhibit an upward 
trend in lipid as this has successfully increased weight gains, but several studies have 
shown that a potential detrimental side-effect of high fat diets is the deposition of excess 
lipid in tissues (Sargent et al., 2002; Tocher, 2003). This may exacerbate the enlarged 
fatty liver problem in farmed cod and so it is important to gain a clearer understanding of 
the mechanisms determining lipid and fatty acid homeostasis and deposition.   
Excess lipid in cod liver is undesirable since in most cases it is not utilised as a 
food or supplement source in mainstream aquaculture.  Hence, lipid that is deposited in 
the liver of cod is in effect wasted energy that can be used for growth.  However, it is 
noteworthy that unlike salmon, there is no effect on edible muscle lipid content. It is 
therefore important to investigate the possibility of incorporating micronutrients, such as 
CLA and TTA, as additives in aquafeeds so that they may be able to counteract any of the 
abovementioned deleterious consequences.   
Although there are a number of studies detailing the effect of TTA in animal 
models (Berge et al., 2005) prior to the initiation of this study there were no documented 
reports of this bioactive fatty acid being assessed as a dietary supplement in the context 
of aquaculture nutrition.  However, recently four studies have been published, which 
largely investigated the effects of dietary TTA on Atlantic salmon lipid metabolism both 
in vitro and in vivo.  Specifically, the first study analysed the effects of dietary TTA on 
feed intake, growth, tissue fatty acid composition and β-oxidation (Moya-Falcon et al., 
2004). This study concluded that administration of TTA altered the fatty acid 
composition of several tissues and increased hepatic mitochondrial β-oxidation but also 
increased mortality and depressed the growth of the fish.  A subsequent study 
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investigated the effect of 0.75 mM TTA on TAG accumulation and secretion by salmon 
hepatocytes in culture (Vegusdal et al., 2005).  The results indicated that hepatocytes 
incubated with TTA secreted less TAG than when incubated with no fatty acid.  It was 
also suggested the TAG formation was retarded in response to dietary TTA inclusion.  A 
third paper investigated the influence of 0.8 mM TTA and temperature on the lipid 
metabolism of cultured Atlantic salmon hepatocytes (Moya-Falcon et al., 2006); 
concluding that ACO activity was not altered in response to TTA administration.  This 
study also elucidated the effect of feeding Atlantic salmon 0.6 % TTA on cellular uptake 
and oxidation of [1-14C]18:1n-9 in hepatocytes.  Although not significant, there was a 
higher production of oxaloacetate and malate in hepatocytes from TTA-fed fish, which 
was purportedly due to increased mitochondrial β-oxidation.  The fourth study examined 
the consequence of feeding dietary TTA to Atlantic salmon smolts, focussing specifically 
on lipid metabolism and gene expression of a number of enzymes implicated in lipid 
homeostasis in muscle and liver (Kleveland et al., 2006).  This study found that there was 
significantly higher mortality and lower growth rate in fish fed 0.6 % TTA compared 
with fish fed FO diets alone.  However, ACO mRNA level and enzyme activity were 
unaffected by dietary TTA suggesting that peroxisomal β-oxidation was not altered.  
Additionally, TTA increased the HSI whilst PPARα and ApoA1 transcripts were 
decreased in liver of salmon.  This study also reported that there were no significant 
effects on the fatty acid composition, lipid content or gene expression profiles of enzymes 
involved in lipid metabolism of muscle, implying that the liver is more responsive to the 
effects of dietary TTA.   
The aims of the present study were to determine the effects of CLA and TTA on 
growth performance, lipid content, composition and metabolism, and immunomodulation 
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in Atlantic cod. The overall objective being to test the hypotheses that CLA and TTA 
have beneficial effects in cod culture including decreased liver size and proportion 
through decreased lipid content, positive health benefits through improved immune 
status, and increased nutritional quality through effects on fatty acid compositions 
including accumulation of bioactive fatty acids, CLA and TTA, in flesh.  Juvenile cod 
were fed for three months on FM and FO diets of basically commercial formulation, but 
containing either 0.5 % or 1 % CLA, or 0.5 % TTA. The effects of the functional fatty 
acids on growth, feed efficiency, body proximate composition, liver weight and lipid 
composition, fatty acid compositions of flesh and liver, key enzymes of fatty acid 
oxidation, and some immune parameters were determined. 
5.2 Materials and Methods 
5.2.1 Experimental Fish 
The dietary trial was performed at Viking Fish Farms, Ardtoe Marine Laboratory, 
Ardnamurchan, Scotland, between October 2005 and January 2006.  Hatchery reared 
Atlantic cod of the 2004 year class were randomly distributed between twelve indoor, 
round tanks of 1.5 m3 volume (1.72 m diameter) supplied with filtered seawater.  The 
initial stocking density was 50 fish of average weight 127 ± 15 g per tank (5.8 kg/m3), 
with 25 fish per tank individually PIT tagged (Passive Induced Transponder, Fish Eagle, 
Gloucestershire, England) prior to stocking.  Water temperature was maintained at 12 oC 
(± 1 oC) throughout the trial, with a light regime of 12L:12D.   
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5.2.2 Experimental Diets 
Four experimental diets were fed to triplicate tanks for three months, with feeding 
supplied to appetite manually in one morning feed over a period of 1 h.  Waste feed 
pellets were collected and counted 1 h later.  The experimental diets were formulated in 
order to satisfy the nutritional requirements of marine fish (National Research Council, 
1993), and were formulated and manufactured by BioMar A/S, Brande, Denmark.  The 
dietary formulations are presented in Table 5.1.   
Table 5.1 Formulations (percentage of dry ingredients) and proximate compositions 
(percentage of total diet) of experimental diets. 
Fishmeal
Sunflower meal
Wheat gluten
Legume seeds
Micronutrients
Fish oil
CLA
TTA
Moisture 7.5 ± 0.1 ab 7.3 ± 0.3 b 8.0 ± 0.2 a 8.0 ± 0.2 a
Lipid 14.8 ± 0.3 15.4 ± 0.8 15.4 ± 0.7 15.4 ± 0.5
Protein 49.9 ± 0.4 50.2 ± 0.1 49.7 ± 0.4 49.5 ± 0.5
Ash 10.6 ± 0.0 ab 10.7 ± 0.1 a 10.5 ± 0.0 b 10.5 ± 0.0 b
FO CLA1 CLA2 TTA
0.0 0.0 0.0 0.5
0.0 0.8 1.7 0.0
8.8 8.0 7.1 8.3
0.4 0.4 0.4 0.4
17 17 17 17
5 5 5 5
17 17 17 17
53 53 53 53
 
Results for proximate compositions are means ± S.D. (n=3).  Micronutrients, includes 
essential amino acids (methionine and lysine), vitamins, minerals. FO, control diet 
containing fish oil alone, CLA1 and CLA2, diets supplemented with 0.5 and 1 % CLA; 
TTA, diet supplemented with 0.5 % TTA. 
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Isonitrogenous diets were based on FM and standard Northern hemisphere FO 
with the latter being replaced partially by 0.5 and 1 % CLA, and 0.5 % TTA (as a 
percentage of the total diet).  Diets were identical in formulation other than fatty acid 
composition with CLA (LUTA-CLATM 60, containing 60 % CLA methyl esters as a 
50:50 mixture of c9t11 and t10c12 isomers; BASF AG, Ludwigshafen, Germany) and 
TTA (supplied by Dr Rolf Berge, Thia Medica A.S., Bergen, Norway) balanced by FO 
(capelin oil, Norsemeal Ltd, London, UK).  The fatty acid compositions of the diets are 
presented in Table 5.2.  
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Table 5.2 Fatty acid compositions (percentage of weight) of experimental diets 
containing CLA and TTA. 
14:0 7.2 ± 0.1 a 6.8 ± 0.2 b 6.2 ± 0.1 c 6.2 ± 0.0 c
15:0 0.6 ± 0.0 0.5 ± 0.0 b 0.5 ± 0.0 b 0.5 ± 0.0 b
16:0 19.7 ± 0.2 a 18.9 ± 0.1 b 18.2 ± 0.0 c 18.7 ± 0.1 b
18:0 4.0 ± 0.0 4.0 ± 0.0 4.0 ± 0.0 3.9 ± 0.0
Total saturated1 31.8 ± 0.3 a 30.5 ± 0.3 b 29.1 ± 0.1 c 29.3 ± 0.1 c
16:1n-7 7.8 ± 0.1 a 7.4 ± 0.1 b 7.0 ± 0.2 c 7.4 ± 0.0 b
18:1n-9 9.9 ± 0.1 c 10.8 ± 0.0 b 11.8 ± 0.2 a 9.8 ± 0.1 c
18:1n-7 3.2 ± 0.0 a 3.1 ± 0.1 a 2.8 ± 0.0 b 3.1 ± 0.0 a
20:1n-9 2.3 ± 0.0 2.2 ± 0.0 2.3 ± 0.2 2.3 ± 0.0
22:1n-11 3.2 ± 0.0 a 3.1 ± 0.0 ab 3.0 ± 0.0 b 3.1 ± 0.0 a
24:1n-9 0.6 ± 0.0 0.5 ± 0.1 0.5 ± 0.0 0.5 ± 0.0
Total monoenes2 27.3 ± 0.2 a 27.4 ± 0.2 a 27.6 ± 0.1 a 26.5 ± 0.0 b
CLA (9c,11t) 0.0 ± 0.0 c 1.8 ± 0.1 b 3.2 ± 0.2 a 0.0 ± 0.0 c
CLA (10t,12c) 0.0 ± 0.0 c 1.7 ± 0.1 b 3.1 ± 0.2 a 0.0 ± 0.0 c
TTA 0.0 ± 0.0 b 0.0 ± 0.0 b 0.0 ± 0.0 b 2.8 ± 0.2 a
18:2n-6 5.7 ± 0.1 b 5.6 ± 0.0 b 5.9 ± 0.0 a 5.6 ± 0.1 b
20:4n-6 1.1 ± 0.0 a 1.0 ± 0.0 b 0.9 ± 0.0 b 1.1 ± 0.0 a
Total n-6 PUFA3 7.8 ± 0.0 a 7.6 ± 0.1 b 7.7 ± 0.1 ab 7.6 ± 0.1 b
18:3n-3 1.0 ± 0.0 a 1.0 ± 0.0 a 0.9 ± 0.0 b 1.1 ± 0.0 a
18:4n-3 2.5 ± 0.0 a 2.4 ± 0.0 b 2.2 ± 0.0 c 2.5 ± 0.0 a
20:4n-3 0.7 ± 0.0 0.7 ± 0.0 0.6 ± 0.0 0.7 ± 0.0
20:5n-3 14.0 ± 0.0 a 13.2 ± 0.2 b 12.3 ± 0.1 c 14.2 ± 0.1 a
22:5n-3 1.9 ± 0.5 1.5 ± 0.0 1.4 ± 0.0 1.7 ± 0.0
22:6n-3 12.8 ± 0.0 b 12.3 ± 0.1 c 11.9 ± 0.1 d 13.4 ± 0.1 a
Total n-3 PUFA4 33.1 ± 0.5 b 31.1 ± 0.3 c 29.3 ± 0.2 d 33.9 ± 0.2 a
Total PUFA 40.9 ± 0.4 a 38.7 ± 0.3 b 37.0 ± 0.3 c 41.5 ± 0.3 a
n-3/n-6 4.2 ± 0.1 b 4.1 ± 0.0 b 3.8 ± 0.0 c 4.5 ± 0.0 a
FO CLA1 CLA2 TTA
 
Values are means ± S.D. (n=3). Superscript letters denote significant differences between 
the diets.  1, includes 20:0, present at up to 0.3 %. 2, includes 20:1n-7 present at up to 0.3 
%. 3, includes 18:3n-6, 20:2n-6, 20:3n-6 and 22:4n-6 present at up to 0.4 %. 4, includes 
20:3n-3, present up to 0.2 %.  
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5.2.3 Sampling and Analysis 
At the initiation of the trial, all fish were anaesthetised with Metomidate (50 
mg/L), identified by PIT tag if present, and individually weighed and fork length 
recorded.  At the end of the trial, 9 fish per tank (27 per dietary treatment) were killed by 
a blow to the cranium then sampled for compositional analyses, with 3 whole fish/tank 
frozen immediately at -20 oC for whole body proximate compositional (proximate) 
analysis.  Blood and head kidney for immunological studies were removed from the 
remaining fish as described in 2.4.1 and 2.4.5 respectively. The fish were then eviscerated 
and used for biometric determinations (hepato-, and viscero-somatic indices) and for 
tissue lipid analyses.  Flesh samples were excised from the epaxial myotomes anterior to 
the first dorsal fin ray (Flesh Quality Cut) and livers were taken from six fish, pooled in 
two samples of 3 fish each, and frozen immediately in liquid nitrogen (livers) or dry ice 
(flesh). Samples of 1-2 g of liver, white and red muscle for biochemical analyses were 
also collected and immediately frozen in liquid nitrogen.  Samples were subsequently 
stored at -80 oC prior to biochemical analysis. 
Blood cell counts and haematocrit measurements were carried out as described in 
sections 2.4.2 and 2.4.3 respectively.  Total lipids of liver, muscle and diet were extracted 
and quantified as described in section 2.3.7 and lipid class analysis was carried out as 
detailed in section 2.3.8.  The method previously employed to produce fatty acid methyl 
ester (FAME) in samples containing CLA described in section 3.2.3, was unsuccessful in 
quantitatively methylating TTA in this trial since degradation of TTA was observed upon 
GC analysis.  It is probable that the breakdown products formed using the 
abovementioned methylation procedure are in fact sulphoxide or sulphone derivatives, 
which are commonly formed during strong acidic hydrolytic conditions (Pavol Bohov, 
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Personal Communication).  A small experiment was conducted to deduce the optimal 
time and temperature at which TTA could successfully be methylated with little to no 
artefact formation.  It was also imperative that the experimental conditions facilitated 
complete methylation of all components including CLA and with little to no residual 
degradation of other fatty acids within the sample.  By varying the time (duration) and 
temperature of the methylation procedure, it was concluded that the optimal reaction 
conditions using acid-catalysed transesterification and facilitating the complete 
methylation of TTA, CLA and all other fatty acids were incubation at 80 oC for 3 h in the 
presence of 2 ml 1 % (v/v) H2SO4 in methanol together with 1 ml of toluene under a 
nitrogen atmosphere.  FAME were subsequently extracted, purified and quantified as 
described in section 2.3.9.  Charring of TLC plates after FAME purification allowed 
visualisation of any non-methylated total lipid.  Since, after 3 h of incubation, there were 
no bands corresponding to non-methylated total lipid on the TLC plates, it was deduced 
that all the fatty acids in the samples had been successfully methylated.  Indeed. the 
levels of CLA and TTA obtained in Table 5.2 expressed as a percentage of total dietary 
lipid show quantitative recovery of these bioactive fatty acids after using the above 
described methylation procedure.  Some key activities associated with fatty acid 
oxidation were determined in liver, white and red muscle.  Peroxisomal β-oxidation 
capacity was estimated as described in section 2.3.3. CPT-1 and ACO activities were 
determined as described in sections 2.3.4 and 2.3.5, respectively. 
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5.3 Results 
5.3.1 Dietary Formulation 
The control FO diet contained 41 % total PUFA, including 14 % 20:5n-3, 13 % 
22:6n-3 and almost 6 % 18:2n-6, 32 % total saturates, mainly 16:0, and 27 % total 
monoenes, mainly 18:1n-9 and 16:1n-7 (Table 5.2).  Inclusion of CLA in the diets 
resulted in levels of total CLA of 3.5 % and 6.3 % of total fatty acids at the 0.5 % and 1 
% dietary inclusion levels, respectively.  CLA inclusion resulted in lower levels of 14:0, 
16:0, 20:5n-3 and 22:6n-3, but 18:1n-9 and 18:2n-6 (the other main components of the 
CLA mixture) increased (Table 5.2).  Inclusion of 0.5 % TTA resulted in TTA at a level 
of 2.8 % of total fatty acids in the diet, together with lower levels of 14:0 and 18:0. 
5.3.2 Growth, Biometry and Whole Body Proximate Compositions 
Growth and biometry of Atlantic cod fed the different dietary treatments are 
presented in Table 5.3 below.  There were no significant differences in final weights, 
growth rates (SGR), or thermal growth coeffeficients in fish fed dietary CLA or TTA.  
There were statistically significant effects on VSI such that it decreased in fish fed 0.5% 
CLA however remained unchanged at the 1% inclusion level.  FCR levels increased as a 
result of 0.5% CLA administration but were unaffected in fish fed 1% CLA and 0.5% 
TTA.  HSI was significantly lower in fish fed TTA however was not affected in fish fed 
CLA.  
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Table 5.3 Growth and biometric parameters of Atlantic cod fed diets containing CLA and 
TTA. 
Initial weight (g)1 125 ± 14 b 130 ± 15 a 125 ± 15 b 127 ± 15 ab
Final weight (g)1 307 ± 50 305 ± 47 309 ± 57 303 ± 44
FCR2 0.80 ± 0.01 b 0.84 ± 0.02 a 0.80 ± 0.02 b 0.83 ± 0.00 ab
SGR2 1.03 ± 0.04 0.98 ± 0.05 1.04 ± 0.02 1.00 ± 0.02
TGC2 1.93 ± 0.08 1.84 ± 0.10 1.95 ± 0.04 1.87 ± 0.04
Gutted weight (%)3 81.5 ± 0.2 c 81.7 ± 0.3 bc 82.2 ± 0.4 a 81.8 ± 0.2 b
Condition factor (K)3 1.14 ± 0.04 a 1.12 ± 0.01 b 1.14 ± 0.03 a 1.12 ± 0.01 b
HSI3 11.0 ± 0.5 b 11.3 ± 0.1 a 10.9 ± 0.3 b 10.6 ± 0.1 c
VSI3 9.3 ± 1.2 a 8.0 ± 0.7 b 8.9 ± 0.2 a 8.8 ± 0.2 a
Mortality
FO CLA1 CLA2 TTA
1 2 1 4
 
Data are presented as means ± S.D, 1n = 146 - 150, 2n = 3, 3n = 27 
Condition factor (K) = (wet weight in g) x 100)/(length in mm3) x1000; FCR, feed 
converstion ratio, TGC, thermal growth coefficient = 100 x (final weight1/3 – initial 
weight1/3)/sum day degrees; HSI, hepato-somatic index; SGR, specific growth rate; VSI, 
viscero-somatic index; FO, control diet containing fish oil alone, CLA1 and CLA2, diets 
supplemented with 0.5 and 1 % CLA; TTA, diet supplemented with 0.5 % TTA.  
There were no significant differences in the whole body proximate composition 
(moisture, lipid, protein and ash) of the fish fed either CLA or TTA compared with fish 
fed FO alone as determined by 1-way ANOVA (Table 5.4) 
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Table 5.4 The whole body proximate composition of Atlantic cod fed diets containing 
CLA and TTA. 
Moisture 73.6 ± 0.6 73.3 ± 0.6 73.8 ± 0.6 73.9 ± 0.7
Protein 60.4 ± 1.4 59.7 ± 1.7 59.1 ± 1.7 60.6 ± 1.4
Lipid 26.2 ± 1.9 28.4 ± 2.2 27.9 ± 2.1 26.7 ± 1.8
Ash 9.6 ± 0.7 9.3 ± 0.5 9.5 ± 0.6 9.9 ± 0.4
FO CLA1 CLA2 TTA
 
Values are means ± SD of 9 fish. There were no significant differences between dietary 
treatment as determined by one-way ANOVA. FO, control diet containing fish oil alone, 
CLA1 and CLA2, diets supplemented with 0.5 and 1 % CLA; TTA, diet supplemented 
with 0.5 % TTA.  
 
5.3.3 Lipid Contents and Class Compositions of Liver and Flesh 
Table 5.5 illustrates the lipid contents and class compositions of liver.  The lipid 
content of the livers, which varied between 50 and 55 % of the wet weight, was 
significantly decreased in response to 0.5 % CLA however was unaltered in fish treated 
with 1 % CLA or TTA.  Neutral lipid, comprising mainly of TAG, was the predominant 
lipid fraction in liver accounting for around 97 % of the total.  There was a trend that 
indicated that fish fed dietary CLA reduced their total neutral lipid and TAG content, 
however this only became significant at the 1 % dietary inclusion level.  Neither dietary 
CLA nor TTA altered the lipid content of cod flesh, which was constant at around 0.8 % 
of wet weight (Table 5.6).  Polar lipids, mainly PC and PE, predominated in flesh 
accounting for 57 to 61 % of total lipid, with neutral lipids accounting for 39 to 43 %. 
FFA and steryl esters were highest in fish fed 0.5 % CLA, whereas flesh TAG was 
slightly, but significantly, higher in fish fed TTA. 
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Table 5.5 Lipid content (percentage of weight) and lipid class compositions (percentage 
of total lipid) of liver of Atlantic cod fed CLA or TTA. 
Lipid content 53.8 ± 2.6 ab 50.0 ± 2.1 b 55.2 ± 2.0 a 55.2 ± 2.0 a
PC 1.5 ± 0.2 b 1.8 ± 0.1 ab 2.0 ± 0.4 a 1.5 ± 0.1 b
PE 1.3 ± 0.1 b 1.3 ± 0.2 b 1.7 ± 0.3 a 0.9 ± 0.3 c
Total polar 2.8 ± 0.3 b 3.1 ± 0.3 ab 3.7 ± 0.7 a 2.4 ± 0.3 b
Total neutral 97.2 ± 0.3 a 96.9 ± 0.3 ab 96.3 ± 0.7 b 97.6 ± 0.3 a
Cholesterol 4.4 ± 0.6 ab 4.9 ± 1.4 ab 5.4 ± 0.3 a 3.9 ± 0.6 b
Triacylglycerol 92.7 ± 0.8 a 92.0 ± 1.6 ab 90.9 ± 0.8 b 93.6 ± 0.8 a
Free Fatty Acid
Steryl ester
tr tr tr tr
tr tr tr tr
FO CLA2 TTACLA 1
 
Values are means ± SD of 6 samples each of tissue pooled from 3 fish. Superscript letters 
denote significant differences between dietary treatments as determined by ANOVA. PC, 
phosphatidylcholine; PE, phosphatidylethanolamine; tr, trace < 0.5%; FO, control diet 
containing fish oil alone; CLA1 and CLA2, diets supplemented with 0.5 and 1 % CLA; 
TTA, diet supplemented with 0.5 % TTA. 
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Table 5.6 Lipid content (percentage of weight) and lipid class compositions  
(percentage of total lipid) of flesh of Atlantic cod CLA or TTA. 
 
Lipid content 0.8 ± 0.0 0.8 ± 0.1 0.8 ± 0.1 0.8 ± 0.0
PC 30.7 ± 1.8 a 27.9 ± 1.6 b 30.8 ± 1.5 a 28.7 ± 1.2 ab
PE 17.9 ± 1.2 a 15.6 ± 0.7 b 17.1 ± 0.6 a 17.6 ± 0.5 a
PS 2.5 ± 0.6 2.8 ± 0.4 2.7 ± 0.4 3.2 ± 0.5
PI 3.8 ± 0.6 4.1 ± 0.6 3.8 ± 0.7 4.3 ± 0.5
PG/CL 2.9 ± 0.7 b 2.8 ± 0.3 b 2.8 ± 0.4 b 3.7 ± 0.2 a
Sphingomyelin 1.5 ± 0.4 1.7 ± 0.3 1.6 ± 0.2 1.6 ± 0.6
Lyso-PC 1.8 ± 0.3 bc 2.2 ± 0.2 a 2.0 ± 0.2 ab 1.5 ± 0.2 c
Total polar 61.2 ± 2.1 a 57.2 ± 1.6 b 60.8 ± 1.2 a 60.5 ± 2.1 a
Total neutral 38.8 ± 2.1 b 42.8 ± 1.6 a 39.2 ± 1.3 b 39.5 ± 2.1 b
Cholesterol 16.1 ± 0.9 15.6 ± 0.3 15.2 ± 1.8 15.7 ± 0.4
Triacylglycerol 6.9 ± 1.2 b 6.3 ± 1.6 b 5.7 ± 1.1 b 9.2 ± 0.8 a
Free fatty acid 11.9 ± 1.2 b 15.1 ± 1.6 a 13.0 ± 1.7 ab 11.5 ± 1.4 b
Steryl ester 3.9 ± 0.4 b 5.9 ± 0.9 a 5.4 ± 0.4 a 3.2 ± 0.6 b
FO CLA 1 CLA2 TTA
 
Values are means ± S.D of 6 samples each of tissue pooled from 3 fish.  Superscript 
letters denote significant differences between dietary treatments as determined by 
ANOVA. CL, cardiolipin; PC, phosphatidylcholine; PE, phosphatidyletholamine; PG, 
phosphatidylglycerol; phosphatidylinositol; PS, phosphatidylserine; FO, control diet 
containing fish oil alone; CLA1 and CLA2, diets supplemented with 0.5 and 1 % CLA; 
TTA, diet supplemented with 0.5 % TTA. 
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5.3.4 Fatty Acid Compositions of the Liver and Flesh 
Dietary CLA and TTA were both incorporated into tissue lipids, but it was 
noteworthy that CLA was deposited to a greater extent in liver lipids (Table 5.7), whereas 
TTA was deposited to a greater extent in flesh (Table 5.8). Thus, CLA accounted for 1.5 
and 2.9 % of total fatty acids in livers of fish fed 0.5 and 1 % CLA, respectively, whereas 
TTA accounted for 0.6 % of liver fatty acids in fish fed 0.5 % TTA (Table 5.7). In 
contrast, TTA accounted for 1.6 % of flesh fatty acids in TTA-fed fish, compared to 0.8 
and 1.9 % CLA in fish fed the lower and higher CLA, respectively (Table 5.8). Dietary 
CLA had no significant effect on the proportions n-3 or n-6 PUFA in either liver or flesh, 
but in fish fed TTA there were decreased percentages of monoenes, n-6 PUFA and 20:5n-
3, but an increased proportion of 22:6n-3 in the flesh (Tables 5.7 and 5.8). Dietary CLA 
resulted in increased percentages of 18:0 and decreased percentages of 18:1n-9 and total 
monoenes in both tissues, but especially liver. 
Chapter 5  
 129
Table 5.7 Fatty acid composition (percentage of weight) of total lipid  
from liver of Atlantic cod fed CLA or TTA. 
14:0 2.9 ± 0.3 b 3.4 ± 0.1 a 3.3 ± 0.2 a 2.8 ± 0.1 b
16:0 15.7 ± 0.5 a 15.6 ± 0.2 a 15.0 ± 0.7 ab 14.7 ± 0.6 b
18:0 5.6 ± 0.2 b 8.3 ± 0.5 a 8.7 ± 0.4 a 4.9 ± 0.2 c
Total saturated1 24.5 ± 0.7 b 27.7 ± 0.6 a 27.3 ± 1.0 22.6 ± 0.9 c
16:1n-7 6.6 ± 0.2 a 6.2 ± 0.1 b 5.9 ± 0.2 c 6.7 ± 0.2 a
18:1n-9 18.8 ± 0.6 a 15.7 ± 0.3 b 15.6 ± 0.3 b 19.6 ± 0.7 a
18:1n-7 5.3 ± 0.2 a 4.8 ± 0.2 b 4.8 ± 0.1 b 5.7 ± 0.4 a
20:1n-9 5.2 ± 0.1 5.1 ± 0.2 5.1 ± 0.3 5.1 ± 0.2
22:1n-11 3.3 ± 0.2 a 3.2 ± 0.1 ab 2.9 ± 0.3 b 3.3 ± 0.3 a
24:1n-9 0.3 ± 0.1 0.3 ± 0.0 0.3 ± 0.0 0.4 ± 0.1
Total monoenes2 40.0 ± 1.1 a 35.6 ± 0.6 b 34.9 ± 0.5 b 41.0 ± 1.1 a
CLA (9c,11t) 0.0 ± 0.0 c 0.9 ± 0.2 b 1.6 ± 0.5 a 0.0 ± 0.0 c
CLA (10t,12c) 0.0 ± 0.0 c 0.6 ± 0.1 b 1.3 ± 0.4 a 0.0 ± 0.0 c
TTA 0.0 ± 0.0 b 0.0 ± 0.0 b 0.0 ± 0.0 b 0.6 ± 0.1 a
18:2n-6 5.4 ± 0.1 5.5 ± 0.1 5.5 ± 0.0 5.5 ± 0.2
20:4n-6 0.8 ± 0.0 0.8 ± 0.0 0.8 ± 0.0 0.8 ± 0.0
Total n-6 PUFA3 7.2 ± 0.2 7.2 ± 0.1 7.2 ± 0.0 7.0 ± 0.3
18:3n-3 1.0 ± 0.0 0.9 ± 0.0 0.9 ± 0.0 1.0 ± 0.0
18:4n-3 2.0 ± 0.1 2.0 ± 0.1 1.9 ± 0.0 2.0 ± 0.1
20:4n-3 0.7 ± 0.0 0.7 ± 0.0 0.6 ± 0.0 0.7 ± 0.0
20:5n-3 11.5 ± 0.6 11.2 ± 0.2 11.2 ± 0.3 11.7 ± 0.5
22:5n-3 1.5 ± 0.1 1.5 ± 0.0 1.5 ± 0.0 1.5 ± 0.1
22:6n-3 11.5 ± 0.8 11.6 ± 0.3 11.5 ± 0.4 11.8 ± 0.7
Total n-3 PUFA4 28.3 ± 1.6 28.0 ± 0.6 27.6 ± 0.8 28.8 ± 1.4
Total PUFA 35.5 ± 1.7 35.2 ± 0.6 34.8 ± 0.8 35.9 ± 1.6
n-3/n-6 3.9 ± 0.2 3.9 ± 0.1 3.8 ± 0.1 4.1 ± 0.1
FO CLA1 CLA2 TTA
 
Values are means ± SD of 6 samples each of tissue pooled from 3 fish. Superscript letters 
denote significant differences between dietary treatments as determined by ANOVA. 
1, includes 20:1n-7 present up to 0.3 %; 2, includes 20:2n-6, 20:3n-6 and 22:4n-6 present 
up to 0.3 %; 3, includes 20:3n-3 present up to 0.3 %; FO, control diet containing fish oil 
alone; CLA1 and CLA2, diets supplemented with 0.5 and 1 % CLA; TTA, diet 
supplemented with 0.5 % TTA. 
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Table 5.8 Fatty acid composition (percentage of weight) of total lipid  
from flesh of Atlantic cod fed CLA or TTA. 
14:0 1.6 ± 0.2 a 1.3 ± 0.1 b 1.3 ± 0.1 b 1.0 ± 0.0 c
16:0 19.3 ± 0.8 ab 19.2 ± 0.8 ab 18.6 ± 0.5 b 20.1 ± 0.4 a
18:0 3.2 ± 0.1 b 4.0 ± 0.1 a 3.9 ± 0.2 a 3.4 ± 0.1 b
Total saturated1 24.4 ± 0.9 24.8 ± 0.8 24.2 ± 0.3 24.8 ± 0.5
16:1n-7 2.9 ± 0.3 a 2.6 ± 0.1 ab 2.4 ± 0.2 b 2.3 ± 0.2 b
18:1n-9 9.2 ± 0.1 a 8.8 ± 0.2 ab 8.5 ± 0.5 b 8.7 ± 0.4 ab
18:1n-7 2.9 ± 0.0 a 2.8 ± 0.1 ab 2.7 ± 0.1 b 2.7 ± 0.1 b
20:1n-9 1.0 ± 0.1 1.1 ± 0.2 1.0 ± 0.1 1.0 ± 0.2
22:1n-11 0.3 ± 0.0 0.3 ± 0.1 0.3 ± 0.0 0.3 ± 0.0
24:1n-9 0.3 ± 0.0 0.3 ± 0.0 0.3 ± 0.1 0.4 ± 0.1
Total monoenes2 16.7 ± 0.4 a 15.9 ± 0.3 ab 15.2 ± 0.8 b 15.4 ± 0.6 b
CLA (9c,11t) 0.0 ± 0.0 c 0.3 ± 0.1 b 0.7 ± 0.0 a 0.0 ± 0.0 c
CLA (10t,12c) 0.0 ± 0.0 c 0.5 ± 0.1 b 1.2 ± 0.1 a 0.0 ± 0.0 c
TTA 0.0 ± 0.0 b 0.0 ± 0.0 b 0.0 ± 0.0 b 1.6 ± 0.3 a
18:2n-6 4.1 ± 0.1 4.0 ± 0.4 4.1 ± 0.3 3.9 ± 0.1
20:4n-6 1.9 ± 0.0 a 1.9 ± 0.1 a 1.9 ± 0.0 a 1.8 ± 0.0 b
22:5n-6 0.6 ± 0.0 0.6 ± 0.0 0.6 ± 0.0 0.6 ± 0.0
Total n-6 PUFA3 7.1 ± 0.2 a 7.2 ± 0.3 a 7.0 ± 0.2 a 6.5 ± 0.1 b
18:3n-3 0.6 ± 0.0 a 0.6 ± 0.1 a 0.6 ± 0.0 a 0.5 ± 0.0 b
18:4n-3 0.9 ± 0.0 a 0.8 ± 0.1 ab 0.8 ± 0.1 ab 0.7 ± 0.0 b
20:4n-3 0.7 ± 0.0 0.7 ± 0.0 0.6 ± 0.0 0.7 ± 0.0
20:5n-3 18.6 ± 0.3 a 18.0 ± 0.9 a 18.2 ± 0.5 a 16.4 ± 0.2 b
22:5n-3 2.2 ± 0.0 a 2.2 ± 0.1 a 2.2 ± 0.0 a 2.1 ± 0.0 b
22:6n-3 28.6 ± 0.6 b 28.9 ± 0.8 b 29.4 ± 1.3 b 31.0 ± 0.7 a
Total n-3 PUFA4 51.7 ± 0.9 51.3 ± 0.5 51.7 ± 0.7 51.4 ± 0.8
Total PUFA 58.9 ± 0.9 58.5 ± 0.8 58.7 ± 0.5 58.3 ± 0.6
n-3/n-6 7.2 ± 0.2 b 7.1 ± 0.2 b 7.4 ± 0.3 b 7.8 ± 0.2 a
FO CLA1 CLA2 TTA
 
Values are means ± SD of 6 samples each of tissue pooled from 3 fish. Superscript letters 
denote significant differences between dietary treatments as determined by ANOVA. 
1, includes 20:1n-7 present up to 0.3 %; 2, includes 20:2n-6, 20:3n-6 and 22:4n-6 present 
up to 0.3 %; 3, includes 20:3n-3 present up to 0.3%; FO, control diet containing fish oil 
alone; CLA1 and CLA2, diets supplemented with 0.5 and 1 % CLA; TTA, diet 
supplemented with 0.5 % TTA. 
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5.3.5 CPT-1 and ACO Activities, and Peroxisomal β-Oxidation Capacity 
There was a trend for CPT-I activity in liver to be increased by dietary CLA and 
TTA, although it was only significant in the case of TTA (Figure 5.1).  In red muscle, a 
dietary level of 1 % CLA resulted in increased CPT-1 activity, but 0.5 % dietary CLA or 
TTA had no effect.  In contrast, CPT-1 activity in white muscle was not affected by any 
dietary treatment.  ACO activity in liver was significantly increased by both dietary CLA 
and TTA (Figure 5.2).  Conversely, ACO activity in both red and white muscle was 
decreased by CLA and TTA, with the effects being significant for CLA in red muscle and 
TTA in white muscle.  In liver, there was a trend that indicated increased peroxisomal β-
oxidation in cod fed dietary CLA, however this increase was not statistically significant.  
Dietary TTA significantly increased the capacity for hepatic peroxisomal β-oxidation 
(Figure 5.3).  In muscle, the peroxisomal β-oxidation capacity of Atlantic cod was 
unaffected by either dietary CLA or TTA (Figure 5.3).  
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Figure 5.1 Effects of CLA or TTA on CPT-1 activity in tissue homogenates 
 of liver, red and white muscle of Atlantic cod. 
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Results are presented relative to the activity in fish fed FO for each tissue and are means 
± SD (n = 6). Different letters denote significant differences between dietary treatments 
within each tissue as determined by ANOVA. 
 
Figure 5.2 Effects of CLA or TTA on ACO activity in tissue homogenates of liver, red 
and white muscle of Atlantic cod.  
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
Liver Red Muscle White Muscle
R
el
at
iv
e 
A
C
O
 A
ct
iv
ity
 (F
O
=1
)
FO
CLA1
CLA2
TTA
b
a a a a
b
b ab
a
ab
ab
b
 
Results are presented relative to the activity in fish fed FO for each tissue and are means 
± SD (n = 6). Different letters denote significant differences between dietary treatments 
within each tissue as determined by ANOVA.  
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Figure 5.3 Effects of CLA or TTA on peroxisomal β-oxidation capacity in tissue 
homogenates of liver, red and white muscle of Atlantic cod.  
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Results are presented relative to the activity in fish fed FO for each tissue and 
are means ± SD (n = 6).  Different letters denote significant differences 
between dietary treatments within each tissue as determined by ANOVA. 
 
5.3.6 Basic Haematology 
There were no statistically significant differences in the red or white blood cell 
counts of fish fed either dietary CLA or TTA compared to fish fed FO alone (Table 5.9).  
However, there was a clear trend suggesting decreased blood cell counts with both 
dietary CLA and TTA, but the high variation between samples made this trend non-
significant.  The PCV was reduced in response to dietary TTA and CLA, significantly so 
in the former. 
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Table 5.9 Effects of conjugated linoleic acid (CLA) and tetradecylthioacetic acid (TTA) 
on basic haematology of Atlantic cod. 
Diet
FO 1.00 ± 0.10 1.00 ± 0.80 30.6 ± 4.4 a
CLA1 0.76 ± 0.10 0.62 ± 0.29 25.7 ± 4.8 a
CLA2 0.81 ± 0.19 0.88 ± 0.43 24.8 ± 2.2 a
TTA 0.81 ± 0.27 0.80 ± 0.36 21.8 ± 4.2 b
(FO =1) (FO =1)
RBC WBC PCV (%)
 
RBC, red blood counts (relative to FO diet), WBC, white blood counts (relative to FO 
diet), PVC, packed cell volume. 
 
5.4 Discussion 
Atlantic cod deposit a larger proportion of lipid in liver compared to salmonids 
even when the former are fed a lower lipid level.  This is a problem to cod farmers since 
deposition of fat in the liver represents diet that is “going to waste” by being deposited in 
a portion of the fish not eaten by the consumer, at least, not in the UK.  Excessive fat 
deposition in liver may also lead to fatty liver syndrome and thus may affect the health of 
the fish.  In cod, the liver is the primary excess fat store that sequesters lipid which is not 
immediately utilised as energy.  Once lipid levels have reached a satisfactory level in cod 
flesh the remaining lipid is then directed to the liver. Thus, high fat diets rich in n-
3HUFA may not be utilised fully.  The biological implications of feeding animals dietary 
CLA and TTA have been discerned in both in vitro and in vivo work in mammalian 
models (Berge et al., 2002; Bhattacharya et al., 2006).  Less clear is the effect these 
bioactive fatty acids have on piscine species, particularly of marine origin, and the 
present study is the first to investigate TTA in a marine fish.  Some recent studies 
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involving CLA-supplemented rodents have elucidated that hepatic steatosis is decreased 
(Wang et al., 2005; Purushotham et al., 2007).  Reductions in liver TAG content after 
CLA supplementation have been verified in rats (Rahman et al, 2002).  In addition, the 
hypolipidaemic effect of TTA has been purported to be due in part, to decreased hepatic 
TAG formation (Willumsen et al., 1997; Berge et al., 1999).  Thus, the primary aim of 
the present trial was to test the hypothesis that dietary CLA or TTA could have beneficial 
effects on lipid metabolism in Atlantic cod, specifically that these bioactive fatty acids 
could lower liver lipid levels, and liver size.  The results clearly show that the hypothesis 
was not proved and that neither of these bioactive fatty acids had a major effect on liver 
lipid content or relative liver size as determined by HSI in cod.  It can be reasoned that, 
although there was a statistically significant decrease in HSI of cod fed TTA, this 
reduction was of relatively little physiological consequence considering the index was 
still over 10 % and there was no change in liver lipid content compared to fish fed FO 
alone.  Conversely, Atlantic salmon smolts fed TTA at 0.6 % of the diet showed a slight, 
but significant, increase in HSI in addition to a higher liver lipid content, although the 
latter was not significant (Moya-Falcon et al., 2004).  In the present trial, CLA inclusion 
did not effect HSI in the cod in agreement with other trials which showed that CLA at up 
to 1 % had no effect on HSI or liver lipid content in juvenile channel catfish (Twibell and 
Wilson, 2003), and HSI was unaffected by dietary CLA at up to 2 % in rainbow trout 
juveniles (Figueiredo-Silva et al., 2005). Conversely, increased HSI in response to 
feeding CLA had been previously reported in hybrid striped bass (Twibell et al., 2000), 
yellow perch (Twibell et al., 2001) and tilapia (Yasmin et al., 2004).  Perhaps 
surprisingly, liver lipid content was reduced by dietary CLA in striped bass and yellow 
perch despite increased HSI (Twibell et al., 2000, 2001).  In Atlantic salmon smolts there 
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were trends of increasing HSI and liver lipid in fish fed CLA at 1 and 2 % of the diet, 
although the data were not statistically significant (section 3.3.2).  Interestingly, liver 
TAG content was significantly decreased in cod fed 1 % CLA in the present trial, 
however it is unlikely that a reduction in TAG had any bearing on liver physiology 
considering there was no change in liver lipid level or HSI.   
As discussed in detail in section 1.4.2, dietary CLA can have beneficial effects on 
body composition by decreasing body fat and, in some cases, increasing lean body mass 
in mice, rats and pigs in particular.  It would seem that these effects have not been 
reciprocated in the present study as evidenced through the lack of influence on whole 
body proximate composition in cod fed dietary CLA compared with cod fed FO alone.  
However, whole body proximate composition was also unaffected by dietary CLA in 
salmon fry (Berge et al., 2004) and smolts (section 3.3.3), and rainbow trout juveniles 
(Figueiredo-Silva et al., 2005).  Similarly, dietary CLA had no effect on tissue lipid 
contents in tilapia (Yasmin et al., 2004) or carcass lipid and intraperitoneal fat in catfish 
(Twibell and Wilson, 2003).  Furthermore, VSI was unaffected by dietary CLA up to 2 % 
in both Atlantic salmon smolts (section 3.3.2) and rainbow trout (Figueiredo-Silva et al., 
2005).  However, intraperitoneal fat was decreased by dietary CLA in hybrid striped bass 
(Twibell et al., 2000) and, in the present trial, visceral fat may have been reduced in cod 
fed 0.5 % CLA as VSI was lower in this group along with a relatively higher HSI, which 
may suggest some redistribution of fat.  However, fat redistribution has not been apparent 
in other trials with fish.  The present trial is the first to record the effects of dietary TTA 
on fish whole body composition.  These data suggest that TTA does not beneficially 
influence body composition to any appreciable physiological extent.  However, dietary 
TTA had been shown to prevent high fat diet induced adiposity in rats (Madsen et al., 
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2002).  Interestingly, the levels of TAG within flesh significantly increased in cod fed 
TTA in the present trial.  It has been proposed that animals fed TTA may instigate a 
greater flux of TAG from serum to surrounding tissue thus providing additional fatty 
acids for catabolism and this may be the case in the cod (Berge et al., 2004).   
An additional objective of this study was to determine whether CLA or TTA 
could influence fatty acid oxidation.  Unfortunately, mitochondrial β-oxidation could not 
be analysed since assays using radioactive isotopes on fresh tissue were not possible at 
the commercial farm site.  Thus, freezing and thawing of the samples disrupted the 
mitochondrial membranes such that only peroxisomal β-oxidation capacity could be 
measured.  Nevertheless, it is noteworthy that fatty acid β-oxidation activity was recently 
measured in a related gadoid, haddock, and it was shown that peroxisomal β-oxidation 
predominates over mitochondrial β-oxidation in liver (Nanton et al., 2003). Similarly, 
fatty acid oxidation in Atlantic salmon liver is principally due to peroxisomal, rather than 
mitochondrial, β-oxidation (Frøyland et al., 2000).  In the present study, hepatic 
peroxisomal β-oxidation capacity was significantly elevated in cod fed dietary TTA.  
Furthermore, both CPT-1 and ACO activities were significantly increased as a result of 
TTA supplementation.  Taken together, these results strongly suggest that hepatic fatty 
acid oxidation is elevated in response to dietary TTA in Atlantic cod.  This does not 
correlate with previous studies of TTA in fish, which revealed that both ACO gene 
expression and activity in liver of salmon were unaffected (Kleveland et al., 2006; Moya-
Falcon et al., 2006).  Contrary to the abovementioned results, CPT-1 activity in cod liver 
was unaffected by dietary CLA, suggesting that mitochondrial β-oxidation would not be 
enhanced.  Perhaps surprisingly, an increase in ACO activity in liver of cod fed dietary 
CLA was not concomitant with elevated peroxisomal β-oxidation capacity.  This lack of 
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association between peroxisomal β-oxidation capacity and ACO activity was also 
observed in muscle of cod fed either CLA or TTA ergo it is difficult to interpret these 
results.  However, it can be assumed that both ACO activity and peroxisomal β-oxidation 
capacity are relatively inconsequential in gadoid muscle considering it is likely that fatty 
acid oxidation in the muscle predominantly occurs in mitochondria (Nanton et al., 2003).  
Previous studies have reported that dietary CLA can increase CPT-1 activity in a variety 
of murine tissues (Rahman et al., 2001; Degrace et al., 2004).  The CPT-1 activity in red 
muscle of cod fed 1 % CLA was significantly increased in the present study; indicative of 
an enhanced mitochondrial β-oxidation capacity.  However, it is known that red muscle 
comprises only a small proportion of total flesh, the remainder of which is composed 
mostly of white muscle.  Thus, red muscle may not influence lipid composition to any 
appreciable extent.  Indeed, these data seem to indicate that white muscle CPT-1 activity, 
peroxisomal β-oxidation, and almost certainly overall fatty acid oxidation is not 
significantly influenced by dietary CLA or TTA in cod muscle.  
A further aim of the present trial was to determine if dietary CLA or TTA had 
beneficial effects on fatty acid compositions in Atlantic cod.  This part of the study 
revealed a very interesting result with TTA accumulating in flesh to a greater extent than 
the equivalent dietary level of CLA and also to a greater extent than in liver. In contrast, 
CLA was incorporated to a greater extent in liver lipids compared to flesh. TAG 
predominates in liver of cod whereas polar lipids predominate in flesh, and so these data 
suggest that TTA may be deposited to a greater extent in PL and CLA to a greater extent 
in TAG.  In Atlantic salmon fed TTA, flesh fatty acid compositions were not reported 
but, of the tissues investigated, the highest incorporation was found in gills with 
approximately equal percentages, 0.8 % and 0.7 % of total fatty acids in PL and TAG, 
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respectively, in fish fed TTA at 0.6 % of total diet (Moya-Falcon et al., 2004).  
Furthermore, TTA in both heart and liver was only recovered in PL and not TAG.  
Consistent with the above, preferential uptake of TTA into PL was also evidenced in rat 
hepatocytes (Grav et al., 1994; Madsen et al., 1997).  Thus it appears that bioactive fatty 
acids similar to, and including, TTA could be efficiently accumulated in ‘lean” fish such 
as cod with low flesh oil contents.  It remains to be established whether fatty acid 
analogues such as TTA are feasible or, indeed, appropriate as supplements for the human 
diet (Berge et al., 2002).  However, CLA may be better delivered to humans via oily fish 
with the level accumulating in salmon and trout fed CLA at 2 % of diet by weight 
reaching 7 % of total fatty acids in flesh (dietary lipid 16 – 17 %), (section 3.3.5; 
Bandarra et al., 2006), or 4 % in flesh of salmon smolts (dietary lipid 34 %) (section 
3.3.5), and 7 % in whole salmon fry fed 2 % CLA (24 % dietary lipid) (Berge et al., 
2004). Similarly, striped bass with high flesh lipid (> 15 %) accumulated CLA to over 7 
% of total fatty acids in fish fed CLA at 1 % of diet, whereas the levels of CLA 
accumulated in yellow perch with only 3 % lipid in the flesh were much lower (Twibell 
et al., 2000, 2001). Consistent with the above, the incorporation of CLA into neutral 
lipids was around 10-fold higher than incorporation into polar lipids in both muscle and 
liver in tilapia (Yasmin et al., 2004). 
There is evidence to suggest that dietary CLA can suppress SCD activity and gene 
expression in mammals (Lee et al., 1998; Choi et al., 2001, 2002; Park et al., 2001; 
Smith et al., 2002; Shang et al., 2005).  In support of the above findings, dietary CLA has 
also been reported to increase the 18:0/18:1n-9 ratio; a proxy for the measurement of 
SCD activity, in liver and flesh of rainbow trout (section 6.3.4), striped bass (Twibell et 
al., 2000), yellow perch (Twibell et al., 2001), salmon (Berge et al., 2004; section 3.3.5) 
Chapter 5  
 140
and sea bass (Valente et al., 2007b).  Furthermore, dietary CLA increased the proportions 
of 18:0 and decreased percentages of 18:1 in liver, muscle and viscera of rainbow trout 
juveniles (Bandarra et al., 2006).  In the present study, increased proportions of 18:0 and 
decreased 18:1n-9 was observed in flesh and, especially, liver of cod fed CLA suggesting 
inhibition of ∆9 desaturation.  Purportedly, suppression of SCD may lead to a lower lipid 
droplet size in cells, which in turn could account in part for the anti-obesity effect 
exhibited in animals supplemented with CLA.  However, experiments utilising SCD-null 
mice have shown that this is not how CLA arbitrates its fat lowering effect (Kang et al., 
2004).  Conversely, the data in the present trial indicate that TTA appears to have had no 
effect on SCD activity in Atlantic cod.  Previously, dietary TTA was shown to have no 
major effects on 18:0/18:1n-9 levels in salmon liver, gill, heart (Moya-Falcon et al., 
2004) or flesh lipids (Kleveland et al., 2006). However, in vitro studies utilising hepatic 
murine cell lines have recorded increased SCD expression after administration of TTA 
(Madsen et al., 1997; Vaagenes et al., 1998).   
CLA suppresses PUFA desaturases and elongase in cell systems (Chuang et al., 
2001a,b; Eder et al., 2002), and CLA decreased C18 PUFA in pig muscle and fat (Ramsay 
et al., 2001), and 22:6n-3 in chicken tissues (Yang et al., 2003).  Additionally, there is 
some evidence to suggest that the influence of dietary CLA on n-3 PUFA distribution is 
tissue specific in fish.  For example, dietary CLA at up to 2 % inclusion was at the 
expense of 20:5n-3 and 22:6n-3 in flesh of salmon smolts and hybrid striped bass (section 
3.3.5; Twibell et al., 2000; Leaver et al., 2006) and whole body (comprising mainly of 
flesh) in salmon fry (Berge et al., 2004).  Similarly, 22:6n-3 levels were also depressed in 
muscle of juvenile rainbow trout fed 1 – 2 % CLA (Bandarra et al., 2005).  Conversely, 
20:5n-3 and 22:6n-3 levels have been shown to rise in liver of rainbow trout (section 
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6.3.4) and hybrid striped bass (Twibell et al., 2000) supplemented with CLA.  In the 
present study, CLA had no effect on PUFA levels in either liver or flesh of cod. This was 
perhaps not unexpected as the activity of the PUFA desaturation/elongation pathway is 
very low in cod (Bell et al., 2006).  In contrast, however, dietary TTA significantly 
increased the percentage of 22:6n-3, and decreased the proportions of 20:5n-3 and total n-
6 PUFA in flesh of cod in the present study, a phenomena also noted in Atlantic salmon 
liver after TTA supplementation (Moya-Falcon et al., 2004).  This could be a result of 
increased conversion of 20:5n-3 to 22:6n-3, but there is no evidence from previous 
studies to support TTA having an effect on fatty acid ∆5/∆6 desaturation or elongation 
(Berge et al., 2002). Therefore, it may be more likely due to specificity of β-oxidation, 
with 22:6n-3 being more resistant to oxidation than 20:5n-3 (Tocher, 2003).  Indeed, 
reduction of hepatic 20:5n-3 levels in rats fed dietary TTA has been suggested to be due 
to selectively increased β-oxidation of this n-3 HUFA (Frøyland et al., 1997). 
Although not consistently observed, some studies had suggested that CLA might 
enhance growth and feed efficiency in young rodents (Pariza et al., 2001).  Thus, a 
further aim of the present trial was to determine if dietary CLA or TTA had beneficial 
effects on growth parameters in Atlantic cod. However, neither CLA nor TTA had any 
effect on growth (SGR, TGC) or feed efficiency (FCR) in the present trial.  In recent 
studies on salmonids, no effects of dietary CLA on growth rates or FCR were observed in 
Atlantic salmon fry (Berge et al., 2004), or smolts (section 3.3.2), or in rainbow trout 
(Figueiredo-Silva et al., 2005) fed diets containing up to 2 % CLA. Similarly, no effects 
on weight gain or feed efficiency were noted in juvenile yellow perch or catfish fed diets 
containing up to 1 % CLA (Twibell et al., 2001; Twibell and Wilson, 2003), or in 
juvenile tilapia fed CLA at up to 5 % of diet (Yasmin et al., 2004). However, growth of 
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tilapia was inhibited by 10 % CLA, as was growth of carp and rockfish at both 5 and 10 
% CLA (Choi et al., 1999).  Therefore, the data are consistent in suggesting that dietary 
CLA does not have any beneficial effects on growth performance in a variety of fish 
species, and can inhibit growth at high inclusion levels.  In contrast, dietary TTA 
inhibited growth in salmon smolts as evidenced by decreased final weights, SGRs and 
TGCs, although FCR was unaffected (Moya-Falcon et al., 2004). 
An important result in the present study was that there were no mortalities in cod 
fed the TTA treatment. Previously, in addition to a reduction of growth (Moya-Falcon et 
al., 2004), TTA was also reported to cause an increase in mortality in salmon (Moya-
Falcon et al., 2004; Kleveland et al., 2006). Therefore, it was hoped that the present study 
would help to elucidate whether the observed rise in mortality in previous studies 
involving fish was due, in part, to a modulation of the innate immune response.  An 
attempt was made to measure the rate of phagocytosis from isolated head kidney 
macrophages (section 2.4.5).  Unfortunately the assay, which had to be completed 
entirely on-site at the commercial farm, did not work as the yeast failed to adhere to the 
slides, possibly due to the low ambient temperature in the laboratory in January.  
Moreover, lysozyme activity failed to produce a result using the methodology outlined in 
section 2.4.4, possibly for similar reasons.  Thus, only basic haematological parameters 
were able to be tested.  Nevertheless, the results proved interesting given that TTA 
decreased both red and white blood cell counts, and packed cell volume, significantly so 
in the latter.  This may have implications on fish health as it implies that TTA may act as 
an immunodepressor.  Obviously, a more thorough examiniation of the immunological 
aspects of dietary TTA with regards to Atlantic cod health is required before any 
conclusive judgment can be made.   
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In conclusion, the results of the present study only partially supported the 
hypotheses that were tested. CLA and TTA at the levels used had few beneficial effects 
in Atlantic cod and did not enhance growth parameters, or improve feed conversion or 
potential yield through decreased adiposity or liver lipid deposition.  However, nutritional 
quality could be enhanced, and cod fed CLA and/or TTA could be beneficial in the 
human diet, through provision of bioactive fatty acids with no detrimental effects on n-3 
PUFA levels.   
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CHAPTER 6. INFLUENCE OF DIETARY CLA AND TTA 
IN RAINBOW TROUT 
6.1 Introduction 
Rainbow trout are a fast growing, robust fish that can tolerate a wide variety of 
environmental conditions and can be easily weaned on to an artificial diet.  Hence, this 
species has been an ideal candidate for aquaculture.  Being intensively farmed since the 
latter half of the 20th century, culture of rainbow trout is expected to reach global 
production levels of circa 500,000 tonnes in the near future (FAO, 2007), making it one 
of the most intensively farmed diadromous fishes on the planet.  As of 2002, rainbow 
trout aquaculture was practised in 64 countries, with the majority of production output 
located in Europe, Japan and North America (FAO, 2007).  An integral part of the ethos 
of fish culture is the ability to be recognised as a consumer friendly alternative to wild 
fish.  Research and development over the past few decades has seen this ideal largely 
achieved, however more work is still required.  One of the most important facets of 
aquaculture research is the optimisation of feed formulations in order to improve both 
fish welfare and consumer satisfaction.   
As previously highlighted in section 1.3.1, high lipid levels are utilised in 
commercial aquaculture diets in order to offset relatively expensive protein as a source of 
energy.  In this way, protein can be ‘spared’ for synthesis of new tissue (Wilson, 1989; 
Bell, 1998).  Although high lipid diets provide an invaluable energy source, they may 
also promote excessive fat deposition in tissues particularly, in the case of rainbow trout, 
in the flesh, which can affect the overall market quality of the fish (Sargent et al., 2002).  
Furthermore, an increase in the production of farmed fish over the last decade, juxtaposed 
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with a decline in finite sources of FO has prompted research into alternative sustainable 
feed formulations, primarily examining the potential for plant-derived oil replacement 
(Sargent et al., 2002; Tacon, 2003).  However, it has been suggested that VO 
replacements may also impact on consumer welfare by reducing the amount of human 
health promoting n-3 HUFA found in oily fish such as rainbow trout (Tocher, 2003). The 
physiological and biochemical influences of potential dietary “functional fatty acids” are 
currently being assessed in an attempt to alleviate the deleterious consequences of 
feeding fish high lipid levels or alternative oil diets.  Two of these prospective 
“functional” dietary supplements are the bioactive fatty acids, CLA and TTA.   
Since the initiation of this project, only a handful of studies have been published 
detailing the influence of dietary CLA or TTA in salmonids, all of which focussed on 
relatively small sized fish (Moya-Falcon et al., 2004; Figueirdo-Silva et al., 2005; 
Kleveland et al., 2006; Leaver et al., 2006; Valente et al., 2007a).  What can generally be 
concluded from these studies was that no appreciable increase in growth or decrease in 
lipid deposition (attributes associated with both CLA or TTA supplementation in studies 
involving mammalian models) have been observed after dietary supplementation with 
these fatty acids in salmonids.  In a commercial context, one valuable result in studies 
involving dietary CLA or TTA supplementation in fish has been the deposition of these 
fatty acids in flesh, thus potentially providing a consumer friendly route through which 
provision of these bioactive fatty acids could be attained for humans.  However, it has yet 
to be determined whether feeding either dietary CLA or TTA to fish at such an early 
juncture in their life-cycle would be economically viable.  Furthermore, and most 
importantly, the effects of CLA or TTA on large rainbow trout, which are actively 
depositing lipid, have hitherto not been investigated and therefore it is unknown if these 
Chapter 6  
 146
bioactive fatty acids can influence growth or trout flesh lipid at an arguably more 
commercially important life-cycle stage.   
The present study aimed to test the hypothesis that feeding dietary CLA or TTA 
to rainbow trout of near market size and weight could increase growth, decrease lipid 
deposition, and enhance fatty acid composition via an increase in n-3 HUFA levels and 
provision of CLA or TTA in flesh lipid in particular.  Additionally, to examine the effects 
of CLA and TTA on lipid metabolism, in the expectation that one of the main 
biochemical modus operandi thought to be responsible for reductions in lipid deposition 
in similar studies investigating the effect of these fatty acids in mammals, namely an 
increase in fatty acid oxidation, would also be elicited in trout.  Currently, there is no 
evidence for the mechanism of the previously observed increased mortality in salmon 
supplemented with TTA (Moya-Falcon et al., 2004; Kleveland et al., 2006;), or any 
information about whether it is as a result of an immunomodulatory response.  Similarly, 
it is unclear whether dietary CLA can influence the immune response in rainbow trout of 
this size.  Thus, an ancillary objective of this study was to determine the effect of CLA or 
TTA on some key non-specific immune parameters. 
Thus, this study reports the influence of CLA and, for the first time, TTA, on 
growth and lipid composition and metabolism in large, near market-size rainbow trout 
grown in seawater.  Trout of almost 440 g were fed for eight weeks on FM and FO diets 
containing either 0.5 % or 1 % CLA, or 0.5 % TTA and growth, feed efficiency, tissue 
lipid content, class and fatty acid compositions determined, along with activities of 
HUFA synthesis and key enzymes of fatty acid oxidation, and the expression of 
associated genes.  A number of immune parameters including blood cell counts and 
lysozyme activity were also investigated. 
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6.2 Materials and Methods 
6.2.1 Experimental Fish and Husbandry 
The dietary trial was performed at BioMar ForsøgsStation, Hirtshals, Denmark, 
between March and May 2006.  Stock, unpigmented rainbow trout  (Skinnerup, 
Moeldrup, Denmark) acclimated to 20 ppt salinity, were randomly distributed between 
twelve indoor, round tanks of 1 m3 volume (1.72 m diameter).  The initial stocking 
density was 25 fish of average weight 437 ± 56 g (< 13 % CV) per tank (~10.5 kg/m3).  
Water temperature was maintained at 15.5 ± 0.2 oC throughout the trial, with a light 
regime of 14L:10D.  Four experimental diets were fed to triplicate tanks for 55 days, with 
the feeding regime based on restricted feeding at 100 % of BioMar recommended feeding 
tables.  The calculated feed ration was offered to the fish for 8 h each day using automatic 
individual belt feeding units.  In order to facilitate accurate calculations of feed intake 
and FCR, feed waste was collected daily via a lift-up system.  
6.2.2 Experimental Diets 
The experimental diets were formulated to satisfy the nutritional requirements of 
salmonid fish (National Research Council, 1993), and were formulated and manufactured 
by BioMar A/S, Brande, Denmark (Table 6.1).  
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Table 6.1 Formulations (percentage of dry ingredients) and proximate compositions 
(percentage of total diet) of experimental diets. 
Component
Fishmeal
Sunflower meal
Wheat Gluten
Legume seeds
Soya
Micronutrients
Fish Oil
CLA
TTA
Moisture 7.3 ± 0.2 7.5 ± 0.1 7.6 ± 0.1 7.5 ± 0.2
Lipid 27.7 ± 1.1 25.7 ± 0.5 24.8 ± 0.7 24.7 ± 1.9
Protein 43.5 ± 0.6 42.1 ± 0.2 42.6 ± 1.1 42.6 ± 0.6
Ash 8.4 ± 0.3 8.4 ± 0.0 8.4 ± 0.3 8.5 ± 0.1
FO CLA1 CLA2 TTA
41
10.7
10
14
10 10
1414 14
10
4141 41
10.7 10.710.7
4
0.4
0
44 4
0.4
0.8 1.7
22.5
0 0.0 0
0.40.4
0
0.5
21.7 20.8 22
 
Results for proximate compositions are means ± S.D. (n = 3).  FO, control diet containing 
fish oil alone; CLA1 and CLA2, diets supplemented with 0.5 and 1 % CLA; TTA, diet 
supplemented with 0.5 % TTA.  There were no significant differences in proximate 
compositions between the diets. Micronutrients, incudes essential amino acids 
(methionine and lysine), vitamins, minerals, and astaxanthin (LucantinØ Pink, BASF), 
Biomar A/S, Brande, Denmark 
Moisture, oil, protein and ash contents of diets were determined by standard 
methods (AOAC, 2000).  The isonitrogenous diets were based on FM and standard 
Northern hemisphere FO with CLA and TTA added to 0, 0.5 and 1 % (CLA), and 0.5 % 
(TTA) as percentages of total diet. Diets were identical in formulation other than fatty 
acid composition with CLA (LUTA-CLATM 60, containing 60 % CLA methyl esters as a 
50:50 mixture of c9t11 and t10c12 isomers; BASF AG, Ludwigshafen, Germany) and 
TTA (supplied by Dr Rolf Berge, Thia Medica A.S., Bergen, Norway) balanced by FO 
(capelin oil, Norsemeal Ltd., London, UK). The fatty acid compositions of the diets are 
presented in Table 6.2.  
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Table 6.2 Fatty acid compositions (percentage of weight) of experimental diets 
containing CLA and TTA. 
14:0 7.8 ± 0.2 7.7 ± 0.2 7.4 ± 0.2 7.9 ± 0.3
15:0 0.7 ± 0.0 0.7 ± 0.0 0.6 ± 0.0 0.7 ± 0.0
16:0 20.2 ± 0.1 20.2 ± 0.3 19.6 ± 0.4 20.4 ± 0.5
18:0 4.2 ± 0.1 4.2 ± 0.1 4.2 ± 0.1 4.2 ± 0.1
Total saturated1 33.3 ± 0.3 33.1 ± 0.6 32.2 ± 0.8 35.5 ± 0.9
16:1n-7 8.3 ± 0.2 a 8.1 ± 0.0 a 7.8 ± 0.0 b 8.2 ± 0.1 a
18:1n-9 8.3 ± 0.0 c 8.8 ± 0.1 b 9.4 ± 0.0 a 8.1 ± 0.1 d
18:1n-7 3.2 ± 0.1 3.2 ± 0.0 3.1 ± 0.1 3.3 ± 0.0
20:1n-9 1.5 ± 0.0 1.4 ± 0.0 1.4 ± 0.0 1.4 ± 0.1
22:1n-11 1.7 ± 0.2 1.7 ± 0.1 1.7 ± 0.0 1.7 ± 0.1
24:1n-9 0.5 ± 0.1 0.5 ± 0.0 0.5 ± 0.0 0.5 ± 0.0
Total monoenes2 23.9 ± 0.4 23.9 ± 0.3 24.2 ± 0.1 23.5 ± 0.3
CLA (9c,11t) 0.0 ± 0.0 c 0.9 ± 0.1 b 2.0 ± 0.2 a 0.0 ± 0.0 c
CLA (10t,12c) 0.0 ± 0.0 c 0.9 ± 0.1 b 2.0 ± 0.2 a 0.0 ± 0.0 c
TTA 0.0 ± 0.0 b 0.0 ± 0.0 b 0.0 ± 0.0 b 1.9 ± 0.1 a
18:2n-6 3.7 ± 0.1 3.6 ± 0.0 3.8 ± 0.0 3.6 ± 0.0
20:4n-6 1.3 ± 0.0 1.2 ± 0.0 1.2 ± 0.0 1.2 ± 0.0
Total n-6 PUFA3 6.3 ± 0.2 6.0 ± 0.1 6.0 ± 0.0 5.8 ± 0.1
18:3n-3 1.1 ± 0.0 1.1 ± 0.0 1.0 ± 0.0 1.1 ± 0.0
18:4n-3 2.8 ± 0.0 2.6 ± 0.0 2.6 ± 0.0 2.7 ± 0.0
20:4n-3 0.9 ± 0.1 1.0 ± 0.3 0.7 ± 0.0 0.7 ± 0.0
20:5n-3 15.3 ± 0.3 a 14.9 ± 0.1 ab 14.4 ± 0.1 b 15.2 ± 0.2 a
22:5n-3 1.8 ± 0.0 1.7 ± 0.0 1.6 ± 0.0 1.7 ± 0.0
22:6n-3 14.2 ± 0.2 a 13.6 ± 0.2 bc 13.2 ± 0.2 c 13.8 ± 0.3 ab
Total n-3 PUFA4 36.4 ± 0.3 a 35.1 ± 0.1 b 33.7 ± 0.3 c 35.3 ± 0.5 b
Total PUFA 42.7 ± 0.3 a 41.1 ± 0.1 b 39.7 ± 0.3 c 41.1 ± 0.6 b
n-3/n-6 5.8 ± 0.2 bc 5.9 ± 0.1 ab 5.6 ± 0.0 c 6.1 ± 0.0 a
FO CLA1 CLA2 TTA
 
Values are ± S.D. (n = 3). Superscript letters denote significant differences between the 
diets as determined by ANOVA.  1, includes 20:0 present at up to 0.3 %; 2, includes 
20:1n-7 present at up to 0. 3%; 3, includes 18:3n-6, 20:2n-6, 20:3n-6 and 22:4n-6 present 
at up to 0.4 %; 4, includes 20:3n-3 present up to 0.2 %. 
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6.2.3 Sampling and Analysis 
At the initiation and termination of the trial, all the fish in each tank were 
anaesthetised with benzocaine (50 mg/L), and weighed individually.  At the end of the 
trial, 8 fish per tank (24 per dietary treatment) were sampled, eviscerated and biometric 
parameters (hepato-, and viscero-somatic indices) determined.  Before the samples were 
eviscerated and used for growth and biometric analyses, blood was removed from the fish 
as described in section 2.4.1.  Liver and flesh samples (Flesh Quality Cut) were taken 
from six fish per tank, pooled in two samples of 3 fish each, and frozen immediately in 
liquid nitrogen (livers) or dry ice (flesh). Samples of 0.5 g of liver and red and white 
muscle from the epaxial myotomes anterior to the first dorsal fin ray were rapidly 
dissected from the remaining six fish (two per tank) and immediately frozen in liquid 
nitrogen for molecular analyses. In addition, samples of 1 - 2 g of liver, white and red 
muscle for biochemical analyses were collected from the same fish and immediately 
frozen in liquid nitrogen.  All samples were subsequently stored at –80 oC prior to 
analyses 
Blood cell counts and haematocrit measurements were carried out as described in 
sections 2.4.2 and 2.4.3 respectively.  Lysozyme activity was measured as detailed in 
section 2.4.4.  Total lipids of liver, muscle and diet extracted and quantified as described 
in section 2.3.7 and lipid class analysis was carried out as detailed in section 2.3.8.  
Samples taken for biochemical analysis were used to estimate peroxisomal β-oxidation 
capacity (section 2.3.3).  CPT-1 and ACO activities were also determined as described in 
sections 2.3.4 and 2.3.5, respectively. 
Total RNA from liver, red and white muscles was isolated, DNase treated and 
reverse transcribed into cDNA as described previously in sections 2.5.1 and 2.5.2.  PCR 
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primers were designed according to the trout cDNA sequences for CPT-I (accession no. 
AF327058), fatty acyl ∆6 desaturase (accession no. AF301910) and fatty acyl elongase 
(accession no. AY605100) as outlined in Table 6.3.  Three reference genes, elongation 
factor-1α (EF1α), β-actin and glyceraldehyde 3-phosphate dehydrogenase (GAPDH), 
were used to normalise the expression data. Primer sequences and PCR product sizes are 
given in Table 6.3.  
Table 6.3 Sequences of Primers and PCR product sizes. 
Gene Accession No. Primer Sequence Product size (bp)
CPT-I AF327058 Forward GCGCTATTCGACCAAAAAGA 133
Reverse CTAGTCGTGACCAGCCGTTT
Desaturase AF301910 Forward ACCTAGTGGCTCCTCTGGTC 119
Reverse CAGATCCCCTGACTTCTTCA
Elongase AY605100 Forward GAACAGCTTCATCCATGTCC 149
Reverse TGACTGCACATATCGTCTGG
Elongation factor 1α AF498320 Forward GAATTCTCCTCCCACAGGAT 119
Reverse ACGATGGGTTTTAATCAGCA
Actin AJ438158 Forward CAAGCAGGAGTACGACGAGT 110
Reverse CTGAAGTGGTAGTCGGGTGT
GAPDH AB066373 Forward GTCTCAGTGGTGGACCTGAC 149
Reverse GCCGTTGAAGTCTGAAGAGA
All genes are from rainbow trout. 
CPT-I, carnitine palmitoyltransferase-I; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.  
 
Quantitative real-time PCR was subsequently carried out essentially as described 
in section 2.5.5.  The suitability of all three reference genes was determined via pair-wise 
correlation analysis using the BestKeeper© software (Pfaffl et al., 2004).  Sample specific 
PCR efficiency (E) was determined using comparative quantitation analysis as part of the 
Rotor-Gene software.  This negates the need for a serial dilution curve of pooled template 
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cDNA and provides a more robust representation of the overall PCR efficiency.  The data 
were subjected to a pair-wise fixed reallocation randomization test© (10000 
randomisations) in order to determine significance between treatments as facilitated by 
Relative Expression Software Tool – Rotor-Gene (REST-RG© - version 3) (Pfaffl, et al., 
2002).  
6.2.4 Statistical Analysis 
All data are presented as means ± S.D (n value as stated). Percentage data and 
data which were identified as non-homogeneous (Bartlett’s test) were subjected to arcsine 
transformation before analysis.  Other than for gene expression (see above), the effects of 
dietary CLA and TTA were determined by one-way analysis of variance (ANOVA) with 
Tukey’s post-tests to determine significance of differences due to functional fatty acids. 
Differences were regarded as significant when P < 0.05 (Zar, 1999). 
6.3 Results 
6.3.1 Dietary Inclusions 
The control FO diet contained around 43 % total PUFA including 15 % 20:5n-3, 
14 % 22:6n-3 and almost 4 % 18:2n-6, 33 % total saturates, mainly 16:0, and 24 % total 
monoenes, mainly 18:1n-9 and 16:1n-7 (Table 6.2).  Inclusion of CLA in the diets 
resulted in levels of total CLA of 1.8 % and 4.0 % of total fatty acids at the 0.5 and 1 % 
inclusion levels, respectively, and inclusion of 0.5 % TTA resulted in TTA at a level of 
1.9 % of total fatty acids in the diet.  CLA and TTA inclusion resulted in lower levels of 
n-3 and total PUFA and increased levels of 18:1n-9.  In addition, inclusion of 1 % dietary 
CLA also decreased the proportions of 20:5n-3, 22:6n-3 and 16:1n-7.   
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6.3.2 Growth and Biometry 
There were no significant differences in final weight, growth rate (SGR), feed 
efficiency (FCR), gutted weight and condition factor in trout fed CLA or TTA compared 
to fish fed the control diet (Table 6.4).  Similarly, viscero- and hepato-somatic indices 
were unaffected by dietary treatment.  Pigmentation, measured using the Minolta light 
meter system, was also unaltered in response to dietary CLA or TTA treatment (Table 
6.4).   
Table 6.4 Growth and biometric parameters of rainbow trout fed diets containing CLA 
and TTA. 
Initial weight (g) 429 ± 17 437 ± 2 450 ± 8 433 ± 12
Final weight (g) 755 ± 46 760 ± 7 777 ± 15 762 ± 21
SGR 1.06 ± 0.07 1.08 ± 0.07 1.02 ± 0.02 1.05 ± 0.03
FCR 0.99 ± 0.06 0.95 ± 0.08 1.03 ± 0.02 0.98 ± 0.01
Gutted weight (%) 83.7 ± 0.8 84.3 ± 0.7 84.6 ± 0.7 83.3 ± 0.6
Condition factor (K) 1.58 ± 0.02 1.58 ± 0.02 1.62 ± 0.04 1.58 ± 0.03
HSI 1.4 ± 0.1 1.4 ± 0.1 1.3 ± 0.1 1.5 ± 0.1
VSI 17.0 ± 1.1 15.7 ± 0.7 15.4 ± 0.7 16.7 ± 0.6
Pigmentation 12.6 ± 0.4 12.8 ± 0.5 12.8 ± 0.3 12.6 ± 0.4
Mortality (n)
FO CLA1 CLA2 TTA
0 0 0 0
 
All data are means ± S.D. with triplicate tanks being experimental units (n=3).  There 
were no significant effects of dietary treatment as measured by ANOVA. Condition 
factor (K) = (wet weight in g) x 100)/(length in mm)3 x 1000; FCR, feed conversion ratio; 
TGC, thermal growth coefficient; HSI, hepato-somatic index; SGR, specific growth rate; 
VSI, viscero-somatic index.   
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6.3.3 Lipid Content and Class Composition 
The hepatic lipid content of trout was significantly decreased in response to 
dietary CLA, but was unaffected in fish fed dietary TTA (Table 6.5).  There were no 
significant effects on lipid class composition in either liver or flesh of trout fed CLA or 
TTA compared to FO alone. However, there was a trend indicating a decrease in total 
neutral lipids in liver of trout fed CLA.  In addition, flesh lipid content did not change in 
response to dietary treatment, as determined by 1-way ANOVA (Table 6.5). 
Table 6.5 Lipid content (percentage of weight) and polar/neutral lipid compositions 
(percentage of total lipid) of liver and flesh of rainbow trout fed CLA or TTA. 
Lipid class
Liver
Lipid content 4.5 ± 0.1 a 3.7 ± 0.3 c 3.9 ± 0.4 bc 4.3 ± 0.4 ab
Total polar 37.6 ± 2.0 40.2 ± 3.7 41.3 ± 3.0 42.3 ± 2.6
Total neutral 62.4 ± 2.0 59.8 ± 3.7 58.7 ± 3.0 57.7 ± 2.6
Flesh
Lipid content 7.2 ± 0.6 7.2 ± 0.3 7.7 ± 0.5 8.2 ± 1.0
Total polar 12.4 ± 3.3 12.3 ± 1.9 11.2 ± 0.9 9.5 ± 1.1
Total neutral 87.6 ± 3.3 87.7 ± 1.9 88.8 ± 0.9 90.5 ± 1.1
FO CLA2 TTACLA 1
  
Values are means ± S.D of 6 samples each of tissue pooled from 3 fish.  Superscript 
letters denote significant differences between dietary treatments as determined by 
ANOVA. 
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6.3.4 Tissue Fatty Acid Composition 
Dietary CLA and TTA were incorporated into both liver and flesh of rainbow 
trout with the bioactive fatty acids deposited at higher levels in flesh compared to liver 
(Tables 6.6 & 6.7).  The total levels of CLA deposited in liver were 0.6 and 1 % of the 
total fatty acids at inclusion levels of 0.5 % and 1 % of the diet, respectively, whilst 
accumulation of TTA reached 0.6 % of total fatty acids at 0.5% dry weight of the diet 
(Table 6.7).  In flesh, levels of total CLA accounted for 1.1 and 1.6 % of the total fatty 
acids in fish fed 0.5 and 1 %, respectively (Table 6.6).  The proportion of TTA as a 
percentage of total fatty acid reached 1.2 % in flesh of fish fed 0.5 % dietary TTA.  Both 
CLA and TTA significantly increased the proportions of hepatic n-3 PUFA, total PUFA 
and 20:4n-6 in liver (Table 6.7).  Both 20:5n-3 and 22:6n-3 tended to be higher in fish fed 
CLA or TTA, however this only reached statistical significance with 20:5n-3 in fish fed 1 
% CLA.  Total saturated fatty acids and 18:0 were increased by CLA whereas total 
monoenes, particularly 18:1n-9 and 16:1n-7, were reduced in livers of fish fed both CLA 
and TTA (Table 6.6).  Similarly in flesh, 18:0 was significantly increased and 18:1n-9 
decreased in fish fed dietary CLA in particular (Table 6.7).  It is noteworthy that in flesh, 
neither CLA nor TTA were deposited at the expense of n-3 HUFA. 
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Table 6.6 Fatty acid composition (percentage of weight) of total lipid  
from flesh of rainbow trout fed CLA or TTA. 
14:0 5.9 ± 0.4 5.6 ± 0.3 5.8 ± 0.2 5.9 ± 0.4
15:0 0.6 ± 0.0 0.6 ± 0.0 0.6 ± 0.0 0.6 ± 0.0
16:0 19.1 ± 0.6 18.9 ± 0.4 18.9 ± 0.4 18.9 ± 0.4
18:0 4.4 ± 0.3 b 5.3 ± 0.2 a 5.0 ± 0.5 a 4.4 ± 0.1 b
Total saturated 30.0 ± 1.2 30.2 ± 0.7 30.2 ± 0.8 29.8 ± 0.7
16:1n-7 7.2 ± 0.4 6.8 ± 0.1 6.9 ± 0.2 7.0 ± 0.2
18:1n-9 13.4 ± 0.6 a 12.4 ± 0.4 b 12.7 ± 0.2 b 12.8 ± 0.6 ab
18:1n-7 3.5 ± 0.1 3.5 ± 0.1 3.4 ± 0.1 3.6 ± 0.1
20:1n-9 2.8 ± 0.3 ab 2.5 ± 0.3 b 3.1 ± 0.2 a 2.8 ± 0.3 ab
22:1n-11 2.5 ± 0.4 ab 2.2 ± 0.3 b 2.9 ± 0.2 a 2.4 ± 0.4 ab
24:1n-9 0.4 ± 0.0 0.4 ± 0.0 0.4 ± 0.0 0.4 ± 0.1
Total monoenes1 30.1 ± 0.5 a 28.1 ± 0.9 b 29.7 ± 0.5 a 29.3 ± 0.8 a
CLA (9c,11t) 0.0 ± 0.0 c 0.6 ± 0.1 b 0.9 ± 0.2 a 0.0 ± 0.0 c
CLA (10t,12c) 0.0 ± 0.0 c 0.5 ± 0.1 b 0.7 ± 0.1 a 0.0 ± 0.0 c
TTA 0.0 ± 0.0 b 0.0 ± 0.0 b 0.0 ± 0.0 b 1.2 ± 0.1 a
18:2n-6 4.8 ± 0.8 5.5 ± 0.7 4.6 ± 0.3 5.4 ± 0.9
20:4n-6 0.9 ± 0.0 1.0 ± 0.0 0.9 ± 0.0 0.9 ± 0.0
Total n-6 PUFA2 6.7 ± 0.8 7.5 ± 0.7 6.4 ± 0.3 7.0 ± 0.9
18:3n-3 1.2 ± 0.2 1.2 ± 0.0 1.2 ± 0.1 1.3 ± 0.1
18:4n-3 1.5 ± 0.1 1.4 ± 0.1 1.6 ± 0.1 1.5 ± 0.1
20:4n-3 1.3 ± 0.1 1.3 ± 0.1 1.1 ± 0.2 1.4 ± 0.2
20:5n-3 8.7 ± 0.3 8.7 ± 0.2 8.4 ± 0.2 8.5 ± 0.2
22:5n-3 2.9 ± 0.1 2.9 ± 0.0 2.7 ± 0.1 3.0 ± 0.2
22:6n-3 17.3 ± 1.1 17.5 ± 0.4 16.8 ± 0.5 16.8 ± 0.6
Total n-3 PUFA3 33.2 ± 1.2 33.2 ± 0.3 32.0 ± 0.8 32.8 ± 0.7
Total PUFA 39.9 ± 1.1 a 40.7 ± 0.8 a 38.5 ± 0.5 b 39.7 ± 0.7 ab
n-3/n-6 5.0 ± 0.7 4.5 ± 0.4 5.0 ± 0.3 4.8 ± 0.6
FO CLA1 CLA2 TTA
 
Values are means ± SD of 6 samples each of tissue pooled from 3 fish. 
1, includes 20:1n-7 present up to 0.3 %; 2, includes 20:2n-6, 20:3n-6  
and 22:4n-6 present up to 0.3 %; 3, includes 20:3n-3 present up to 0.3 %. 
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Table 6.7 Fatty acid composition (percentage of weight) of total lipid  
from liver of rainbow trout fed CLA or TTA.  
14:0 2.0 ± 0.2 1.8 ± 0.2 1.8 ± 0.1 1.8 ± 0.1
16:0 13.1 ± 1.1 a 12.6 ± 1.0 a 12.2 ± 0.5 ab 10.8 ± 1.1 b
18:0 8.2 ± 0.3 d 13.4 ± 0.5 b 14.8 ± 0.5 a 9.6 ± 0.4 c
Total saturated1 23.7 ± 1.3 b 28.3 ± 1.1 a 29.3 ± 0.5 a 22.6 ± 1.4 b
16:1n-7 4.7 ± 0.4 a 2.8 ± 0.3 bc 2.6 ± 0.2 c 3.2 ± 0.3 b
18:1n-9 17.7 ± 2.0 a 10.8 ± 1.8 bc 9.0 ± 0.9 c 12.2 ± 1.6 b
18:1n-7 3.4 ± 0.1 a 2.7 ± 0.2 b 2.6 ± 0.1 b 3.5 ± 0.2 a
20:1n-9 2.3 ± 0.3 a 1.9 ± 0.3 b 1.5 ± 0.1 c 2.6 ± 0.2 a
24:1n-9 0.4 ± 0.0 0.5 ± 0.1 0.5 ± 0.1 0.5 ± 0.1
Total monoenes2 29.0 ± 2.2 a 19.1 ± 2.2 c 16.8 ± 1.2 c 22.5 ± 2.2 b
CLA (9c,11t) 0.0 ± 0.0 c 0.4 ± 0.1 b 0.7 ± 0.0 a 0.0 ± 0.0 c
CLA (10t,12c) 0.0 ± 0.0 c 0.2 ± 0.0 b 0.4 ± 0.0 a 0.0 ± 0.0 c
TTA 0.0 ± 0.0 b 0.0 ± 0.0 b 0.0 ± 0.0 b 0.9 ± 0.1 a
18:2n-6 1.7 ± 0.1 ab 1.5 ± 0.1 c 1.6 ± 0.1 bc 1.8 ± 0.1 a
20:4n-6 2.2 ± 0.2 b 3.0 ± 0.4 a 2.9 ± 0.2 a 3.1 ± 0.4 a
22:4n-6 0.6 ± 0.0 0.6 ± 0.1 0.6 ± 0.1 0.6 ± 0.1
Total n-6 PUFA3 5.2 ± 0.4 b 6.0 ± 0.5 a 5.8 ± 0.3 ab 5.8 ± 0.3 ab
18:3n-3 0.5 ± 0.1 0.5 ± 0.0 0.5 ± 0.1 0.6 ± 0.0
20:4n-3 0.6 ± 0.1 b 0.6 ± 0.0 b 0.7 ± 0.1 b 0.9 ± 0.2 a
20:5n-3 9.4 ± 0.4 b 10.2 ± 0.7 ab 10.5 ± 0.5 a 9.6 ± 0.5 b
22:5n-3 3.7 ± 0.4 b 3.6 ± 0.4 b 3.6 ± 0.3 b 4.9 ± 0.7 a
22:6n-3 27.7 ± 1.2 31.0 ± 1.8 31.5 ± 1.6 31.8 ± 1.0
Total n-3 PUFA4 42.2 ± 1.8 b 46.1 ± 1.9 a 47.0 ± 1.4 a 48.2 ± 1.0 a
Total PUFA 47.3 ± 2.1 b 52.0 ± 1.9 a 52.9 ± 1.5 a 53.9 ± 1.1 a
n-3/n-6 8.2 ± 0.4 7.8 ± 0.7 8.1 ± 0.3 8.4 ± 0.5
FO CLA1 CLA2 TTA
 
Values are means ± S.D. of 6 samples each of tissue pooled from 3 fish. Superscript 
letters denote significant differences between dietary treatments as determined by 
ANOVA.1, includes 15:0 and 20:0 present is some samples at up to 0.2 %; 2, includes 
20:1n-7 and 22:1n-11 present in some samples at up to 0.3 %; 3, includes 20:2n-6 and 
20:3n-6 present in some samples at up to 0.4 %; 4, includes 18:4n-3 and 20:3n-3 present 
in some samples at up to 0.2 %. 
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6.3.5 Peroxisomal β-Oxidation Capacity, CPT-1 and ACO Activities 
Peroxisomal fatty acid β-oxidation capacity was not affected in fish fed CLA or 
TTA (Figure 6.1).  There was a trend that suggested an increase in metabolic flux of 
palmitate in muscle of fish fed CLA, however the deviation between samples made the 
pattern non-significant.  Dietary CLA had no effect on CPT-1 activity in any of the three 
tissues, liver, white and red muscle, relative to fish fed the control FO diet (Figure 6.2).  
In white muscle, CPT-1 activity was also unaffected by dietary TTA.  However, there 
was a significant increase in CPT-1 activity in liver and red muscle of trout fed the diet 
containing 0.5 % TTA.  ACO activity mirrored CPT-1 activity in all tissues of trout fed 
TTA such that liver and red muscle ACO activity significantly increased whereas white 
muscle ACO activity was unaffected (Figure 6.3).  There was a trend for dietary CLA to 
increase ACO in liver and red muscle, but this effect was only significant in red muscle 
in fish fed the higher level of CLA.  The overall flux through the HUFA synthesis 
pathway, as measured by summing all the desaturated products of 18:3n-3, was 
unaffected by dietary CLA or TTA (Figure. 6.4).  However, both 1 % CLA and 0.5 % 
TTA significantly increased the amount of radioactivity recovered in the hexaene fraction 
of the total radioactivity recovered from hepatic microsomes incubated with radiolabelled 
18:3n-3.  Conversely, the amount of radioactivity from labelled 18:3n-3 recovered in the 
pentaene fraction was significantly less in CLA-treated fish compared with controls. 
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Figure 6.1 Effects of CLA or TTA on peroxisomal β-oxidation capacity  
in tissue homogenates of liver, red and white muscle of rainbow trout.  
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Results are presented relative to the activity in fish fed FO for each tissue  
and are means ± SD (n = 6).  There were no statistically significant  
differences between dietary treatments within each tissue. 
 
Figure 6.2 Effects of CLA or TTA on CPT-1 activity in tissue  
homogenates of liver, red and white muscle of rainbow trout. 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
Liver Red Muscle White Muscle
R
el
at
iv
e 
C
PT
-1
 A
ct
iv
ity
 (F
O
=1
)
FO
CLA1
CLA2
TTA
a a a
b
b
b
b
a
 
Results are presented relative to the activity in fish fed FO for each tissue and are means 
± SD (n = 6). Different letters denote significant differences between dietary treatments 
within each tissue. 
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Figure 6.3 Effects of CLA or TTA on ACO activity in tissue homogenates of liver, red 
and white muscle of rainbow trout 
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Results are presented relative to the activity in fish fed FO for each tissue and are means 
± SD (n = 6). Different letters denote significant differences between dietary treatments 
within each tissue.  
 
Figure 6.4 Effects of dietary oil content and conjugated linoleic acid (CLA) and 
tetradecylthioacetic acid on highly unsaturated fatty acid (HUFA) synthesis in the liver 
microsomes 
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Results are presented relative to the activity in fish fed FO for each tissue and are means 
± SD (n = 6). Different letters denote significant differences between dietary treatments 
within each tissue 
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6.3.6 Gene Expression of CPT-1in Liver, Red and White Muscles, and 
Fatty Acyl ∆6 Desaturase and PUFA Elongase in Liver 
Neither dietary CLA nor TTA had any significant effect on the gene expression of CPT-1 
in liver or red muscle compared to fish fed FO alone (Figure 6.5).  However, CPT-1 
expression was significantly increased in white muscle as a result of dietary CLA and 
TTA inclusion relative to fish fed FO alone.  The expression of fatty acyl ∆6 desaturase 
was significantly lower in fish fed CLA and TTA compared to fish fed FO alone, whereas 
the expression of PUFA elongase was increased by dietary CLA (Figure 6.6).   
 
Figure 6.5 Effects CLA or TTA on the expression of CPT-1 in the liver, red and white 
muscle of rainbow trout.  
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Results are presented relative to the activity in fish fed FO and are means ± SD (n = 6). 
Different letters denote significant differences between dietary treatments. 
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Figure 6.6 Effects of CLA or TTA on the expression of fatty acyl ∆6 desaturase and 
elongase genes in liver of rainbow trout.  
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Results are presented relative to the activity in fish fed FO and are means ± SD (n = 6). 
Different letter denote significant differences between dietary treatments. 
 
6.3.7 Innate Immunological Response 
There was no significant difference in the packed cell volume (haematocrit) of 
rainbow trout fed CLA or TTA relative to fish fed the control (FO).  Likewise, there was 
no difference in red or white blood cell counts in rainbow trout fed either CLA or TTA 
compared with the control (Table 6.8). Furthermore, the serum lysozyme activity of fish 
was unaltered in response to either dietary CLA or TTA in rainbow trout. 
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Table 6.8 Effects of dietary oil content and conjugated linoleic acid (CLA) on basic 
haematology and selected immunological parameters of Atlantic salmon 
Diet
FO 1.00 ± 0.09 1.00 ± 0.49 62.2 ± 6.5 430.0 ± 62.2
CLA1 1.12 ± 0.21 0.95 ± 0.25 65.9 ± 6.3 439.7 ± 45.2
CLA2 1.15 ± 0.20 0.90 ± 0.26 63.2 ± 3.6 444.5 ± 49.9
TTA 1.04 ± 0.23 0.93 ± 0.29 64.8 ± 7.0 456.0 ± 34.8
RBC WBC PCV (%) Lysozyme
(FO =1) (FO =1) (U/min/ml)
 
RBC, red blood cell count (relative to FO diet); WBC, white blood cell count (relative to 
FO diet); PCV, packed cell volume. 
6.4 Discussion 
Considering the myriad of beneficial effects TTA, and particularly CLA have elicited in 
many different animal models and cell culture systems, the main focus of this study was 
to test the hypothesis that these bioactive fatty acids can have similar beneficial effects in 
trout culture, namely through enhanced growth and/or altered lipid deposition.  It was 
also proposed, as a result of feeding trout dietary CLA or TTA, that improved nutritional 
quality could be attained through incorporation of these bioactive fatty acids and 
additional n-3 HUFA levels in the flesh.  Thus, it was also important to analyse the 
capacity for CLA and TTA to accumulate in rainbow trout flesh as this fish may provide 
a vehicle through which these fatty acids could be delivered to the consumer.  An 
additional aim of this trial was, to determine the influence of both dietary TTA and CLA 
at a biochemical level by analysing the activity of key enzymes thought to be pivotal in 
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lipid metabolism, as well as give a preliminary insight into the immunological response 
of fish fed these bioactive fatty acids.   
  The results have shown that the hypotheses were only partly proved.  These fatty acids 
can be easily incorporated into the diet; the flesh accumulates CLA and TTA to a 
relatively greater extent than liver that shows lower percentages of these fatty acids 
which, when combined with the relatively high muscle lipid content, means the flesh of 
trout can deliver a reasonable dose of the bioactive fatty acids.  Specifically, this study 
indicates that both CLA and TTA were accumulated in rainbow trout flesh, with levels 
reaching 1.6 and 1.2 % of total fatty acids, respectively.  Obviously, there is potential for 
an increase in market value of the fish fed CLA or TTA as a result of this finding, if 
indeed these bioactive fatty acids prove to be indubitably beneficial for human health and 
can be included in the diets at a cost-effective level.  This is with particular reference to 
TTA, which has hitherto yet to achieve FDA approval.  Indeed, TTA is still largely 
untested in humans (Berge et al., 2002), although two recent studies suggest it may have 
lipid-lowering and anti-inflammatory effects (Aukrust et al, 2003; Fredriksen et al., 
2004).  As mentioned previously, the effects of CLA and TTA on trout are not without 
precedent, however the number of papers in the peer-reviewed literature on fish are very 
few compared to studies conducted using mammalian models.  Nevertheless, previous 
studies involving CLA supplementation in fish have indicated that this fatty acid can 
accumulate to a much higher level in fish tissues compared to the endogenous levels 
found in ruminant tissues.  For instance, muscle (flesh) CLA concentrations in fish fed 1 
% CLA have reached 8 % of total fatty acids in hybrid striped bass (Twibell et al., 2000), 
3.4 % in European sea bass (Valente et al., 2007b), 2.9 % in perch (Twibell et al., 2001) 
and 3.5 % in Atlantic salmon (section 3.3.5).  Recent studies investigating the influence 
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of dietary CLA on smaller rainbow trout have also indicated that muscle CLA 
concentration can reach 4 – 5 % of the total lipid content (Bandarra et al., 2006; Valente 
et al., 2007a).  Therefore, it is clear that the levels of CLA accumulated in the flesh in the 
present trial with large trout were lower than the levels obtained in previous studies 
involving smaller trout fed an equivalent CLA concentration.  This is entirely consistent 
with the notion that the kinetics of fatty acid composition changes will be more rapid in 
smaller fish.  Thus, it is likely that higher levels of dietary CLA and TTA could be 
accumulated in larger fish given a longer period of dietary supplementation.  In addition, 
there appeared to be degree of selectivity between the individual CLA isomers, such that 
the c9t11 was more effectively incorporated into the liver and flesh of trout; a finding 
also acknowledged in previous studies involving trout (Bandarra et al., 2007; Valente et 
al., 2007a) and other animals (Ostrowska et al., 2003; Degrace et al., 2004).  This may 
have implication on market quality considering the diverse physiological and biochemical 
effects attributed to each isomer.  For instance, it is now accepted that t10c12 CLA is 
responsible for the observed attenuation of fat deposition in rodents in particular (Pariza 
et al., 2001).  
Hitherto, the influence on dietary TTA on the fatty acid composition of rainbow trout had 
not been investigated.  However, in Atlantic salmon TTA accumulated in muscle 
averaging 0.5 % of total fatty acids at dietary inclusion levels of 0.6 % (Kleveland et al., 
2006).  In the present study using fish that are more representative of market size, trout 
fed TTA at a slightly lower dietary concentration were able to accumulate more TTA in 
muscle compared to Atlantic salmon in the previous trial, that were of a significantly 
smaller size.  Importantly, in trout, the accumulation of CLA and TTA did not 
significantly affect the levels of the n-3HUFA in flesh and therefore there was no effect 
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on flesh fatty acid compositions that could be considered detrimental or likely to 
compromise the established nutritional benefit of fish for the human consumer.  This is in 
line with previous studies that showed no detrimental effect on 20:5n-3 and 22:6n-3 
levels in muscle or whole body of salmon fed similar dietary inclusion levels of 0.6 % 
TTA and 1 % CLA, respectively (Berge et al., 2004; Kleveland et al., 2006).  On the 
contrary, liver n-3 PUFA levels significantly increased in this study in response to dietary 
TTA and CLA in addition to a trend indicating a rise in the proportion of 22:6n-3 in fish 
fed these bioactive fatty acids. A related increase in 22:6n-3 and 20:5n-3 levels was also 
observed in the liver of hybrid striped bass fed CLA (Twibell et al., 2000).  In the present 
study, the increase in hepatic n-3 PUFA and appreciable rise in 22:6n-3 level correlates 
with an increase in level of radioactivity recovered in the hexaene fraction of the HUFA 
synthesis assay.  It is noteworthy that only 10 % of the total radioactivity recovered was 
represented by the hexaene fraction and that the majority of this fraction could only 
contain 24:6n-3 since the reaction was carried out in microsomes whereas peroxisomes 
are required for conversion of 24:6n-3 to 22:6n-3 in trout (Buzzi et al., 1997).  However 
in the present study, total HUFA synthesis, as measured by the sum of all desaturated 
products recovered, was low in all dietary treatments, as expected in trout (Buzzi et al., 
1996), and fish in general (Tocher, 2003), fed essentially FO diets, and there was no 
effect of CLA and TTA on overall HUFA synthesis.  Thus, the effects of CLA and TTA 
were specifically to increase the proportion of the products of the pathway recovered as 
hexaenes rather than an increase in the overall activity of the HUFA synthesis pathway.  
Consistent with this, dietary CLA at inclusion levels up to 1 % had no effect on the 
HUFA synthesis pathway in salmon fed diets with similar oil content (section 4.3.1).  It is 
noteworthy that the hepatic 18:3n-3/20:5n-3 ratio, regarded as an indicator of ∆6 
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desaturase activity in fish, was not significantly effected by either TTA or CLA.  
However, in the present trial, ∆6 desaturase expression was significantly less in fish fed 
CLA and TTA relative to fish fed FO diets alone; a result which was not replicated in 
salmon fed an equivalent dietary level of CLA.  In contrast, as has been described 
previously, dietary CLA increased both ∆5 and ∆6 desaturase expression in salmon. 
Obviously, the discrepancy between HUFA synthesis and ∆6 desaturase expression in 
trout warrants further investigation, however, the general low level of HUFA synthesis, 
perhaps combined with an observed compensatory increase in PUFA elongase 
expression, may have mitigated the effect of decreased desaturase expression in this trial.  
Suppression of desaturase activity has been reported previously in studies investigating 
the effects of CLA in transformed yeast  (Chuang et al., 2001a) and t10c12 CLA in 
HepG2 cells (Eder et al., 2002).  In fact, a lack of a direct correlation between desaturase 
expression and activity has previously been observed in further studies involving yeast 
cell systems incubated with CLA (Chuang et al., 2004), and also between ∆6 desaturase 
fatty acid indices and expression in plasma from humans fed CLA (Thijssen et al., 2005).   
In the present study the ratio of 18:0/18:1n-9, a surrogate marker for stearoyl CoA 
desaturase (SCD) activity, was increased in response to dietary CLA in liver and, to a 
lesser extent, flesh lipids.  These data correlate well with studies previously in striped 
bass (Twibell et al., 2000), yellow perch (Twibell et al., 2001), salmon (Berge et al., 
2004; section 4), cod (section 5) and sea bass (Valente et al., 2007b).  In addition, dietary 
CLA increased the proportions of 18:0 and decreased percentages of 18:1 in liver, muscle 
and viscera of rainbow trout juveniles (Bandarra et al., 2006).  Suppression of SCD 
expression and/or activity has also been observed in rats (Wendel and Belury, 2006; 
Purushotham et al., 2007), mice (Lee et al., 1998; Viswanadha et al., 2006), pigs (Smith 
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et al., 2002), poultry (Shang et al., 2005) and mammalian cell lines (Choi et al., 2001, 
2002) in response to t10c12 CLA, c9t11 CLA or a combination thereof.  Conversely, the 
data in the present trial indicate that TTA may have only a moderate effect on SCD 
activity in trout.  The hepatic 18:0/18:1n-9 ratio or SCD index was only slightly altered 
and there was no effect on these indices in flesh of trout fed TTA.  Previously, dietary 
TTA was shown to have no major effects on 18:0/18:1n-9 levels in salmon liver, gill and 
heart (Moya-Falcon et al., 2004) or salmon flesh lipids (Kleveland et al., 2006), or cod 
liver or flesh lipids (section 5.3.4).  Similarly, TTA had no effect on 18:0/18:1n-9 levels 
in hepatocytes from salmon fed 0.6 % TTA or in hepatocytes incubated with 0.8 mM 
TTA (Moya-Falcon et al., 2006).  
As aforementioned, another primary objective of this study was to determine 
whether CLA or TTA could reduce the deleterious consequences of feeding fish high fat 
diets, which include increased lipid deposition in liver and flesh in particular.  It is widely 
accepted that dietary CLA can have a beneficial effect on body composition in mammals 
through decreased body fat mass and, in some instances, increased lean body mass, 
particularly in mice, rats and pigs (Wang and Jones, 2004).  Similarly, TTA has been 
shown to prevent high fat diet-induced adiposity in mammals (Madsen et al., 2002).  It is 
unlikely that any apparent change in SCD activity as speculated above, would lead to a 
reduction in body fat mass since studies carried out on SCD-null mice have shown that 
CLA does not effect body fat gain compared with wild type mice (Kang et al., 2004).  
Certainly, evidence provided in the present study generally supports earlier work 
performed in fish, which shows that neither dietary TTA nor CLA have any effect on 
piscine muscle lipid content, despite the fact the SCD indices were altered.  In the present 
trial, flesh lipid content was unaffected by dietary CLA or TTA.  In two previous trials on 
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salmonids, total lipid content of flesh in salmon and trout was not reduced by dietary 
CLA, although these trials used smaller animals compared to the present trial, around 87 
g for the salmon smolts and only 5 g for the trout (section 3.3.4; Bandarra et al., 2006).  
One caveat when studying juvenile fish is that they may not be at an optimum age to 
conclusively determine if CLA or TTA can have desirable effects on adiposity and lipid 
deposition.  This is because fish of a smaller size do not actively deposit lipid to the same 
extent as larger fish.  Hence, this investigation focused on trout which grew from over 
400 to around 800 g, and the trial was performed in seawater.   
Unfortunately, due to an on-site freezer malfunction while samples were awaiting 
transportation to Stirling, whole body proximate composition was not measured in the 
present trial.  However, it may be reasoned from previous work detailing the influence of 
dietary CLA on whole fish proximate composition that it is unlikely that any significant 
effects would have been observed.  Indeed, it has been consistently shown in previous 
trials that CLA had no significant effect on whole body proximate composition in fish 
(Twibell and Wilson, 2003; Berge et al., 2004; Figueirdo-Silva et al., 2005; Valente et 
al., 2007a).  Similarly, 0.5 % TTA had no effect on cod proximate composition as 
observed in the similar study discussed in the previous chapter.  In addition, there was no 
indication from any of the other biometric or tissue lipid analyses data that would suggest 
that reduction in overall body lipid content had occurred in trout fed CLA or TTA in the 
present study in trout.  Therefore, the inability of CLA and TTA to display any 
commercially important effects on lipid deposition in studies using smaller fish is also 
reflected in the present study, despite the use of larger fish.   
Despite the lack of alteration in flesh lipid levels, liver lipid was slightly lowered 
by dietary CLA in the present study, akin to results obtained previously in striped bass 
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(Twibell et al., 2000), yellow perch (Twibell et al., 2001) and 97 g trout (Valente et al., 
2007a).  Nevertheless, the decrease in liver lipid deposition as a consequence of CLA 
supplementation did not significantly influence the HSI and was therefore unlikely to 
represent a significant reduction in liver TAG content in the present study.  This is in 
contrast to studies that have shown that dietary CLA can increase HSI in hybrid striped 
sea bass (Twibell et al., 2000) and increase hepatic steatosis in mice (Park et al., 1997; 
DeLaney et al., 1999; Clement et al., 2002; Takahashi et al., 2002).  However, feeding 
CLA reduced liver TAG levels (Rahman et al., 2002) and decreased hepatic steatosis in 
Wistar rats (Purushotham et al., 2007).  Thus, it is plausible that the effects of CLA on 
liver physiology are species specific.   
In rodents, studies have suggested that CLA increased fatty acid oxidation via an 
increase in CPT-1 activity (Rahman et al., 2001; Degrace et al., 2004; Zabala et al., 
2006).  However, in the present trial with trout, neither CPT-1 nor ACO activities were 
increased in liver by dietary CLA, and hepatic CPT-1 expression was also unaffected by 
either bioactive fatty acid.  In concordance with this finding on ACO, peroxisomal β-
oxidation capacity was also unaffected by dietary CLA.  Collectively, these data suggest 
that the lipid lowering effect of CLA is unlikely to be due to an increase in hepatic fatty 
acid oxidation.  However, it is important to note that the effects of CLA on hepatic CPT-1 
activity are t10c12 isomer-dependent in hamsters (Macarulla et al., 2005) and mice 
(Degrace et al., 2004), and this may be the case in fish.  It would be interesting to 
investigate whether the two main biologically active CLA isomers reveal antagonistic 
effects on CPT-1 activity.  Certainly, it is clear from previous investigations that there is 
a lack of synergy between the c9t11 and t10c12 isomers in some cases (Brown et al., 
2003a; Brandebourg and Hu, 2005).  In contrast, TTA increased both CPT-I and ACO 
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activities in trout liver, but peroxisomal β-oxidation capacity remained unchanged 
compared with fish fed the control diet.  The increase in ACO and CPT-1 activities was 
not reflected in lower liver lipid, similar results to those obtained previously in cod 
(section 5.3).  The lack of association between tissue lipid levels and indicators of fatty 
acid oxidation was also observed in the trout muscle tissue since TTA increased CPT-1 
and ACO activities in red muscle and 1 % CLA increased red muscle ACO activity with 
no measurable effect on muscle lipid deposition.  However, it is known that red muscle 
comprises only a small proportion of total flesh, the remainder of which is composed 
mostly of white muscle.  Thus, red muscle lipid and fatty acid metabolism may not 
influence overall flesh lipid composition to an appreciable extent.  Although it is likely 
that mitochondrial β-oxidation is more prevalent than peroxisomal β-oxidation in 
salmonid muscle (Frøyland et al., 2000), peroxisomal β-oxidation capacity was 
unaffected by dietary CLA or TTA in white and red muscle.  This correlates with data 
which suggest that both CPT-1 and ACO activities were unaffected by CLA or TTA in 
white muscle.  Considering the lack of effect of the bioactive fatty acids on CPT-I 
activity, the increased CPT-I expression in white muscle of fish fed both CLA and TTA 
was a contradiction, but could perhaps be attributed to posttranslational modification.  In 
C57BL/6J mice, CPT-I activity was significantly more sensitive to malonyl-CoA 
inhibition in CLA-fed animals compared to controls (Degrace et al., 2004).  This has also 
been purported to be the case in hamsters supplemented with CLA (Bouthegourd et al., 
2002).  A similar mechanism could account for the lack of association between CPT-1 
expression and activity in the present trial, at least in fish fed CLA. 
CLA has been studied to a far greater extent than TTA and so more potential 
effects are known.  For instance, CLA may have effects on growth performance in 
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mammals as some studies have suggested that it can enhance growth and feed efficiency 
in young rodents (Pariza et al., 2001).  However, these effects on growth have not been 
replicated in previous trials on a variety of fish species (Twibell et al., 2001; Twibell and 
Wilson, 2003; Berge et al., 2004; Yasmin et al., 2004; Manning et al., 2006), including 
smaller rainbow trout (Figuierdo-Silva et al., 2005; Valente et al., 2007a).  The present 
trial with near market size fish also showed no effect of CLA or TTA on growth.  Final 
weight, SGRs and FCRs were all unaffected by both CLA and TTA. 
Previously, significantly depressed growth and increased mortality was reported 
in salmon smolts fed 0.6 % TTA (Moya-Falcon et al., 2004; Kleveland et al., 2006).  It 
was particularly noteworthy that in the present study, there was no detrimental effect on 
growth or mortality in trout fed 0.5 % TTA.  This was supported by the preliminary 
immunological analyses, which showed that TTA had no effect on blood cell number, 
packed cell volume or lysozyme activity.  Of course, further investigations are required to 
determine whether the adverse effects associated with TTA in earlier studies were a result 
of using smaller fish, higher doses, or different species of fish.  The ability of dietary 
CLA to modulate the innate immune response of juvenile rainbow trout has been 
documented previously (Clarke, 2003; Marshall, 2003).  However, both studies 
concluded that growth was not affected by CLA in juvenile trout fed up to 2 % dietary 
CLA compared with control diets.  Additionally, packed cell volume and blood cell count 
remained constant regardless of dietary treatment.  Serum lysozyme activity was also 
shown to be unaltered in response to dietary CLA and a number of other immunological 
parameters, including respiratory burst by head kidney macrophages, phagocytic ability 
of head kidney macrophages and specific antibody titres were also unaffected at levels up 
to 1 % dietary CLA (Marshall, 2003).  Thus, it may be surmised that CLA or TTA at 
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dietary concentrations equivalent to the present study, could be supplemented to rainbow 
trout at a commercial level without compromising the innate immune response of the 
fish.  However, it is not possible to draw any conclusive result on the immunomodulatory 
response in rainbow trout fed either CLA or TTA, as only a select number of 
immunological parameters have been investigated. 
In conclusion, the results of the present study only partly support the hypotheses 
tested.  Thus CLA and TTA did not beneficially alter the lipid content of the flesh in 
commercial size rainbow trout grown in seawater.  However, trout preferentially 
accumulated both CLA and TTA in the flesh compared to liver, with no detrimental 
effect on flesh n-3 HUFA levels.  Both CLA and TTA could also be successfully 
incorporated into the diet with no evident detrimental effect on fish health. Therefore, if 
CLA or TTA are proved to be beneficial in the human diet, trout may be a convenient and 
consumer-friendly source of these fatty acids, thus enhancing the nutritional quality 
through provision of n-3 HUFA and bioactive fatty acids. 
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CHAPTER 7. DISCUSSION, CONCLUSIONS AND 
FUTURE PERSPECTIVES 
7.1  General Discussion 
The overall objective of this research work was to determine the influence of 
dietary fatty acid nutraceuticals, namely conjugated linoleic acid (CLA) and 
tetradecylthioacetic acid (TTA) on growth performance, flesh quality, and a number of 
physiological and biochemical parameters in commercially important farmed finfish 
species.  The scientific rationale for this work was based on previous studies in mammals, 
which provided strong evidence in favour of CLA and/or TTA eliciting beneficial effects 
including growth enhancement, augmentation of immune function, and decreased lipid 
deposition in particular.  To this end, this project was designed to test the hypothesis that 
dietary CLA and TTA would elicit similar effects in finfish, the corollary of which could 
bring larger, leaner, healthier fish to market. 
The first trial aimed to determine the effects of dietary CLA and oil level on 
growth, biometry, lipid and fatty acid metabolism of Atlantic salmon smolts.  This trial 
also set out to elucidate a biochemical mechanism of action in salmon based on preceding 
cumulative evidence, which suggested that enhanced fatty acid oxidation was the primary 
mechanism for the reduction in body fat observed in rodents fed dietary CLA.  The 
experiment was designed to include different dietary oil inclusion levels in order to 
determine the relationship between dietary CLA and fat levels and whether they 
interacted to moderate the effects of CLA supplementation.  The results of this trial 
proved that dietary CLA, at the dose formulations used, did little to influence fish at a 
physiological level, irrespective of dietary oil level.  Arguably the most important finding 
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at this stage in the research work was that the levels of CLA deposited in salmon flesh 
were much higher than levels that could be obtained naturally from meat and dairy 
produce alone.  Ergo, it was ascertained that farmed Atlantic salmon could be used as a 
vehicle for the provision of this bioactive fatty acid, which in turn could lead to enhanced 
nutritional quality of the fish.  Of course, the assumption that dietary CLA is indeed 
beneficial to human health is an ideal yet to be irrefutably proven.   
The second part of this trial investigated mechanisms of action of CLA and 
established, for the first time in fish, the effects of dietary CLA on fatty acid β-oxidation, 
specifically peroxisomal β-oxidation capacity, CPT-1 gene expression and enzyme 
activity, and HUFA synthesis in tissues of Atlantic salmon.  Despite the lack of 
significant effects at a whole body level and gross physiological evidence, data from this 
part of the study revealed that dietary CLA significantly increased both CPT-1 activity 
and expression in muscle, and also HUFA synthesis activity in liver in conjunction with 
increased expression of ∆5 and ∆6 fatty acyl desaturase genes.  Thus, these data 
suggested that dietary CLA could enhance mitochondrial β-oxidation in muscle and may 
increase n-3 HUFA levels in liver.  Indeed, levels of 22:6n-3 and 20:5n-3 in liver were 
significantly increased in response to dietary CLA although this was not reflected in flesh 
fatty acid compositions.  Emerging evidence in studies involving mammals have 
implicated peroxisome proliferator-activated receptors (PPARs) in the regulation of lipid 
homeostasis (Desvergne et al., 2006) and suggested CLA can directly influence 
metabolism via interaction with these transcription factors (Moya-Camarena et al., 1999). 
Further to elucidating a possible biochemical modus operandi, the present research work 
aimed to investigate the effects of dietary CLA on PPAR transcript levels in muscle and 
liver of salmon.  The results showed that PPAR transcript levels were significantly 
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increased in response to dietary CLA.  However, recent evidence has proved that the 
effects on body fat distribution after CLA supplementation are not mediated by PPAR 
and that, unlike mammals, fish may have multiple forms of each PPAR isoform, some of 
which are not structurally homologous in comparison to their mammalian counterparts 
(Anderson et al., 2000: Leaver et al., 2005).  The limited understanding of the role PPAR 
play in fish lipid metabolism made it difficult to interpret these results.  However, based 
on recent evidence in mammalian studies (Desvergne et al., 2006), it is entirely 
reasonable to suggest that a rise in PPARα and PPARβ levels may have enhanced fatty 
acid oxidation as observed in this study. 
The second major dietary trial aimed to test the hypothesis that dietary CLA or 
TTA could decrease fat deposition in Atlantic cod, specifically in liver, which is the 
major site of lipid deposition in this species.  This entirely novel work concluded that 
neither dietary CLA nor TTA influenced growth or biometry or whole body proximate 
composition in Atlantic cod. At a biochemical level, the data obtained from the fatty acid 
oxidation studies provided evidence in favour of an increase in hepatic fatty acid 
oxidation specifically via increased ACO activity, which was concomitant with elevated 
peroxisomal β-oxidation capacity in cod fed both dietary CLA or TTA.  However, 
unfortunately, lipid content of the liver remained unchanged in cod fed dietary CLA and 
TTA. The trial also showed that both CLA and TTA could be deposited in the flesh of 
cod, which could ultimately result in a consumer friendly route for provision of these 
bioactive fatty acids to the human diet.  
At this stage of the project, it was theorised that juvenile fish of the size used thus 
far, may not be suitable candidates for analysis since smaller fish that are not actively 
depositing lipid may attenuate the many previously observed effects of feeding dietary 
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CLA or TTA found in other animal models.  In consequence, a third major dietary trial 
was conducted for the first time with larger, closer to market-size rainbow trout in order 
to determine the effects of CLA and TTA on lipid and fatty acid metabolism, 
immunomodulation, and parameters of the fatty acid oxidation pathway.  Unfortunately, 
the results again indicated that growth and biometry of these fish were not significantly 
altered in response to either dietary CLA or TTA.  However, lipid content in liver was 
significantly decreased by CLA and there was a trend for decreased VSI in trout fed 2 % 
CLA, whereas TTA had no such effects.  At a biochemical level, CLA increased CPT-I 
gene expression but not activity, whereas TTA increased the activity of both CPT-I and 
ACO, consistent with increased gene expression in the case of CPT-I, but increased ACO 
activity was not reflected in peroxisomal β-oxidation activity.  Lack of correlation 
between CPT-I expression and activity as observed with CLA may be related to increased 
sensitivity of CPT-I to malonyl-CoA inhibition in CLA-fed trout; an incongruity 
previously observed in rodent studies (Degrace et al., 2004).   
In line with previous studies (Chuang et al., 2001a; Eder et al., 2002), ∆6 
desaturase transcript levels were significantly lower in trout fed up to 1 % CLA compared 
with the control.  This is in contrast to the earlier trial with Atlantic salmon, which 
showed an increase in ∆6 desaturase gene expression in fish fed dietary CLA and was 
also consistent with previous work done in rodents (Takahashi et al., 2003). Whatever the 
cause for this difference in the effects of CLA on fatty acyl desaturase gene expression  
between the salmon and trout, it is apparent the mechanism of action of CLA (and TTA) 
is still unclear and warrants further investigation in both mammals and fish.  
Interestingly, one of the more consistent findings of this project was that dietary CLA 
increased 18:0 and decreased 18:1.  Based on these data, it can be surmised therefore that 
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SCD was inhibited in fish fed dietary CLA.  This particular finding correlated well with 
previous studies in fish fed dietary CLA (Twibell et al., 2000, 2001; Valente et al., 
2007a). 
Presently, the aquaculture industry relies heavily on vaccines and 
chemotherapeutants in the fight against disease.  The use of antibiotics and chemicals to 
treat disease outbreaks are no longer favoured largely due to environmental issues, which 
in turn fuel consumer anxieties that farmed fish are not a safe alternative to wild fish.  
Compounding this issue is that while vaccination is a useful tool in combating disease, 
not all diseases affecting the aquaculture industry can be controlled via vaccination.  
Thus, a subsidiary aim of this research was to examine the potential for dietary CLA to 
enhance the immune function in farmed fish.  Although this area was not extensively 
studied, the results indicated that CLA did not beneficially influence any of the 
parameters tested.   
In summary, this research work has established that CLA and TTA do not confer 
any physiologically significant beneficial alterations in overall body composition or 
growth of a number of farmed finfish species.  However, there are a number of 
methodological considerations, which may have had implication in the present work and 
that could be addressed in future work involving similar dietary trials in fish.  Aside from 
the issue regarding the use of juvenile fish as abovementioned, it is possible that the type 
of CLA preparation used in these experiments, and all other dietary trials with fish, may 
have influenced the results obtained.  This project, together with the majority of peer-
reviewed literature, have used mixtures of c9t11 and t10c12 CLA, usually around 1:1, in 
dietary trials involving fish.  In mammals, various in vitro and in vivo work has 
established that each of the two main CLA isomers confers different metabolic effects.  
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For instance, t10c12 CLA is now widely accepted as the isomer responsible for changes 
in body composition (Pariza et al., 2001).  Moreover, there is some evidence to suggest 
that both CLA isomers act antagonistically towards one another.  For example, in vitro 
studies using primary cultures of differentiating pre-adipocytes have shown that TAG 
content decreased when these cells were administered t10c12 CLA (Brown and 
McIntosh, 2003).  In contrast, TAG levels rose subsequent to c9t11 CLA administration 
in the same cells.  Similarly, c9t11 CLA tended to diminish the inhibitory effect of 
t10c12 CLA on glycerol-3-phosphate dehydrogenase activity in porcine adipocytes 
(Brandebourg and Hu, 2005).  It is not unreasonable to suggest that similar antagonistic 
effects could have prejudiced the outcome of the results in terms of the hypotheses tested.  
Recent studies have ascertained that the moiety of both CLA and TTA can have a 
profound effect on the metabolic influence of these fatty acids.  In COS-1 cells, the 
addition of a methyl group to the alpha position of CLA and TTA caused an increased 
activation of PPARα in comparison with non-methylated forms of these fatty acids 
(Larsen et al., 2005).  Additionally, methylated TTA increased peroxisomal, but not 
mitochondrial, β-oxidation in rats (Vaagenes et al., 1999).  Unfortunately, the majority of 
the papers detailing the effects of dietary CLA in fish have not specified whether CLA 
was supplied as either a methyl ester, or esterified in TAG and so it is impossible to 
compare these data in this regard.  However, the research work described in this thesis 
incorporated CLA into the diets in the form of methyl ester.  It is unclear whether 
structural modification of this type would influence the outcome of these data in the 
present research work involving fish.  Nevertheless, this issue should be considered in 
future investigations involving dietary trials incorporating methyl ester derivatives of 
CLA and/or TTA. 
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There were some technical difficulties that arose during the course of this work.  
Most of these difficulties were imposed by logistical limitations intrinsic to the design of 
the experimental phase of the research.  For example, it was impossible to perform assays 
involving radioactive isotopes on-site in Denmark and Ardtoe due to respective 
government legislation and licencing issues.  Thus tissues were required to be frozen 
prior to analysis at the laboratories in Stirling.  It was known that freeze/thawing of the 
samples disrupts the mitochondrial membranes and in doing so, prevented the analysis of 
total and mitochondrial β-oxidation capacity.  However, peroxisomal integrity is reputed 
to be maintained after freeze-thawing and so measurement of peroxisomal β-oxidation 
was theoretically possible.  To conclusively prove this, a pilot experiment was carried out 
at the laboratory in Stirling comparing β-oxidation capacity in fresh and frozen liver and 
muscle tissues in the presence or absence of potassium cyanide (KCN, data not shown).  
KCN inhibits mitochondrial β-oxidation by disrupting the electrochemical gradient 
between the membranes and so total β-oxidation is measured in absence of KCN and 
only peroxisomal β-oxidation activity is measured in the presence of KCN. This 
experiment elucidated that KCN-treated fresh tissue produced the same β-oxidation 
capacity as frozen tissue therefore it was concluded that peroxisomal β-oxidation could 
be accurately determined in these trials.  
The second major constraint was the lack of immunological data that was 
obtained during this project.  This was partly due to logistical constraints given that the 
necessary equipment to perform some of the assays was not available at the trial sites, 
and partly due to unforeseen experimental difficulties, which could not be rectified due to 
time constraints.  Thus, it was difficult to draw any comprehensive conclusions on the 
influence of both dietary CLA and TTA on immunomodulation in the fish.  However, as 
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aforementioned, overall the preliminary data obtained in this research did not suggest that 
there was any major or physiologically significant immunological benefit in feeding 
dietary CLA or TTA to farmed fish.   
In discussion of the constraints in the present study, the cost of replicated 
nutritional trials must be acknowledged and appreciated.  Costs are great and very often 
can be a limitation to dietary trials and compromises sometimes have to be considered.  
In the present study, all studies were fully replicated (triplicates) tank studies.  However, 
providing sufficient funding was available there are several ways in which dietary trials 
on bioactive fatty acids such as CLA and TTA could be improved. Therefore, prospective 
work should encompass trials that are carried out during late summer and that utilise 
larger fish.  Ideally, sea-caged Atlantic salmon of around 1 Kg, which are rapidly 
growing, increasing in weight and subsequently depositing more flesh lipid, should be 
used.  Similarly, it may be possible to better gauge the influence of dietary CLA and TTA 
in cod that are a minimum of 500 g initial weight.  In addition, hitherto, all dietary trials 
investigating the influence of CLA and TTA in fish have not exceeded 12 weeks (3 
months) in duration.  Thus, it would be interesting to carry out longer trials of a minimum 
of 6 months attaining finishing weights of around 2.5 - 3 Kg and 1 - 1.5 Kg for salmon 
and cod, respectively.  In addition to testing the bioactive fatty acids in fish of a much 
more appropriate physiological stage, it would also be possible to ascertain the deposition 
levels of CLA and TTA in the flesh of fish ready for harvest and give a clearer indication 
of the levels that can be supplied to consumers via fish flesh and also the time required to 
reach maximum deposition.   
Arguably another very important aim should be to determine the effects of 
feeding dietary CLA or TTA in combination with alternative, sustainable lipid sources, 
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i.e. diets containing VO.  As aforementioned in Chapter 1, aquafeeds will increasingly 
contain plant products. The aim of the current EU FP6 integrated project, Aquamax, is to 
reduce FM to under 50 % of current use (replaced with plant meals etc.) and reduce FO 
down to possibly zero (100 % replacement with VO) in diets for Atlantic salmon.  
Obviously, this will affect fish fatty acid composition and also may affect lipid 
homeostasis and deposition patterns.  Additionally, there are some perceived effects such 
as increased adiposity and free oil problems (oil leaking from flesh that can cause 
problems for processors such as smokers) associated with high marine product 
replacements.  Thus, it would be interesting to determine whether dietary CLA or TTA 
could mitigate some of these potential problems.  
The present research work has gone some way in bridging the gap between the 
extensive knowledge base with regards to the influence of dietary CLA in rodent and 
other mammalian models, and the relative lack of information from similar trials 
involving fish.  Other than the studies described in this thesis, virtually no mechanistic 
studies have been performed with CLA in fish. Nonetheless, it is clear that further work 
is required in order to gain a more comprehensive understanding of the effects of dietary 
CLA and TTA at biochemical and molecular level, and thus of their mechanisms of 
action in farmed fish. For salmon the recently completed BBSRC project “TRAITS” has 
produced a large, trait-targeted 17K feature cDNA microarray for salmon.  The traits 
targeted were lipid metabolism (alternative diets), protein metabolism (ration etc.), 
immune function and parr-smolt transformation. The TRAITS project has contributed to 
a relatively new field of research termed transcriptomics, which has provided for the first 
time, the possibility of determining changes in gene expression levels in salmon, at a 
global level, using so-called microarray technology.  The potential implication of this 
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work would allow examination of the effects of CLA or TTA on thousands of genes 
within many different metabolic pathways; the application of which would lead to a 
much clearer understanding of the mechanism of action of these bioactive fatty acids.  
Two key examples of this would be the uncoupling proteins (UCP) and the sterol 
response element-binding protein (SREBP) transcription factors. 
  Recent studies involving CLA-fed mammals have elucidated a number of 
potential factors that are likely to contribute to the overall biochemical mode of action.  
For instance, UCPs (particularly UCP-2 and UCP-3) are key regulators of energy 
expenditure and diet-induced thermogenesis in mammals and are ubiquitously expressed 
throughout the tissues of the body.  Both are known to be up-regulated in response to 
t10c12 CLA in ob/ob mice (Roche et al., 2002) whilst UCP-2 mRNA expression was 
increased in adipose and muscle tissue of rats fed c9t11 CLA (Ryder et al., 2001; Choi et 
al., 2004).  Another study noted that UCP-2 expression in brown adipose tissue was 
increased in AKR/J mice as a result of 1 % dietary CLA (West et al., 2000).  Moreover, 
UCP-2 expression in both brown adipose tissue and skeletal muscle tissue was 
significantly increased in ICR and C57BL/6J mice fed 2 % CLA (Takahashi et al., 2002). 
Feeding the CLA-producing bacteria Lactobacillus rhamnosus PL60 to C57BL/6J mice 
also resulted in increased UCP-2 mRNA expression in adipose tissue (Lee et al., 2006).  
It is therefore reasonable to suppose that CLA supplementation causes an up-regulation 
of UCP-2 expression that could contribute to an increase in energy expenditure. 
There is increasing evidence to suggest that a family of nuclear transcription 
factors, namely SREBPs, are also modulated by CLA both in vitro and in vivo.  
Collectively, SREBPs are involved in the transcriptional activation of more than 30 genes 
associated with cholesterol, fatty acid, TAG and PL synthesis.  One isoform, SREBP-1a, 
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has the ability to activate all SREBP-responsive genes (Desvergne et al., 2006)  SREBP-
1c on the other hand, is responsible for mediating the expression of genes involved in 
fatty acid synthesis while SREBP-2 controls cholesterol synthesis.  The majority of 
studies detailing the influence of dietary CLA on SREBP gene expression have shown 
that these transcription factors are significantly reduced as a result of supplementation.  
For instance, inhibition of proteolytic activation of SREBP-1 is thought to cause a 
suppression of milk fat synthesis in t10c12 CLA-fed dairy cows (Peterson et al., 2004).  
Recently, both SREBP-1a and SREBP-1c gene expression were down-regulated in 
adipose tissue of hamsters administered t10c12 CLA (Zabala et al., 2006).  In pigs, pre-
adipocyte proliferation and differentiation was inhibited in response to dietary t10c12 in a 
mechanism involving down-regulation of SREBP-1c gene expression (Brandebourg and 
Hu, 2005).  Conversely, dietary c9t11 CLA has been known to increase SREBP-1c 
mRNA expression in adipose tissue of ob/ob mice (Roche et al., 2002), suggesting that 
metabolic effects of CLA may be isomer dependant and in this case, antagonistic.  
Importantly, SREBP-1c and PPARγ interact with each other to execute pre-adipocyte 
differentiation  (Granlund et al., 2003).  It is likely that concomitant decreases in SREBP-
1c and PPARγ gene transcription observed in the abovementioned studies, are 
responsible for the overall reduction in transcriptional activation of lipogenic genes in 
animals administered t10c12 CLA.  It may be that SREBP plays a more important role in 
fish in comparison to PPAR.  However, the associated drop in transcript levels of 
SREBPs in other animals including pigs (Brandebourg and Hu, 2005) and hamsters 
(Zabala et al., 2006) was also associated with a drop in PPARγ levels, something not 
observed in the present study.  Clearly, more studies will be required to determine 
whether dietary CLA exerts its effects via a SREBP-dependant mechanism in fish.  In 
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addition, a more detailed evaluation of the effects of CLA and TTA on immune function 
is also required, particularly considering the potential for dietary TTA to cause increased 
mortality in Atlantic salmon (Kleveland et al., 2006).  
In conclusion, the present research work has provided new insights to the effects 
of dietary CLA and TTA on the physiology and biochemistry of some key species of 
farmed fish.  However, this novel research has also broached many ideas and hypotheses, 
which will require further elucidation in order to gain a more thorough understanding of 
the effects of both these bioactive fatty acids as dietary supplements in aquaculture. 
7.1 Summary of Results and Conclusions  
In summary, the results of this research work have indicated the following:- 
 
• There were no effects on growth performance as evidenced through measurement 
of final body weight, SGRs or TGC 
• There were no effects on feed efficiency as measured via FCR 
• There were few physiologically significant effects on fat levels of fish as 
evidenced by no major effects on carcass proximate compositions or tissue (flesh 
or liver) lipid levels 
• No evidence for any redistribution of body fat with no physiologically significant 
effects on HSI and VSI 
• Both CLA and TTA could be incorporated into fish flesh thus providing a vehicle 
through which these bioactive fatty acids can be delivered to the consumer. 
• There were a number of effects on fatty acid metabolism including CLA clearly 
inhibiting SCD (∆9) desaturase leading to increased 18:0 and decreased 18:1 in 
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cod and trout in particular, and possibly increased ∆6 and ∆5 desaturase 
expression and activity (at least in salmon) leading to increased hepatic n-3HUFA 
• There were some significant effects on gene expression of enzymes and 
transcription factors thought to be pivotal in modulating lipid and fatty acid 
metabolism however the data did not always correlate with activities.  Morover, 
the effects on gene transcription and biochemistry had little impact at the whole 
body level   
• Although not extensively studied, there were no indications that CLA (or TTA) 
had any major beneficial health effects as there were no effects on immune status, 
including basic haematology or some parameters of immune function 
• No detrimental effects of the bioactive fatty acids (as had been previously 
reported in other trials), were observed in the present trials. 
 
7.2 Future Perspectives 
Considering the range of effects that CLA, and to a lesser extent other bioactive 
fatty acids like TTA, have been shown to have in mammals, both in dietary trials and cell 
model systems, many of which could be potentially beneficial in aquaculture, it is 
disappointing that in the trials to date, there have been no substantial advantages of 
including these functional fatty acids in diets for farmed fish.  However, there are still 
some trials that could perhaps provide final definitive conclusions.  Points 1-3 below 
summarise the applied research that is still required to conclusively establish if CLA, or 
TTA, could have significant beneficial effects in fish farming.  Points 4 and 5 represent 
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the basic scientific research required to determine the mechanisms of action  
underpinning the actions of bioactive fatty acids like CLA. 
1. Larger fish. It is important that larger fish at more appropriate time in their 
life/growth cycle be investigated. For salmon this would require a seawater pen 
trial on fish of around 1 Kg  (probably around May-October), a stage when they 
will be growing rapidly, producing large increases in overall weight and actively 
depositing lipid in the flesh. Similarly, for cod a seawater pen trial using fish of 
around 0.5 Kg or more would be desirable – perhaps starting in pre-starved fish. 
2. Increased length of trial. The length of trials should be longer and would, ideally, 
be at least double the duration of the trials in the present study, with probably 
around 6 months as a minimum. Combined with the larger initial size of the fish, 
this would result in fish at the end of the trials being much closer to market size 
and weights, around 2.5-3 Kg for salmon and at least 1-1.5 Kg for cod.  
3. Alternative diets (i.e. VO replacement).  Diets for farmed fish will increasingly 
contain plant products. This will have consequences for FA compositions, of 
course, but also may affect lipid homeostasis and deposition patterns etc.  There 
are already reports of perceived effects such as increased adiposity and free oil 
problems associated with high marine product replacements. Clearly it is essential 
that a full investigation of the effects of bioactive fatty acids such as CLA and 
TTA should also include trials with these diets that although currently termed 
“alternative” will increasingly become the “standard”.  In terms of dietary 
formulation it is also worth considering the chemical form of the bioactive fatty 
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acid that is supplemented, and so a trial comparing, say, CLA added as methyl 
ester versus addition as TAG may be illuminating. 
4. Additional analysis. a) Total and mitochondrial β-oxidation. The pathways of 
fatty acid oxidation are crucial in these trials with CLA and TTA that have known 
effects on these pathways. In the present trial, legal and logistic problems limited 
the β-oxidation studies, and so the assays performed were a compromise to obtain 
the maximum information possible with frozen tissue samples. Similar problems 
would arise with the trials described above as they all have to be performed at 
Feed Trial Units that are, essentially, simply fish farms. However, innovative 
ways should be sought for measuring total and mitochondrial β-oxidation.  b) 
Transcriptomics.  For salmon the trait-targeted 17K feature cDNA microarray will 
be extremely useful for looking at the effects of bioactive fatty acids on global 
gene expression, investigating many pathways and areas of metabolism 
simultaneously.  
5. Individual isomers.  In the case of CLA, it is already known in studies with 
mammalian systems that specific isomers are responsible for eliciting different 
individual effects. Investigation of individual isomers has not been attempted with 
fish and cannot be done with dietary trials due to then cost of purified isomers. 
However, several potentially very useful fish cell lines are available including 
those from Atlantic salmon (AS) and rainbow trout (RTH, hepatic and RTG, 
gonad).  Although no cell line is available for cod, lines are available for other 
marine species including turbot (TF) and sea bream (SAF-1).  As well as studying 
individual isomers, cell line studies could be very useful for more detailed 
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analysis, both biochemical (enzyme assays) and molecular (gene expression) in 
studies designed to elucidate the mechanisms of action of these interesting 
bioactive or functional fatty acids. 
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APPENDIX I 
10 X TBE electrophersis buffer, per litre 
108g Tris (BioRad labs, Hercules, CA, U.S.A) 
55g Boric Acid (BioRad labs, Hercules, CA, U.S.A) 
8.3g EDTA (BDH) 
LB Medium 
25 g  LB Broth (MERCK) 
1 L Distilled H2O 
LB/Ampicillin/X-gal/IPTG plates 
25g LB Broth (MERCK) 
15 g Agar Bacteriological No. 1 (Oxoid, Hampshire, U.K.) 
1 mg X-gal (5-bromo-4-chloro-3-indoyl-β-galactopyranoside) 
0.8mg IPTG (isoproylthio-β-D-galactoside)
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APPENDIX II  
GFXTM Micro Plasmid Prep Kit (Amersham Biosciences) 
Components of Kit. 
Solution I: 100 mM Tris-HCl (pH 7.5), 10 mM EDTA, 400 µg/ml RNase I 
Solution II: 1 M NaOH, 5.3% (w/v) SDS (5.3X concentrated solution) 
Solution III Buffered solution containing acetate and chaotrope. 
Wash Buffer Tris-EDTA buffer in 80% ethanol. 
 
Cell Lysis 
• 1.5 ml of an overnight E. coli culture was transferred to a 1.5 ml 
microcentrifuge tube then centrifuged at full speed for 30 sec to pellet the 
cells. 
• As much supernatant as possible was removed by aspiration without 
disturbing the pellet. 
• An additional aliquot of culture (to give 2-3 ml total volume of culture) 
was added to the microcentrifuge tube, centrifuged at full speed for 30 sec 
and the supernatant removed by aspiration as described above. 
• The pellet was then resuspended in 300 µl solution I with vigorous 
vortexing 
• Three hundred µl of solution II was added to the microcentrafuge tube 
then mixed by inverting the tube 10-15 times. 
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• Six hundred µl of solution III was added and mixed by inverting the tube 
until a flocculent precipitate appeared with inverting continuing until the 
precipitate was evenly dispersed. 
• The microcentrifuge tube containing the flocculent precipitate was then 
centrifuged for 5 min at room temperature to pellet the cells. 
• One GFXTM column for each preparation was prepared by placing the 
column into a collection tube. 
 
DNA purification 
• Approximately half of the supernatant was transferred to the prepared 
GFXTM column, incubated for 1 min and centrifuged at full speed for 30 s. 
• The flow-through was discarded by emptying the collection tube and the 
remaining supernatant transferred to the same GFXTM column. 
• The GFX column was incubated for a further minute at room temperature 
before being centrifuged for 30 s at full speed. 
• The flow-through was once again discarded as above. 
• Four hundred µl of wash buffer was added to the column. The column was 
centrifuged at full speed for 30 s to remove the buffer and dry the matrix 
prior to elusion. 
• The GFX column was transferred to a clean microcentrifuge tube and 50 
to 75 µl of H2O added to the top of the glass fibre matrix in the GFX 
column. 
• The column was incubated at room temperature for 1 min before being 
centrifuged for 1 min to remove the purified plasmid DNA.
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APPENDIX III – PUBLISHED PAPERS 
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